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Abstract 
Osteoarthritis (OA) is a degenerative condition caused by dysregulation of 
multiple molecular signalling pathways. This dysregulation results in damage to 
cartilage, a smooth and protective tissue that enables low friction articulation of 
synovial joints. Matrix metalloproteinases (MMPs), especially MMP13, are key 
enzymes in the cleavage of type II collagen which is a vital component for 
cartilage integrity. Various stimuli have been identified as inducers of MMP 
expression such as excessive load, injury and inflammation.  
Although previously considered a non-inflammatory arthritis, recent research 
has shown that inflammation may play an important role in OA development. A 
novel meta-analysis of microarray data from OA patients was used to create a 
cytoscape network representative of human OA. This enabled the identification 
of key processes in OA development, of which inflammation was prominent. 
Examining various different signalling pathways highlighted a role for 
transforming growth factor beta (TGFβ) in protecting against pro-inflammatory 
cytokine-mediated MMP expression. Indeed, TGFβ plays key roles in all facets 
of cartilage biology including development and maintenance of cartilage 
integrity. With age there is a change in the ratio of two TGFβ type I receptors 
(ALK1/ALK5), a shift that results in TGFβ losing its protective role in cartilage 
homeostasis. Instead, TGFβ promotes cartilage degradation and this correlates 
with the spontaneous development of OA in murine models. However, the 
mechanism by which TGFβ protects against pro-inflammatory responses and 
how this changes with age has not been extensively studied. 
Mathematical modelling has previously revealed how stochastic changes in 
TGFβ signalling during ageing led to the upregulation of MMPs. I have 
expanded the TGFβ section of this model to incorporate the pro-inflammatory 
stimulus interleukin-1 (IL-1) + oncostatin M (OSM) in order to investigate how 
TGFβ mediates MMP repression, specifically MMP-13. TGFβ signalling appears 
to interact with the activator protein 1 (AP-1) complex, which has an important 
role in MMP upregulation. However, the model indicates this interaction alone is 
insufficient to mediate the full effect of TGFβ, predicting it may also reduce 
MMP-13 mRNA stability. Furthermore, the model enabled me to predict how 
age alters these interactions; it suggested TGFβ would provide limited 
repression with a prolonged inflammatory response.  
Combining the modelled genes with the microarray network provided a global 
overview of how alterations in one pathway can affect others and lead to OA 
development. This study therefore demonstrates the power of combining 
computational biology with experimentally-derived data to provide insight into 
the importance of TGFβ signalling, and how age-related changes can lead to 
cartilage damage and OA development.  
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Chapter 1. Introduction 
1.1 Osteoarthritis 
1.1.1Tear, flair and repair 
Osteoarthritis (OA) is a spectrum of degenerative disorders that become much 
more prevalent with age, to the extent that more than half of people aged over 
65 years suffer from the disease (Hugle et al. 2012).  It is a debilitating condition 
that primarily affects knee, finger, spine and hip joints, with the resulting 
damage causing disability for sufferers. The result is significant pain during 
even the most simple of tasks which greatly diminishes the patient’s quality of 
life. OA development was regularly accredited to a cumulative effect of load 
over a person’s life which results in “wear and tear” of the joint (Radin et al. 
1972). This led people to label OA as a natural consequence of ageing, 
meaning that development of potential treatments was improbable (Radin et al. 
1972). The result of this is limited treatment with no therapies that directly target 
the disease; instead the focus is on relieving symptoms and improving function. 
This is done through the use of painkilling medication in combination with 
physical therapy, as well as educating the patient to manage their weight, with 
the last resort being total joint replacement (Park and Choi 2016).  
Further research into OA has shown this idea of wear and tear to be inaccurate. 
Although age is the biggest contributing factor to OA development, it is a result 
of many age-associated changes, rather than the joint gradually wearing down 
over time. Current understanding is that it best fits the theory of “tear, flair and 
repair”(Hugle et al. 2012). In this explanation “tear” refers to what was 
previously thought to be the causes of OA such as obesity, excessive usage or 
misaligned joints. “Flair” encompasses the roles of inflammation and “repair” 
covers the ability of the joint to recover from damage or create new tissues.  
This change in thinking towards OA has led to more research and in recent 
years our understanding has greatly increased, making the possibility of 
therapeutic intervention much more credible. Where and when to target in OA 
progression remains difficult due to the multifactorial nature of OA development 
(van der Kraan and van den Berg 2008). OA has both mechanical and 
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molecular causes. Therefore, increasing knowledge of both these causes as 
well as how they interact will be key in developing therapies for OA.  
Age can affect the “tear”, “flair” or “repair” components of development. Studies 
have demonstrated that a person’s gait as well as the morphology of their joint 
can change as they age, resulting in extra damage (Pai et al. 1997). They 
suggest this is a result of age-related muscle degeneration, especially around 
the joint region resulting in altered biomechanics that leads to damage (Waters 
and Baumgartner 2011). Obesity can be a major cause for OA, not just because 
of the excess load on joints, but also because of a change in cytokine 
expression that can result in OA development (Thijssen et al. 2014). Many older 
individuals are in situations where they have both obesity and altered 
biomechanics which can in turn exacerbate the effect obesity has.  
1.1.2 Cartilage  
The hallmark of OA development is the proteolytic degradation of articular 
cartilage, a resilient and smooth elastic tissue needed for the low friction 
movement of synovial joints (Mort and Billington 2001). The resulting damage 
leads to pain in patients during movement. 
1.1.2.1 Extracellular matrix 
Cartilage is made up of three regions: the superficial tangential zone, the middle 
transitional zone and the deep zone. All three of these regions are made up of 
different quantities of the primary components of cartilage: water, collagen, 
proteoglycan and non-collagenous proteins (Fig 1.1). Water is the most 
abundant making up 80% of the wet weight of cartilage (A. J. Sophia Fox et al. 
2009). Water functions to transport nutrients and minerals through the cartilage 
as well as providing lubrication and structural support by supplying functional 
resistance in the tissue (Linn and Sokoloff 1965). Collagen is the most abundant 
structural macromolecule in the extracellular matrix (ECM). Type 2 collagen 
makes up 90-95% of collagen found but types 1,4,5,6,9 and 11 are also 
present, altogether making up 60% of the dry weight of cartilage (A. J. Sophia 
Fox et al. 2009). The less abundant collagens serve to stabilise the type 2 
collagen structures (Maroudas 1979) (Fig 1.1). The role of collagens is to 
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stabilise the matrix whilst also providing tensile and shear strength to the tissue 
(Maroudas 1979). Proteoglycans are heavily glycosylated protein monomers. In 
articular cartilage they make up 10-15% of the dry weight and are divided into 
aggregating and nonaggregating proteoglycans (A. J. Sophia Fox et al. 2009). 
The most abundant is aggrecan, which provides cartilage with osmotic 
properties that allow it to resist compressive loads (Buckwalter et al. 1990). The 
nonaggregating proteoglycans interact with collagen to help facilitate a variety 
of functions such as fibrillogenesis and interfibril interactions (Buckwalter et al. 
1990) (Fig1.1). Type 2 collagen fibrils form interwoven networks that provide 
tensile strength, whilst the proteoglycans embedded within the matrix draw in 
water that allows cartilage to resist compression (Dingle et al. 1987). Figure 1.1 
illustrates how collagen and aggrecan interact in cartilage. Destruction of both 
collagen and aggrecan in OA sufferers means they suffer discomfort during 
activities that cause compression, such as walking, demonstrating why OA is 
such a debilitating condition (Silman AJ 2001; Park and Choi 2016).  
Figure 1 1 Internal structure of articular cartilage. Illustrates the interactions 
inside of the cartilage extra-cellular matrix. Type 2 collagen and Aggrecan are the 
largest components and interact to give cartilage its structure and properties. Taken 
from (Alice J. Sophia Fox et al. 2009) 
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Although proteoglycan degradation is problematic for cartilage, damage can be 
reversed after the removal of the stimulus (Mort and Billington 2001). Type 2 
collagen, on the other hand, cannot be resynthesised so any damage to the 
tissue is irreversible (Mort and Billington 2001). The ability of cartilage to repair 
is low due to a lack of progenitor cells. As a result, mesenchymal stem cells are 
believed to be vital in the homeostasis and repair of the connective tissues 
(Chang et al. 2011). As we age there is a decrease in not only the amount of 
stem cells, but also their ability to propagate, which leaves joints less able to 
react to, or recover from, damage to the connective tissues (Chang et al. 2011). 
How the joint region changes is illustrated in Figure 1.2. A change in the bone 
and cartilage morphology leads to an obvious inflammatory response and 
exposed bone that can cause pain for the patient during movement.   
 
Figure 1.2 Transition from homeostasis to osteoarthritis. Healthy articular cartilage 
(left) undergoes a number of phenotypic changes resulting in the development of 
osteoarthritis. During OA development chondrocytes become activated instead of being 
quiescent. The resulting changes to all three of the cartilage regions as well as 
subchondral bone results in a painful joint that can no longer function as required. The 
increase in cartilage calcification, surface fibrillation and chondrocyte clusters all contribute 
to degradation in cartilage matrix. Adapted from Goldring (2012) 
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1.1.2.2 Chondrocytes  
Chondrocytes are the only cell type found in healthy cartilage. They are highly 
specialised, secreting all the structural components of cartilage. This essentially 
localises chondrocytes, as the matrix they secret restricts their ability to migrate 
to other areas (Dingle et al. 1987). Restricted movement results in chondrocytes 
maintaining that area of cartilage. Throughout life, chondrocytes allow 
remodelling of cartilage by facilitating degradation then replenishing 
macromolecules (Buckwalter et al. 2005). They are responsible for cartilage 
homeostasis and must secrete both anabolic and catabolic molecules 
(Buckwalter et al. 2005). Throughout this thesis I will refer to anabolic and 
catabolic changes. Figure 1.3 summarises how these changes can cause or 
prevent cartilage damage. When this system becomes dysregulated most 
commonly, but not exclusively, by ageing or injury-based inflammation 
chondrocytes can no longer maintain or restore cartilage.  
Figure 1.3 How anabolic and catabolic changes can affect cartilage. Signalling 
pathways can lead to the maintenance of healthy cartilage or its destruction. Stable 
quiescence refers to the state that healthy chondrocytes are held in, prior to 
terminal differentiation or hypertrophy. Aggrecan degradation is reversible whilst 
degradation of Collagen 2 is permanent.  
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Although proliferation in chondrocytes is rarely seen, even in healthy joints, 
there is a level of senescence induced with age. In vitro proliferation of cells 
from young donors differs to those from OA patients, the latter showing no signs 
of proliferation (Dozin et al. 2002). As proliferation is low, telomere shortening is 
not predicted to be the major driver of this senescence. Instead it is believed to 
be a result of oxidative stress, because reduced expression of oxygen 
scavengers such as superoxide dismutase has been shown in OA cartilage 
(Regan et al. 2005). 
Evidence suggests age driven alterations in chondrocyte metabolism and signal 
transduction aligns with OA development (Cravero et al. 2009; Davidson et al. 
2009). This is when degeneration of the articular cartilage and development of 
OA becomes evident.  
Chondrocytes are an unusual cell type as they are in, and prefer, a constant 
state of hypoxia. These cells are exposed to oxygen ranging from 10% at the 
surface to less than 1% in the deep zones (Silver and Maroudas 1975). They 
produce more aggrecan and type 2 collagen under hypoxic conditions, and also 
have lower synthesis of cartilage-degrading molecules, when compared to 
normoxia (Strobel et al. 2010). Not just surviving, but thriving in these 
conditions, means that chondrocytes have had to develop regulatory pathways 
for hypoxic conditions. Hypoxia inducible factor 1 (HIF-1) is believed to be key 
in maintaining correct homeostasis in these conditions (Houard et al. 2013). 
Under normoxia HIF-1 levels are low because hydroxylation leads to 
ubiquitination and proteolytic inactivation, whereas hypoxic conditions allow 
HIF-1 levels to stay high. Inflammatory stimuli can also increase HIF-1 levels 
leading people to believe it is not just a hypoxia gene but a so-called “stress 
responder” that can help to maintain chondrocytes in unfavourable conditions 
(Mariani et al. 2014). Similarly to HIF-1, HIF-2 is upregulated under hypoxic 
conditions and appears to have an anabolic effect in cartilage, by signalling 
through SOX9 (Thoms et al. 2013). Conversely, it can also lead to catabolic 
changes and has been shown to have a role in OA development, upregulating a 
variety of matrix-degrading enzymes (Yang et al. 2010). 
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1.1.2.3 Cartilage formation and maintenance 
The importance of cartilage combined with its limited ability to self-repair means 
that both its formation and maintenance must be tightly regulated, as any 
change to homeostatic conditions results in a significant loss that cannot be 
replaced (Mort and Billington 2001). Due to the importance of maintenance it is 
regulated with a high level of complexity by a multitude of interacting pathways. 
Dysregulation of these pathways often leads to OA-like phenotypes, so 
examining the maintenance pathways often highlights how distorted regular 
signalling can become during a multifaceted disease such as OA. 
The transforming growth factor β (TGFβ) superfamily, including bone 
morphogenetic proteins (BMPs), play a major role in chondrocyte phenotypic 
changes and differentiation progression. TGFβ can hold chondrocytes in stable 
quiescence preventing terminal differentiation, whilst also leading to the 
upregulation of aggrecan and collagen type 2 production (Yang et al. 2001). 
BMPs are important in the regulation of all stages of chondrogenesis (Nishimura 
et al. 2012); their effect mainly being mediated through the master regulator of 
chondrogenesis SOX9 (Pan et al. 2008). BMP signalling can also activate 
chondrocyte proliferation and matrix synthesis, making the BMPs important in 
protecting against cartilage damage. Blocking BMP activity has been shown to 
result in increased damage for mouse models (Horiki et al. 2004; Lories et al. 
2006). Conversely, both TGFβ and BMP when bound to certain receptors can 
induce MMP-13 expression, as well as chondrocyte terminal differentiation 
leading to cartilage damage by signalling through SMADs 1/5/8 (Papathanasiou 
et al. 2012; Blaney Davidson et al. 2009). Insulin-like growth factor 1 (IGF-1) is 
a potent inducer of matrix metabolism, and introduction to monolayer or explant 
cultures induces a plethora of anabolic changes including: matrix synthesis, 
augmented proliferation and differentiation of progenitor cells, and maintenance 
of chondrocytes in hypertrophy (Papathanasiou et al. 2012; Fukumoto et al. 
2003).  IGF-1 introduction also blocks catabolic responses in both these 
cultures (Goodrich et al. 2007). IGF-1 and TGFβ have been shown to interact. 
TGFβ induces chondrogenesis but this effect is both strengthened and 
expanded upon addition of IGF-1, allowing greater matrix production than either 
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individually (Rosselot et al. 1994). TGFβ can also increase the amount of IGF-1 
receptors enhancing its impact (Yaeger et al. 1997). IGF-1 loses potency in old 
and OA tissues resulting in it no longer being able to reduce catabolic activity, 
although it can still result in some matrix synthesis when combined with BMP-7 
(Loeser et al. 2002; Chubinskaya et al. 2007).  
Other critical cartilage maintenance pathways are Wnt/β-Catenin, Nuclear 
Factor-Kappa B (NF-κB), Hedgehog (Hh)/Smoothened (Smo) and the Mitogen-
Activated Protein Kinase (MAPK) Pathways. Wnt signalling is comprised of 
multiple proteins that mediate several Wnt pathways. Wnt/β-Catenin however, 
has specific roles in chondrogenesis, chondrocyte differentiation and most 
importantly the cross-talk between cartilage and subchondral bone required for 
the development of both to form an effective joint (Usami et al. 2016). The 
relevant MAPK pathways are c-Jun N-terminal kinase (JNK), p38 and 
extracellular signal-regulated kinases (ERK-1/2). All three have distinct roles in 
cartilage matrix synthesis and homeostasis (Berenbaum 2004). NF-κB is 
important in the remodelling of the extracellular matrix, as well as bone 
resorption (Rigoglou and Papavassiliou 2013). Hh is expressed as a response 
to mechanical stress (Ng et al. 2006) in the growth plate and has roles in 
chondrogenesis, chondrocyte proliferation and regulating the rate of 
hypertrophy (Chen et al. 2008). All of these pathways can lead to OA if 
dysregulated, either by an inability to perform their normal anabolic changes or 
because they lead to catabolic activity. Their interactions are very important in 
making sure they have the desired effect but if one or more are severely 
dysregulated it can lead to problems in the others. This is when OA 
development becomes apparent.  
1.1.3 Subchondral bone 
Subchondral bone refers to the bony components that lie distal to calcified 
cartilage. These are made up of both subchondral bone plate and subchondral 
trabecular bone (G. Li et al. 2013). Changes in subchondral bone can underpin 
both the initiation of OA as well as the progression towards late stage OA (G. Li 
et al. 2013).  It is a very dynamic structure that has become adapted in order to 
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respond to mechanical forces and stresses, by means of bone modelling and 
remodelling (Yuan et al. 2014). Bone remodelling is essential to retain structural 
integrity, allowing the bone to repair damage and maintain homeostasis of 
calcium and phosphorous metabolism (Kini and Nandeesh 2012). The 
resorption and formation of bone occurs at specific sites and follows a well-
defined sequence of events (Kini and Nandeesh 2012). In early OA an increase 
in bone remodelling and subchondral bone loss occurs, which results in an 
altered joint shape that can affect load transmission in a way that causes 
excess cartilage destruction (Guangyi Li et al. 2013). By late stage OA a further 
increase in bone remodelling, combined with a slow turnover, results in 
densification of the subchondral plate and eventually complete loss of cartilage 
(Yuan et al. 2014). These changes in bone structure also lead to the formation 
of osteophytes. These bony appendages that form as outgrowths of cartilage on 
bone under diseased conditions (van der Kraan and van den Berg 2007) cause 
discomfort in patients (Yuan et al. 2014).  
1.1.4 Mechanical stress 
The ability of articular cartilage to respond to mechanical simulation is important 
in maintaining joint integrity (Castrogiovanni and Musumeci 2016). It distributes 
force across the joint whilst also providing a smooth lubricated surface that can 
facilitate movement; all of this ultimately reduces damage (Castrogiovanni and 
Musumeci 2016). In response to mechanical simulation cartilage can produce 
both anabolic and catabolic molecules (Responte et al. 2012) (Fig 1.3). The 
duration or the extent of loading can affect its response, as well as the age of 
the tissue or its morphology (Responte et al. 2012). Components of the ECM 
are altered during loading. For example, water is gradually expelled from 
tissues. This is designed so cartilage can withstand a lifetime of cyclic loading 
(Coleman et al. 2013).  
Chondrocytes have a pluripotent response to loading depending on its 
frequency and intensity. How they respond can be vital for chondrocyte survival 
(Buschmann et al. 1999). A sedentary life-style can cause static loading which 
results in little or no strain on the joint. Chondrocytes respond to this by both 
reducing protein synthesis but also increasing catabolic pathways resulting in 
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cartilage degeneration (Sanchez-Adams et al. 2014).  In response to a normal 
load that is cycled throughout the day (not constant), chondrocytes will promote 
matrix synthesis, reduce proinflammatory pathways and also stimulate anti-
catabolic pathways (Sanchez-Adams et al. 2014). In response to heavy load, 
either cyclic or acute, chondrocytes will increase matrix degradation, apoptosis 
and necrosis. An acute stimulus will also increase proinflammatory cytokines 
and inflammatory mediators (Sanchez-Adams et al. 2014). The transduction of 
strain into physiological responses is mediated in a number of ways including 
ion channels (Mobasheri et al. 2005), integrins (Millward-Sadler and Salter 
2004) and internal structures such as cilia (Wann et al. 2012). These signals 
lead to activation of a number of pathways including, but not limited to, 
TGFβ/Smad, FOS like 1 (FOSL1), Hedgehog signalling, E2F transcription factor 
1 (E2F1) and protease-activated receptor 2 (PAR-2) signalling (S. Dunn et al. 
2016; Correa and Lietman 2017; Sanchez-Adams et al. 2014). Latent TGFβ can 
also be activated directly by the shearing of synovial fluid which happens during 
regular movement (Albro et al. 2012). The shear activation of TGFβ appears 
important in the metabolic activity of cartilage, specifically synthesising DNA 
and ECM proteins, whilst also inhibiting the catabolic effects of IL-1, tumour 
necrosis factor-alpha (TNF-α) and more generally MMPs (Albro et al. 2012). It 
also induces the loss of proteoglycans (Albro et al. 2012), which as long as it is 
not in excess is useful for the normal turnover of healthy cartilage. All of these 
effects help to maintain the integrity of cartilage.  Despite this, excess active 
TGFβ can have negative effects leading to inflammation, cartilage damage and 
osteophyte formation. TGFβ can also have these negative effects in aged 
tissue, without being in excess. It has been shown in aged tissue when joints 
are sufficiently loaded to activate TGFβ, it signals through catabolic rather than 
anabolic signalling pathways (Madej et al. 2013)(Fig 1.3).  
1.1.5 Aggrecanases  
Aggrecanases are proteolytic enzymes that target large proteoglycans such as 
aggrecan. Early in OA development there is a degradation of aggrecan. 
Originally it was believed that Cathepsin D was the major aggrecanase that was 
responsible for this degradation, because of studies showing its activity was 
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upregulated in OA cartilage, and inhibition of it prevented cartilage degradation 
at pH5 (Sapolsky et al. 1973). Later it was discovered that OA cartilage has a 
neutral pH and Cathepsin D does not have any effect at neutral pH (Woessner 
1973). Although now firmly established as collagenases, Matrix 
metalloproteinases (MMP)s were originally explored as important 
aggrecanases. This was because they were shown to not only degrade 
proteoglycans at neutral pH but also to be present in both cartilage and bone 
(Galloway et al. 1983). However, MMPs cleave proteoglycans at the 
Asn341~Phe342 bond (Fosang et al. 1996). It was later discovered that in the 
synovial fluid of OA patient the majority of Aggrecan fragments where cleaved 
at the Glu373~Ala374 rather than Asn341~Phe342 (Lark et al. 1995). It was also 
found that tissue inhibitors of metalloproteinases (TIMP) could not block the 
cleavage at this site, implying that something other than MMPs was cleaving 
proteoglycans in OA patients (Little et al. 2002). 
This led to the discovery of A Disintegrin and Metalloproteinase 
with Thrombospondin motifs (ADAMTS), proteases which are zinc-dependant 
enzymes comprise of a N-terminal pro-domain, a catalytic domain, a disintegrin 
domain, one or more thrombospondin (TS) motifs, a cysteine-rich domain and a 
spacer domain of variable length (Kelwick et al. 2015). ADAMTS-4 was the first 
to be purified from IL-1-stimulated bovine cartilage (Tortorella et al. 1999) but 
since then many others have be discovered. ADAMTS 4 and 5 are considered 
to be the most activate aggrecanases and therefore most responsible for the 
Glu373~Ala374 cleavage in OA development (Sandy and Verscharen 2001; Little 
et al. 2007). Knocking out or blocking ADAMTS5 in mice leads to a reduction in 
OA severity (Glasson et al. 2005). The same is not true for ADAMTS-4 or -1 
(Little et al. 2005; Glasson et al. 2004). However, there is some evidence that 
ADAMTS-4 is important in human cartilage degradation, making ADAMTS-4/5 
the leading aggrecanase targets in OA drug development (Song et al. 2007).  
1.1.6 Collagenases 
Collagenases are enzymes that destroy peptide bonds in collagen, destroying 
extra-cellular structures in the case of OA cartilage. Whilst it is difficult to 
ascertain the exact order that cartilage matrix components are degraded, 
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studies suggest that Aggrecan protects from collagen degradation and must be 
degraded before collagen (Pratta et al. 2003). This being said, once collagen is 
degraded it cannot be reversed (unlike aggrecan) so any damage done is 
permanent. Fibrillar collagen can only be degraded by a relatively small number 
of mammalian enzymes; cathepsin K and  MMPs -1,-8,-13 and -14 (Linda 
Troeberg and Hideaki Nagase 2012). MMP-13 is thought to be the collagenase 
that has the biggest role in OA development (Neuhold et al. 2001). It is 
upregulated in OA tissues and has been shown to induce spontaneous cartilage 
damage in mice, with MMP-13 null mice being protected against OA 
development (Little et al. 2009). It is believed that MMP-1 is also highly 
important but it is more difficult to study as the murine MMP-1 homolog varies 
greatly from human MMP-1 (Balbıń et al. 2001). MMP activity is limited by their 
endogenous inhibitors TIMPs, which bind to and inhibit pro and active MMPs 
(Brew et al. 2000). The two domain TIMPs are a family made up of four proteins 
TIMP-1,-2,-3 and -4. TIMPs all have strong binding efficiencies for MMPs; some 
can also inhibit other molecules such as ADAMTS. 
MMPs are calcium-dependent, zinc-containing endopeptidases, that are made 
up of three regions: one pro-peptide, the catalytic domain, and the haemopexin-
like C-terminal domain linked by a hinge region (Massova et al. 1998). The pro-
peptide is present on the newly synthesised MMPs (known as pro-MMPs) and 
must be cleaved in order for the enzyme to become active (Massova et al. 
1998). The C-terminal domain is thought to be involved in protein-protein 
interaction. It determines substrate specificity and is also where TIMPs bind and 
regulate MMPs (Kjeldsen et al. 1993). Finally, the catalytic domain contains the 
active site which requires zinc to be bound to its three histidine residues found 
in the conserved sequence HExxHxxGxxH (resulting in the name zinc-binding 
motif) (Cerdà‐Costa and Xavier Gomis‐Rüth 2014).  
Due to the incredibly damaging effect of MMPs on collagen, drugs that inhibit 
them have long been desired in order to slow down or prevent OA progression 
(Wang et al. 2015). Problems arise because catalytic sites of MMPs are highly 
homologous, meaning drugs that target them are rarely specific and lead to off 
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target effects (Wang et al. 2015). MMP-13 is unique because it has a deep S1′ 
subsite; this has been suggested as a target for more specific MMP-13 
inhibitors (Wang et al. 2015). LS 1-0635 is an MMP-13 inhibitor that has proven 
chondroprotective effects. Unfortunately it causes noticeable musculoskeletal 
toxicity in rats (Janusz et al. 2006). PF152 is another inhibitor which in canine 
models reduced cartilage lesions, decreased biomarkers of type II collagen and 
aggrecan degradation and inhibited human cartilage degradation ex vivo in a 
dose-dependent manner (Settle et al. 2010). In some areas up to an 85% 
decrease in disease progression was seen (Settle et al. 2010). There is no 
denying that these drugs have chondroprotective effects in animal models. 
However, the off target effects need to be addressed before moving to human 
patients. 
MMP-3, despite not being an active collagenase, is important to collagen 
destruction. It is highly upregulated in OA tissue and can activate pro-MMPs, 
making it important in activating latent MMP-1 and -13 (Swingler et al. 2009). 
Mice null in MMP-3 are protected against both collagen loss and aggrecan 
cleavage at Asn341~Phe342 (Van Meurs et al. 1999). Despite this, it has been 
shown that these null mice can develop more severe surgically-induced OA  
(Clements et al. 2003). Signifying MMP-3’s role in OA is not as apparent as it 
initially appears. MMP-3, although important in activating both collagenases and 
aggrecanases appears to also have cartilage-protecting effects in some 
situations (Clements et al. 2003).  
TIMP-3 is seen as the central inhibitor of cartilage degeneration as it can 
inactivate ADAMTS4 and 5 (Kashiwagi et al. 2001).  Addition of TIMP-3 can 
limit cartilage damage for explant culture (Gendron et al. 2003), which is not 
seen when repeated with TIMP-1 or -2. TIMP-3 can also block cartilage 
degradation in a rat surgical model (Black et al. 2006). Reduced levels of TIMP-
3 are seen in OA tissue with no change in mRNA, suggesting  degradation of 
TIMP-3 is increasing with age in chondrocytes (Morris et al. 2010). TIMP-2 has 
little or no effect on explant culture whilst TIMP-1 can block glycosaminoglycan 
release but only in human explants (Gendron et al. 2003). TIMP-4 shows 
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decreased expression in OA tissues and a single nucleotide polymorphism has 
been linked to OA development (Lee et al. 2008). Unfortunately, despite all of 
this, the MMP inhibitory effect of TIMPs appears to be low in OA cartilage, with 
attempts to regulate MMP overproduction with TIMPs having little clinical effect 
(Clutterbuck et al. 2009). 
1.1.7 Inflammation 
It was originally believed that OA was a non-inflammatory arthropathy, but it has 
since been shown that inflammation plays both chronic and acute roles in the 
development of OA (Shen et al. 2017). Chronic low grade inflammation starts to 
develop as we age. This has been linked to pain and function in ageing adults 
that have OA (Stannus et al. 2013). The term inflamm-ageing was first 
presented by Franceschi et al. (2000) and refers to the increasingly pro-
inflammatory environment that can occur with age. They proposed that the 
macrophage played a central role as the pro-inflammatory mediator, having a 
more potent effect as we age.  Further studies have shown that there is more 
than just an increase in pro-inflammatory markers. Anti-inflammatory cytokine 
IL-10 is decreased in many patients, but there is an increase in several other 
anti-inflammatory markers (Morrisette-Thomas et al. 2014). Morrisette-Thomas 
et al. (2014) used principle component analysis to show how these markers 
correlated with disease. They found two groups, one that correlated with age, 
mortality and disease state, and another group that correlated with the innate 
immune system, age and chronic disease (including OA). Surprisingly, this 
second group was actually representative of protection from disease. 
Morrisette-Thomas et al. (2014) suggested age-related inflammation will result 
in the upregulation of pro- and anti-inflammatory mediators and the balance of 
these factors will determine an individual’s susceptibility to age-related disease. 
Inflammation can drive the expression of collagenases and under normal 
conditions this can be important in the healthy turnover of matrix components. 
As shown by increased accumulation of type II collagen in MMP-13 knockout 
mice (Masaki Inada et al. 2004). However, a number of factors can contribute to 
increased inflammation with age, such as senescent cells which become more 
prevalent with age and also secrete inflammatory mediators (Greene and 
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Loeser 2015). Obesity contributes by increasing load on joints whilst also 
leading to adipose-induced inflammatory cytokine production (Greene and 
Loeser 2015).  Age-related changes to joint tissues and surrounding bone can 
all be affected by age and this change can result in increased inflammation 
(Greene and Loeser 2015). Over-activity of chemokines can activate catabolic 
pathways and cause chondrocyte hypertrophy (Houard et al. 2013). Damaged 
matrix itself can also lead to the activation of Toll-like receptors, which in turn 
can upregulate pro-inflammatory mediators and reactive oxygen species 
leading to further damage (Houard et al. 2013).  
Inflamed synovium and activated chondrocytes can result in the overproduction 
of cytokines and growth factors that can cause joint damage leading to OA 
development. The main pro- and anti-inflammatory cytokines in OA are 
considered to be; pro-inflammatory - IL-1, 6, 8, 15 and 17, TNF-α and anti-
inflammatory- IL-4, 10, 11 as well as IL-1 receptor antagonist (IL-1Ra) (Rahmati 
et al. 2016). This is not an exhaustive list but they have all frequently been 
reported to be elevated in OA patients.  
An increase in anti-inflammatory cytokines and growth factors such as IL-4,-10,-
13 and TGFβ is observed in synovial fluid taken from OA patients (Martel-
Pelletier et al. 1999; Sutton et al. 2009). Their effect is mediated in a number of 
different ways to counteract the effect of the pro-inflammatory cytokines and 
growth factors. This includes feedback that reduces the expression of their 
opposite numbers, competing with receptors to reduce pro-inflammatory effects, 
and/or actively targeting downstream factors that may be produced (Sutton et 
al. 2009). The effect of anti-inflammatory cytokines or growth factors can be 
changed during injury or age. When this happens or the balance of anti to pro-
inflammatory mediator changes in patients, OA begins to develop. Therefore, 
discovering the core reasons for these changes could be key in finding potential 
therapies for OA. 
1.1.7.1 TGFβ 
TGFβ signalling is unique in that it can have both catabolic and anabolic affects 
depending on which of its receptors it activates. In healthy cartilage TGFβ 
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signals through both Activin A Receptor Like Type 1 (ACVRL1 or ALK1) and 
TGFβ receptor 1 (ALK5). However, it predominantly signals through AlK5 which 
leads to Smad 2/3 phosphorylation which then blocks terminal differentiation, 
chondrocyte hypertrophy and also stimulates the production of matrix 
components (Blaney Davidson et al. 2009).  Problems arise if the balance is 
switched towards ALK1 signalling which causes increased Smad 1/5/8 
phosphorylation. This mediates the opposite effects to SMAD 2/3 leading to 
chondrocyte hypertrophy, terminal differentiation and matrix breakdown by 
MMPs such as MMP-13 (Blaney Davidson et al. 2009).  Age has been 
suggested as the major driving factor for conversion from ALK5 to ALK1 
signalling; highlighting how dysregulation can occur in the aging system (W. Hui 
et al. 2014). This change can also be mediated by crosstalk with other 
pathways: Wnt signalling, for example, has been shown to effect the expression 
of a number of proteins downstream that can skew TGFβ signalling towards the 
catabolic ALK1 pathway (M. H. van den Bosch et al. 2014).  
In OA development it has been shown on multiple occasions that the addition of 
TGFβ can prevent cartilage breakdown by pro-inflammatory mediators such as 
IL-1 and OSM. This effect is believed to be the result of not only down 
regulation of MMPs but also maintaining levels of TIMPs (Hui et al. 2003, 2001, 
2000). Despite the positive effect TGFβ can have on cartilage, blocking its 
activity in an OA model results in a reduction of osteophyte formation 
(Scharstuhl, Glansbeek, et al. 2002), suggesting a negative effect in bone. 
Genetic studies have shown that mutations in in TGFβ signalling can lead to OA 
susceptibility in patients. Microarray studies have also consistently highlighted 
the increase in ALK1/ALK5 ratio being important during OA development across 
a range of organisms.  
The conflicting effects of TGFβ make it a fascinating area of research. Its ability 
to protect the chondrocytes not only diminishes with age but an increase in 
ALK1 signalling makes it detrimental. This combined with its negative effects in 
bone make it an attractive target for combating OA. Understanding not only 
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where but at what time to target this TGFβ signalling may be vital for developing 
therapeutics.   
1.1.7.2 Notch  
There are 4 notch single-pass transmembrane cell surface receptors (notch 1-4) 
which become activated upon binding with membrane ligands Delta-like 1,2 and 
4 or jagged 1 and 2 (D'Souza et al. 2010). Once bound the notch receptor is 
cleaved by proteinases resulting in the Notch intracellular domain (ICD) being 
released into the cytoplasm. It then translocates to the nucleus where it forms a 
complex with the recombination signal binding protein for Ig kappa J (RBPjκ), 
becoming active and inducing the expression of many downstream target genes 
(Kopan and Ilagan 2009).  
The expression of notch-related molecules (notch, delta and jagged) was 
examined in cartilage dissected from both normal and osteoarthritic patients. 
These molecules were found to be greatly overexpressed in comparison to 
healthy tissue, with their peak expression localised to the most damaged areas 
(Mahjoub et al. 2012).  Its involvement in OA was further confirmed by Sassi, 
Gadgadi, et al. (2014) who showed that blocking notch signalling in OA 
chondrocytes could reduce the presence of OA markers, including MMP-13, 
whilst simultaneously upregulating healthy cartilage indicators aggrecan and 
collagen 2.  
How exactly the Notch pathway contributes to OA is unclear but it affects 
chondrocytes in a number of different ways. Differentiation has shown to be 
regulated by the RBPjk pathway (Kohn et al. 2012) playing a vital role in 
endochondral ossification (a key component of physiological skeletal growth). 
Dysregulation of Notch signalling can lead to chondrocytes undergoing 
hypertrophic differentiation, followed by the conversion of cartilage tissue into 
bone tissue. Ultimately this leads to destruction of the matrix as well as causing 
eroding of the joint surface (Hosaka et al. 2013). Results from transient and 
constant gain of function mice (Liu et al. 2015) showed that constant Notch 
signalling resulted in OA development, but transient activation could lead to 
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protection. Despite this, transient Notch activation increases damage in the 
event of injury.  
1.1.7.3 PKC 
Protein kinase c (PKC) represents a family of serine/threonine kinases that 
were first  identified during the purification of kinases from bovine cerebellum 
(Takai et al. 1977) and have since been divided into 3 groups of isoforms; 
Conventional PKC (α, βI, βII, and γ), novel PKC (δ, ϵ, η, θ) and atypical PKC (ζ, 
ι) (Griner and Kazanietz 2007). PKC has been linked to multiple different 
processes that contribute to OA development. It has been shown to increase 
signalling in both early and late stage OA. A further increase during late stage 
suggests it may play a role in increasing chondrocyte apoptosis (Q. Chen et al. 
2012).  
Cartilage can be damaged during joint injury and this causes a release of 
fibroblast growth factor (FGF). This leads to activation of PKC, which through a 
series of cross signalling events leads to the upregulation of MMP-13 and 
further cartilage damage (Im et al. 2007). Similarly, PKC has been shown to 
play a role during inflammation-driven MMP-13 expression, as blocking its 
activity during treatment with the potent cytokine stimulus IL-1+OSM reduces 
the upregulation of MMP-13 (Litherland et al. 2010).  
Despite this, PKC has been shown on multiple occasions to have a protective 
effect under mechanical strain. Both Hamanishi et al. (1996) and Yeh et al. 
(2009) showed that PKC was downregulated under mechanical stress in OA 
tissues. Hamanishi et al. (1996) experimentally induced mechanical strain in the 
knees of rabbits, which would normally lead to an OA like phenotype. However, 
adding a potent upregulator of PKC, 12-O-Tetradecanoylphorbol-13-Acetate 
(TPA) for three weeks post operation saw an almost complete preservation of 
cartilage. Yeh et al. (2009) looked at both SW1353 and osteoarthritic cells 
under varying levels of mechanical stress. They found that the levels of PKC 
fluctuated and this coincided with an increase in levels of plasminogen activator 
inhibitor-1 (PAI1), a gene which has a protective effect on chondrocyte cells.   
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1.1.7.4 Indian Hedgehog 
Indian Hedgehog (IHH) binds to its receptor patched allowing the release of 
Smo protein into the cytoplasm. Smo can then move to the cilia where it is 
phosphorylated by casein kinase 1 (CK1)/ G-protein coupled receptor kinase 
(GRK2). This phosphorylation leads to a series of downstream signalling events 
that result in an activated version of the transcription factor Glioma-Associated 
Oncogene Homolog 1(Gli1), which can then increase the expression of a 
number of different genes that lead to OA development such as: MMP-13, 
Runx-2 and Col10a1.   
The primary cilium is present in chondrocytes and serves as a mechanosensory 
organelle that can transduce mechanical signals into a biological response 
(Shao et al. 2012). One such response is an increase in IHH expression. This is 
almost exclusively linked to an increase in hydrostatic pressure; thus provides 
evidence of a mechanism by which abnormal loading (obesity or injury) can 
result in OA development. It has been demonstrated on a multitude of 
occasions that increasing the pressure on chondrocyte cell cultures leads to an 
upregulation of IHH. The increased IHH correlates with changes in chondrocyte 
morphology and OA progression by increasing expression of genes that leads 
to cartilage degradation and chondrocyte hypertrophy (Wei et al. 2012; Shao et 
al. 2012). By creating chondrocyte-specific knockout mice Zhou et al. (2014) 
demonstrated that IHH has a causative role in OA, rather than just being an 
artefact of increased pressure on the joint. These mice showed significantly less 
cartilage damage as well as a reduction in key OA markers MMP-13 and 
Col10a1.   
The IHH signalling pathway represents an exciting opportunity for future study 
as it is the primary biological response to increased mechanical stress. As 
mechanical stress can have both positive and negative effects, understanding 
IHH signalling may provide an insight into how pathway regulation is altered 
under different forms of stress.   
1.1.7.5 Wnt/β-catenin 
Wnt genes have consistently been some of the most highly expressed in OA 
tissues (Hopwood et al. 2007; Meng et al. 2005). This dysregulation of Wnt 
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signalling has been linked with early and late OA (Sassi, Laadhar, et al. 2014). 
The Wnt/ β-Catenin pathway has an effect on chondrocyte differentiation, 
cartilage matrix catabolism and chondrocyte apoptosis (Luyten et al. 2009). 
 
β-catenin is central to canonical Wnt signalling and under normal conditions is 
ubiquitinated for destruction by GSK-3β (M. Wang et al. 2011). However, when 
Wnt binds to Frizzled and its co-receptors LDL-receptor-related protein (LRP) 
5/6, it leads to alterations in the downstream signalling of both Dishevelled 
(Dsh) and Axins 1/2, resulting in the deactivation of GSK-3β (M. Wang et al. 
2011). This in turn allows the survival of β-catenin which migrates to the nucleus 
where it binds Lymphoid enhancer-binding factor-1 (LEF-1) / T-cell factor (TCF), 
causing an upregulation of target genes (M. Wang et al. 2011). 
 
Genetic studies have shown that people with altered Frizzled proteins are more 
susceptible to the development of certain forms of OA (Loughlin et al. 2004). 
Mice models expressing chondrocyte specific constitutively active β-Catenin  
demonstrated the role it can have in OA development (Wawra et al. 2007). After 
8 months these mice had many OA phenotypes including a complete loss of 
articular cartilage (Wawra et al. 2007). β-Catenin appears to mediate its affect 
through controlling chondrocyte maturation, osteophyte formation and MMP-13 
expression (Wawra et al. 2007). Despite this, there are reports that suggest 
high levels of β-Catenin may not be a cause of OA, but rather a consequence. 
Normal chondrocytes require low levels for certain functions. OA driven 
dedifferentiation may then lead to increased β-Catenin attempting to re-
establish these functions (Chun et al. 2008). Wnt/β-catenin also has reported 
interactions with a number of other pathways linked to OA such as: Indian 
hedgehog and TGFβ (Mariani et al. 2014; Baarsma et al. 2011). 
1.1.7.6 IL-1 +OSM Pathway  
 IL-1 is a multifunctional cytokine; it induces many systematic changes, altering 
gene expression in processes such as metabolism, neurology and 
endocrinology (Dinarello 1988). It is a potent pro-inflammatory stimulus that 
may be the principal cytokine in OA development as it results in the 
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upregulation of many matrix-degrading enzymes (Bellehumeur et al. 2009), in 
particular MMP-1 and -13. It can also stimulate its own upregulation by 
chondrocytes (Bellehumeur et al. 2009). IL-1Ra is produced to provide inhibition 
to IL-1 but reduced levels lead to damage and OA progression (Abramson and 
Amin 2002). Many drug studies have attempted to reduce the effect IL-1 has in 
joints, predicting that blocking its effect will reduce, if not elevate, OA in patients 
(Jotanovic et al. 2012). 
OSM is a pleiotropic cytokine that belongs to the IL-6 group of cytokines, 
regulating growth in a number of cell lines (Cawston et al. 1995). It signals 
though a series of cell surface receptors containing the protein gp130 (Richards 
2013). OSM upregulates chondroprotective elements such as TIMPs and was 
originally believed to provide protection against IL-1-mediated cartilage 
destruction. However, this was shown to be inaccurate as combining the two 
cytokines results in an increase in MMP production (Cawston et al. 1995) as 
well as increased cartilage damage. Raised levels of OSM were detected in 
rheumatoid and osteoarthritis synovial fluid correlating with joint inflammation 
(Cawston et al. 1998; Tsuchida et al. 2014). Blocking OSM also alleviates 
cartilage damage (Plater-Zyberk et al. 2001). This is because although OSM 
does not lead to damage alone it can synergise with IL-1, TNF-α and also 
retinoic acid, increasing the inflammatory response and damage caused by any 
of these pro-inflammatory mediators individually (Shingleton et al. 2006; 
Cawston et al. 1995; Hui et al. 2003).   
IL-1 alone can result in a rapid release of proteoglycans in cartilage, and this 
effect is obviously damaging but can be reversed upon the removal of stimulus.  
The combined effect of IL-1 and OSM is more damaging as it has been shown 
to result in the destruction of more than 90% of collagen from bovine cartilage at 
14 days (Milner et al. 2001). This degradation of collagen cannot be reversed 
and is most likely mediated by the potent increase and activation of MMPs by 
IL-1 and OSM, namely MMP-1/-13.   
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1.2 Computational modelling  
1.2.1 Advantages of a systems approach 
The complexity of the interactions between inflammatory pathways, along with 
their changing effects over time, will be difficult to fully ascertain but 
computational modelling may be a tool that could provide a wealth of 
information. Mapping the understood parts of the pathway and attempting to 
represent the unknown elements to replicate results can provide us with a 
testable hypothesis as well as a much deeper understanding of the importance 
of certain components. Searching for these interactions experimentally would 
not only be expensive but also labour intensive for potentially few results. 
Although model construction can be laborious and time consuming they provide 
an in-depth look at the pathways as well as a cost effective method of testing 
drug compounds or exploring pathway interactions. It has the added advantage 
that it can capture the two different states of the same system. Stochastic 
simulations can capture the changing nature of a system and highlight the 
moment when it changes from one form of signaling to another, whether this 
effect is gradual or instant.  
1.2.1.1 Successes of modelling  
Development of pharmaceutical interventions can be aided greatly by modelling 
for three major reasons. (i) They can show novel molecular functions by 
capturing signaling behaviors that would not normally be obvious. (ii) It allows 
you to change conditions with relative ease i.e. concentration of a receptor 
which would be very difficult to alter experimentally. You can then gain an 
understanding of what changes these effects may have with a smaller 
investment of both time and money. (iii) They provide an extensive overview of 
the signaling pathway, documenting many proteins involved, as well as how 
they interact. This can serve as a useful reference for anybody working in a 
similar area. 
Past studies have used models in complex situations to gain solutions for 
various problems. Zhao et al. (2013) developed models that allow them to study 
individual cancer subtypes with the same model structure. Using these they 
looked at three different breast cancer metastases: brain, lung and bone. They 
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identified that for each metastasis there were different protein and drug targets. 
By comparing them they found some targets specific to all of them. After 
validating these targets experimentally they found two current drugs that could 
be repositioned for treatment of these cancers: Sunitinib (for which a clinical 
study is now at stage 2) and Dasatinib (Zhao et al. 2013). AstraZeneca also 
improved a cancer drug Iressa by linking the efficacy of the drug to impaired 
receptor internalisation and reliance on downstream AKT signalling (Hendriks et 
al. 2006). As well as directly finding drug targets, modelling can aid in the 
design of optimal functioning drugs. Antisense oligonucleotides can work as 
targets to RNA to have beneficial effects. However, their design is confusing as 
chemical modifications can increase potency normally, but sometimes making 
them smaller and lower affinity can have a similar effect. Pedersen et al. (2014) 
made a model of their binding that allowed a better understanding of this finding 
in what they called the “optimal binding affinity”. Experiments supported their 
finding allowing them to advise the best way to apply modifications to create 
potent oligonucleotide drugs.  
1.2.2 Modelling complex systems 
Simulating complex biological pathways is a goal that can be difficult to achieve 
and because of this there have been a number of approaches utilised to 
facilitate model development. Deciding which of these approaches to follow is 
not always obvious, as multiple techniques can be used for the same problem. 
These techniques include ordinary differential equations (ODEs), Boolean 
network, Petri nets (PN), linear programming (LP) based model and agent-
based models (ABM) (Ji and Yan 2017). A good model must be sufficient in 
replicating the data it was built upon and formulating predictions on independent 
data. Prior understanding of the previously mentioned methods can allow one to 
make a justified model that can generate sensible hypotheses for further study.  
1.2.2.1 Petri network models 
PN type models have been used to model systems such as EGF signalling (Lee 
et al. 2006). They work by having two nodes; places and transitions (commonly 
represented as circles and boxes). Places change in the model through the use 
of transitions; they can be either inputs or outputs of transitions (known as arcs). 
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Each arc has a required number of tokens to be activated. Signalling cascades 
are represented by imputing a number of tokens as a signalling input. These 
can then be separated throughout the model to form outputs. PN can be used to 
simulate signalling pathways and gene regulatory networks concurrently, 
asynchronously, distributed, parallel, non-deterministically, and stochastically. 
They are limited as they cannot simulate deterministically and their primitive 
conception means graphical representation can be confusing. This means 
models must be optimized, making large systems difficult to simulate at this 
time.  
1.2.2.2 ODE models  
ODE modelling utilizes a series of differential equations to capture all available 
kinetic information for a biological system. Increasing computation power has 
allowed these types of models to become more viable and as a result they have 
grown into the most commonly used type of modelling for looking at time 
dependant alterations in biological systems (Resat et al. 2009). ODE models 
work by representing biological molecules as species. These species can then 
interact with each other but every reaction has an associated function. 
Functions take into account the speed of the reaction (using parameters), as 
well as the initial concentration of all molecules involved. The species continue 
to interact with each other and the equations are constantly solved over a time 
frame. This allows us to measure the change in species concentrations over 
time, showing the systems behaviour. How the species interact can be 
represented by a number of different rate laws: the law of mass action, Hill 
function, and Michaelis-Menten Kinetics (Ji and Yan 2017). Which law is used 
can change the behaviour of the model as well as how we can simulate it, so 
choosing the correct rate law is important in creating an accurate model. The 
advantage of ODE modelling is that it can accurately predict the kinetic changes 
in small networks. They can also test how abnormal interactions can alter such 
a system (i.e. for disease or for treatments). Their main weakness is that they 
require a lot of computing power so for larger networks it becomes very difficult 
to use accurately, especially if some parameters are unknown and estimation 
techniques must be used.  
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1.2.2.3 Boolean network models  
Boolean network models are a special case of discrete dynamic models. Their 
structure is a series of nodes that are represented by 1 or 0 to denote active or 
inactive. A discrete time variable is then used to determine the state of each 
node as time progresses. Boolean functions are used to determine the state of 
each node, using logic operators AND, OR and NOT to produce an effect. The 
network states can be updated by synchronisation. (Wang et al. 2012). 
Alternatively they can be updated by asynchronisation, where the state of a 
node is determined by the combination of the states of its parent nodes at a 
given time point (Wang et al. 2012). These types of networks lie between static 
and continuous dynamic models making them a tractable and powerful 
approach to modelling large-scale biological systems. A major advantage of 
Boolean networks is they do not require parameters, making them useful for 
describing large scale systems dynamically and allowing intervention 
predictions, as well as modelling poorly understood systems. However, Boolean 
networks only allow us a limited biological insight due to their inherent 
qualitative nature to both time and the state of the nodes.  
1.2.2.4 Other types of models 
Both LP and ABM are unique techniques that have, on rare occasions, been 
adapted to model biological systems. LP is important in mathematics and has 
been adapted to modelling by incorporating some Boolean methods, making it a 
parameter-free system.  ABM is mainly used in cancer models for examining 
specific inputs on the system as a whole but is limited by variability and multiple 
models need to be tested to make conclusions (Daub and Merks 2015).  
1.2.3 Stochastic simulations 
Computational models are typically run deterministically. This type of simulation 
has known inputs that result in a unique but uniform set of results. Every 
deterministic run gives the same output and they are used to explore signalling 
behaviours and underlying mechanisms. Biology however, is not that simple 
and stochastic simulations provide a way of modelling the inherent variation of 
biological systems. Stochastic simulations add variation to all the reactions in 
the model meaning that every run of the model is different. This allows one to 
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better understand the random variation that can occur in your system, and also 
uncover random dynamic signalling that may go unnoticed in a deterministic 
simulation. For example, if a receptor was to spontaneously signal earlier than 
expected it could cause a totally unexpected output and this would only be 
discovered by stochastic simulation.  
The Gillespie algorithm was first presented in 1976 and has since become a 
powerful tool in computational modelling (Gillespie 1976). The algorithm allows 
you to simulate variation as it works by the principle that molecules in a vessel 
must collide in order for a reaction to take place. It assumes that collisions are 
frequent but proper energy and orientations are infrequent. This means that the 
concentration of a given substrate affects the chance that it will react, but does 
not guarantee that the most abundant molecules will always interact. When 
simulating a model it takes your initial inputs, then randomly generates which 
reaction will occur. The chance of a reaction occurring will be based 
proportionally on the number of substrate molecules. It will then update the time 
step and recalculate the chances of a reaction occurring based on the updated 
molecule numbers. This will continue until the time scale is exceeded or the 
number of reactants reaches zero.  
The nature of the algorithm means that it is normally used for systems when the 
molecular numbers are low, as with higher numbers the variation is reduced 
and the output is similar to deterministic simulations. The Gillespie algorithm is 
regularly used but not the only option; stochastic simulation can also be 
performed using the Gibson and Bruck, direct or Corana algorithms, all of which 
are available through COPASI. Hybrid systems also exist that allow stochastic 
simulations at low molecule numbers but changes to deterministic when they 
reach a higher molecule number set prior to the simulation. 
1.3 Large scale bioinformatics analysis  
Increasingly, next generation sequencing is becoming both powerful and 
inexpensive, meaning we can generate a large volume of data for disease in a 
time scale previously unimaginable (Schadt et al. 2010). This has led to an 
increase in microarray data being publically available through online databases 
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i.e. gene expression omnibus (GEO) (R. Edgar et al. 2002). Surprisingly, the 
exponential growth in available data has not coincided with a shift in our 
understanding of biology. This is a result of discovering new areas of 
importance such as genetic variability, epigenetic modifications, and post-
transcriptional regulation mechanisms (Davidsen et al. 2016). It is also because 
our ability to analyse these data has not progressed at the same speed as its 
generation. For a multifactorial disease such as OA understanding all the ways 
it can develop is incredibly difficult. Although computational modelling is helping 
to understand the complexities of disease, other facets of systems biology are 
also proving to have a powerful role. Next generation sequencing for OA allows 
us to look at a number of potential causes at once. However, the problem is 
now how to analyse all of these data. Finnson et al. (2012) assembled a list of 
microarray data (Table.1.1) from OA patients and highlighted the difference in 
TGFβ throughout these studies. It demonstrated a common problem, that 
microarray data between two studies may show completely different results. 
This means that we have to validate findings and also really think about how we 
analyse microarray data. New ways of understanding microarray data may be 
beneficial for a range of diseases. Meta-analyses are a combination of multiple 
studies that have been useful in identifying common behaviours in both cancer 
(D. R. Rhodes et al. 2004) and more generally responses to chemical stress 
(Schuttler et al. 2017). OA has a number of publically available datasets and 
collaborating with Francesco Falciani’s group in Liverpool I have created a 
meta-analysis of these to create an overview of OA. This analysis has 
highlighted a lot of interesting pathways and genes that may drive future work 
into the development of OA. Overlaying my model genes to this array has also 
allowed us to develop a more global understanding of how my model functions 
in a way that, to my knowledge, has not been performed before.  
1.4 Scope of thesis 
OA is a very debilitating disease that affects a large proportion of the ageing 
community. Cartilage degradation is the hallmark of OA progression and is 
ultimately caused by the proteolytic cleavage of type II collagen (Mort and 
Billington 2001). The collagenases MMP-1 and MMP-13 have major roles in this 
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process. Under normal conditions inflammation can upregulate these 
collagenases, leading to the normal turnover of matrix components and helping 
to maintain cartilage homeostasis (Masaki Inada et al. 2004). However, with 
age, injury or genetic mutation, inflammatory pathways can become chronically 
activated, resulting in an over-expression of collagenases and cartilage damage 
(Shen et al. 2017).  
As described in this chapter there are numerous inflammatory pathways that 
can lead to cartilage damage, many of which are still not fully understood. 
Currently there are no therapeutic treatments that directly target OA 
progression. Thus, a better understanding of the basic biology leading to OA 
development will hopefully reveal areas for drug targets. As chondrocytes are 
the only cell type in cartilage (Dingle et al. 1987) it is important to understand 
how they react to, and regulate, inflammatory responses. In particular how 
inflammatory pathways drive the upregulation of MMP-13, which is believed to 
be the most important MMP in cartilage damage (Neuhold et al. 2001). 
Exploring the effect activating these pathways will have on a chondrocyte cell 
line should help me understand how MMP-13 is regulated by chronic 
inflammation.   
Computational modelling provides a method of studying complex systems with 
reduced expense, whilst also allowing easy control of a system that may be 
difficult to manipulate experimentally. Making use of these computational 
techniques to better understand inflammatory pathways may be pivotal in 
developing therapeutic targets.  Building a model requires experimental data, 
not only to provide information on the network structure but also for model 
calibration and to test model predictions. The data generated in chondrocyte 
cell lines can provide data around which to build a model of inflammation as 
well as provide a model for testing theoretic hypotheses.   
All areas of systems biology are growing in popularity and with increasing 
computational power and reduced cost they are becoming more viable as 
powerful tools in understanding biological processes. Public repositories provide 
a wealth of microarray studies, and new techniques can provide a way of 
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extracting useful information from these data. Meta-analyses of publically 
available OA datasets provide a way of looking at OA in a novel way. Exploring 
these types of analysis can provide insight into the key OA process as well as 
the genes that are responsible for driving them.  
1.5 Aims 
1. Use a novel meta-analysis of publically available microarray data to build 
a network representative of OA in humans. Then use this to explore key 
processes in the development of OA.  
 
2. Explore the effect activating inflammation related pathways has on a 
chondrocyte cell line. Use these findings to create experimental data for 
model construction and calibration.  
 
3. Build a dynamic mathematical model representative of inflammatory 
damage in chondrocytes. Explore how the model output changes with 
age and injury.  
 
 
4. Based on the findings design experiments that can test model 
predictions. If the predictions are correct move on to look at therapeutic 
targets in a model that incorporates ageing. However, if the predictions 
are not supported by experimental data then modify the model 
accordingly.  
 
5. Use the network representative of human OA to examine how 
components in the computational model may interact with other genes, 
and pathways important in OA development.  
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Chapter 2 Methods 
2.1 experimental methods  
2.1.1 Molecular Biology Reagents  
For plasmid preparation, mini/maxi-prep kits were obtained from Qiagen 
(Hilden, Germany).All custom primer oligonucleotides were synthesised by 
Sigma-Aldrich (St. Louis, USA) or Applied Biosystems (Warrington, UK). 
Plasmid sequencing was undertaken by Source Bioscience (Nottingham, UK).  
For molecular cloning, all restriction endonucleases and their buffers were 
obtained from Thermo Fisher (Loughborough, UK). Ligation was undertaken 
using an In-Fusion HD kit from Clontech (Mountain View, USA). The 
QuikChange site-directed mutagenesis kit was bought from Agilent (California, 
United States). Both the LIVE/DEAD® Viability/Cytotoxicity and Subcellular 
Protein Fractionation Kits were bought from Thermo Fisher (Loughborough, 
UK). Amersham ECL Prime Western Blotting Detection Reagents were 
purchased from GE Healthcare (Chicago, USA). PCR clean up kits were bought 
from Qiagen (Hilden, Germany). 
2.1.2 Chemicals and consumables 
All reagents were obtained from Sigma-Aldrich (St. Louis, USA) unless stated 
otherwise. All cell culture medium was obtained from Thermo Fisher 
(Loughborough, UK) unless stated otherwise. Dulbecco’s Phosphate buffered 
saline (PBS) was obtained from both Sigma-Aldrich (St. Louis, USA) and 
Thermo Fisher (Loughborough, UK). Unless otherwise stated, all cell culture 
dishes, flasks and plates were manufactured by Corning (New York, USA) and 
purchased from Sigma-Aldrich or VWR International (Radnor, USA). 
2.1.3 Cytokines and activating compounds 
IL-1α was a gift from Dr Keith Ray (GlaxoSmithKline, Stevenage, UK) and is 
dissolved in Dulbecco's Modified Eagle's medium, sterile filtered with a 0.22µm 
polyethersulfone (PES) filter then stored at -20°C stored until use. Recombinant 
OSM was made in-house at a concentration of 60 µg/ml in PBS with 0.1% (w/v) 
bovine serum albumin and stored at -80°C until use.  
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Sodium butyrate and Purmorphamine were bought from Sigma-Aldrich (Poole, 
UK ) . Bryostatin-1 and QS11 were purchased from Tocris bioscience (Bristol, 
UK) and finally TGFβ was from Peprotech (Rocky Hill, USA). All compounds 
were made up in DMSO except for TGFβ which was made up in acetic acid.  
2.1.4 Cell line 
Background: SW1353 chondrosarcoma cell lines were purchased from the 
American type culture collection. The cells originate from a primary grade II 
chondrosarcoma of the right humerus, obtained from a 72 year old female 
Caucasian. They were cryopreserved in culture medium supplemented with 
10% DMSO. 
Reagents:  
 Serum-containing media: Dulbecco’s modified Eagle’s medium (DMEM)-
F12, 10 % (w/v) foetal bovine serum (FBS), 2mM L-glutamine, 200IU/ml 
penicillin, 200µg/ml streptomycin. 
 Serum-free media: DMEM-F12, 2mM L-glutamine, 200IU/ml penicillin, 
200µg/ml streptomycin. 
 Trypan blue  
 Trypsin  
 PBS 
Method: Prior to use SW1353 cells were resurrected from cryopreservation by 
rapidly thawing at 37°C, the adding 9ml of Serum-containing media. The tube 
was then centrifuging at 1100x g for 5 minutes and the supernatant was 
discarded. The dry pellet was then resuspended in 12ml Serum-containing 
media and moved to a T75 flask. Cells were passaged at least once prior to 
use. To passage the cells they were allowed to grow until around 90% 
confluent, which normally takes around 3 to 4 days. The cells were then washed 
with PBS, before incubating for 5 minutes at 37°C with 2mL trypsin, a serine 
protease that detaches the adhered cells from the plate. 8ml of Serum-
containing media was then added to inhibit trypsin and the cells were moved to 
a 12ml tube, then centrifuging at 1100x g for 5 minutes.  The supernatant was 
removed and the dry pellet resuspended in 10ml Serum-containing media. Cells 
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were then counted by mixing 10μL of cell suspension with 10μL of trypan blue. 
This was then added to the chamber of a Fuchs Rosenthal haemocytometer. 
Four (normally the corners) squares were then counted and an average cell 
count taken. Cells were then plated out as required for experimental design. 
One sixth of the cells were also moved to a fresh T75 with 11ml Serum-
containing media to continue growing the cell line. Cells were typically retained 
for around 18-22 passages. Plated out cells were cultured in Serum-containing 
media and prior to treatment were serum starved overnight in Serum-free 
media. 
2.1.5 RNA extraction 
Background: In order to measure gene expression in a monolayer cell culture 
the mRNA must first be extracted and stabilised. RNA is highly unstable so to 
avoid degradation all steps were performed on ice and a commercially available 
buffer was used.  
Reagents:  
 Cells-to-cDNA II Cell Lysis Buffer (Thermo Fisher, Loughborough, UK) 
 PBS 
Method: For gene expression experiments the cells were always cultured in a 
96 well plate.  After stimulation cells were placed on ice and the media was 
removed and discarded, the cells were then washed with ice-cold PBS. After 
which 30 μl of Cells-to-cDNA II Cell Lysis Buffer was added to the cells, which 
were then scratched with a pipette tip for 10 seconds to help break the cell 
membrane. The buffer/lysate mix was then moved to a 96 well PCR plate and 
heated at 75°C for 15 minutes in a PCR thermocycler. This process inactivates 
RNases to help protect RNA from degradation. The lysates were then DNase1 
treated, stored at -80°C or reverse transcribed immediately thereafter.   
2.1.6 DNase1 treatment  
Background: After RNA extraction the lysates will contain not only RNA but also 
genomic DNA. When qPCR primers do not span an exon-exon boundary, or if 
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there are pseudogenes for the target in the genome, this can lead to DNA being 
amplified instead of cDNA. PCR products generated from the genomic DNA will 
be indistinguishable from those amplified from cDNA. However, treatment with 
DNase1 will remove genomic DNA prior to Reverse-Transcription preventing 
amplification. The RNA is still highly unstable so all steps were performed on 
ice.  
Reagents:  
 RNase-free, DNase1 (Thermo Fisher, Loughborough, UK) 
 RNase and DNase-free water  
Method:  1μl of water was mixed with 1μl of DNase1 per treatment well. 2μl of 
this mix was then added to each well of the lysates generated during RNA 
extraction, and then incubated for 15 mins at 37°C. After which the lysates were 
heated for 5 minutes at 75°C, this inactivated the DNase1, preventing it from 
effecting the reverse transcription products.  The lysates were then stored at -
80°C or reverse transcribed immediately thereafter.  
2.1.7 Reverse-Transcription (RT)  
Background: For quantification the mRNA extracted must be converted to 
cDNA. cDNA differs from genomic DNA in the same way mRNA differs from 
RNA, this is that the introns have been spliced out. Commercially available 
reverse transcription enzymes contain a ribonuclease H activity to prevent the 
transcription of RNA, ensuring the production of cDNA.  
Reagents 
 Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV), 
200units/µL (Thermo Fisher, Loughborough, UK) 
 5x First Strand buffer (250mM Tris-HCl (pH 8.3), 375mM potassium 
chloride, 15mM Magnesium Chloride) (Thermo Fisher, Loughborough, 
UK)  
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 Random Hexamers (NNN NNN), 0.2µg/µL (Integrated DNA 
Technologies, Coralville, USA)  
 RNase and DNase-free water  
 100mM Dithiothreitol (DTT) (Thermo Fisher, Loughborough, UK) 
 dNTPs, 2.5mM each (Thermo Fisher, Loughborough, UK) 
 RNaseOUT™ Recombinant Ribonuclease Inhibitor, 40units/µL (Thermo 
Fisher, Loughborough, UK)  
Method: Mix one comprised of; 3 µl dNTPs and 1 µl random hexamers 
(0.2µg/µl). Mix two comprised of: 4µl of 5 times first strand buffer, 2µl DTT, 
0.125µl RNase OUT, 0.5µl MMLV and 1.375µl water. Both mixes were made in 
advance for the number of wells being reverse transcribed then stored on ice. 
For the reverse transcription, 4µl per well of mix 1 was added to 8µl of lysate 
generated during RNA extraction. This mix was then heated at 70°C for 5 
minutes. Immediately afterwards the sample was chilled on ice and stayed ice-
cold whilst 8µl of mix two was added using a repeater pipette. This mix was 
then returned to the PCR block for 50 minutes at 37°C for transcription, then a 
further 15 minutes at 70°C to denature the enzyme activity of MMLV. The 
resulting cDNA was stored at -20°C until use or at 4°C for short term storage.  
2.1.8 TaqMan® quantitative polymerase chain reaction (qPCR)  
Background: Taq polymerases uses oligonucleotide primers to replicate the 
cDNA generated during reverse transcription. Primers are ideally designed to 
be in different exons close to, or spanning, an exon boundary preventing any 
amplification of residual genomic DNA. If this is impossible DNase treatment 
prior to reverse transcriptions allows the use of single exon spanning primers. A 
probe is also added that contains a fluorophore coupled to the 5’ end and a 
fluorescence quencher at the 3’ end. A laser in the qPCR machine will excite 
the fluorophore but only when the quencher is not present. When Taq 
polymerase extends the new strand, its 5’ to 3’ exonuclease activity cleaves the 
probe, thus separating the fluorophore from the quencher and a signal can be 
detected. The relative fluorescence can then be measured to quantify the 
amount of cDNA in the sample. Increased cDNA may be the result of increased 
 
 
 
35 
 
 
cell numbers or RNA extraction efficiency in a particular culture so to normalise 
for this an endogenous control must be used.  The ΔΔCT method then allows 
fold change quantification of the gene of interest relative to another condition 
(normally control). Throughout this thesis I will use GAPDH and 18s as 
indigenous controls, unless stated other.  
Reagents:  
 TaqMan® Gene Expression Master Mix (Thermo Fisher, Loughborough, 
UK) 
 TaqMan™ Fast Advanced Master Mix (Thermo Fisher, Loughborough, 
UK) 
 RNase and DNase-free water  
 Oligonucleotide primers 30µM (Applied Biosystems, Warrington, UK and 
Sigma-Aldrich, Poole, UK ) 
 Oligonucleotide probes 30µM (Applied Biosystems, Warrington, UK and 
Sigma-Aldrich, Poole, UK ) 
Protocol: The primers were designed using Primer Express software version 1.0 
(Applied Biosystems, Warrington, UK) or the universal probe library (Roche, 
Burgess Hill, UK). The sequences of primers used in this thesis are shown in 
Table.2.1. A master mix was created initially for the number of wells required 
containing; 4.5µl of TaqMan Gene Expression or Fast Master Mix, 0.1µl probe, 
0.2µl forward and reverse primers. 20µl of cDNA sample generated during 
reverse transcription were then diluted in 30µl of water; there was also a further 
25-fold dilution for 18S samples. 5µl of this diluted sample was then moved to 
an optical bottom 96-well qPCR plate (Applied Biosystems, Thermo Fisher) 
along with 5µl of the master mix. The relative gene expression of these samples 
was then determined using either a Lightcycler (Roche, Burgess Hill, UK) or a 
7900HT PCR system (Applied Biosystems, Warrington, UK). Cycling conditions;  
Normal assay  
1. Initial denaturation stage of 95ºC 10 minutes  
2. 40 cycles of 95ºC for 15 seconds then 60ºC for 60 seconds.  
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Fast assay  
1. Initial denaturation stage of 95ºC 30 seconds  
2. 40 cycles of 95ºC for 1 second then 60ºC for 15 seconds 
Analysis: Comparing CT values from different genes can show you the relative 
level of one gene compared to the other. To do this gene X is simply divided by 
gene Y, after normalisation. However, when comparing CTs determined from 
the Roche probe libary another step must first be added to confirm the binding 
efficiency of the probes. Samples are diluted 1/2, 1/4, 1/8, 1/16 and 1/32 and 
qPCR ran with the given primers. A slope is then determined for the CT values. 
After which, the CT values are altered by subtracting the endogenous control 
then dividing by the slope.  This must be repeated for the comparison gene and 
these altered CT values are then used to determine the relative concentrations.  
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2.1.9 Preparation of whole cell lysates 
Background: In order to measure the protein content of a cell via SDS-PAGE 
they must first be lysed. Full lysis of cells releases proteins from all 
compartments to give you the complete protein content. The lysis buffer is 
designed in order to effectively lyse cell whilst also inhibiting proteases and 
phosphatases. This produces the maximal yield, whilst maintaining protein 
phosphorylation states.  Whole cell lysis can be performed on monolayer 
cultures or suspended cells.      
 
 
 
Table 2.1 Primers and probes for TaqMan assays, human genes.   
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Reagents:  
 RIPA buffer; 150mM Sodium chloride, 1% trition x100 (v/v), 0.5% sodium 
deoxycholate (w/v), 0.1% SDS (v/v), 50mM Tris (w/v)  pH8 and 1 
Complete protease inhibitor Mini tablet/10 ml of buffer. 
 PBS 
Monolayer culture method: 6 well plates or 10cm dishes were lysed, after 
appropriate stimulations, by removal of media followed by washing with ice cold 
PBS. 100µl of ice cold RIPA buffer was then added to the cells on ice. The cells 
were incubated on ice for 30 minutes, whilst constantly being moved by an 
orbital shaker. A cell scrapper was then used to ensure full lysis of the cells and 
the resulting lysates were moved to a 1.5ml microcentrifuge tube. The samples 
were then centrifuged at 12,000g for 20 minutes at 4°C. The supertanium was 
then moved to a clean 1.5ml microcentrifuge tube and stored at -80°C or used 
immediately.  
Suspended cell method: Following trypsinisation 1 million SW1353 cells were 
placed into a 1.5ml microcentrifuge tube, then centrifuged at 500g for 5 minutes. 
The media was then removed and the cells were washed with ice cold PBS. 
After which 100µl of ice cold RIPA buffer was then added to the cells on ice. 
The cells were then vortexed at full speed for 10 seconds then incubated on ice 
for 30 minutes, whilst constantly being moved by an orbital shaker. The 
samples were then centrifuged at 12,000g for 20 minutes at 4°C. The 
supertanium was then moved to a clean 1.5ml microcentrifuge tube and stored 
at -80°C or used immediately. 
2.1.10 Subcellular protein fractionation  
Background: Fractionation of subcellular proteins allows the separation of 
membrane, cytoplasmic, chromatin-bound, cytoskeletal and nuclear soluble 
extracts from monolayer or suspended cells. The first buffer causes selective 
permeabilisation and the release of cytoplasmic components. The second 
reagent can then dissolve plasma, mitochondria and ER-golgi membranes 
whilst leaving behind the nuclear membrane. This pellet must then be recovered 
in order to allow the third agent to yield the soluble nuclear extract. To release 
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chromatin bound nuclear proteins the third buffer must be supplemented with a 
micrococcal nuclease. Finally the remaining reagent can be added to extract the 
cytoskeletal proteins. These extract can then as separate protein extracts and 
processed.  
Reagents:  
 Subcellular Protein Fractionation Kit (Thermo Fisher, Loughborough, 
UK). 
 PBS 
Method: Following trypsinisation 1 million SW1353 cells were placed into a 
1.5ml microcentrifuge tube, then centrifuged at 500g for 5 minutes. The media 
was then removed and the cells were washed with ice cold PBS. The amount of 
buffer used is then governed by the size of the packed cell volume. For 
adherent cells this is normally estimated. However, as I knew I was using one 
million cells and it is known that this equates to around 10µl packed cell volume, 
the relevant amounts were used. 100µl of ice cold  cytoplasmic extraction buffer 
(CEB) containing protease inhibitors was added to the dry pellet and then 
incubated at 4ºC, whilst constantly being moved by an orbital shaker for 10 
minutes. The samples were then centrifuged for 5 minutes at 500g. The 
supernatant (cytoplasmic extract) was then moved to a clean pre-chilled 1.5 
microcentrifuge tube and stored at -80ºC. 50µl ice-cold membrane extraction 
buffer (MEB) was then added to the remaining pellet and vortexed at the 
highest setting for 5 seconds. The samples were then then incubated at 4ºC, 
whilst constantly being moved by an orbital shaker for 10 minutes. The 
supernatant (membrane extract) was then moved to a clean pre-chilled 1.5 
microcentrifuge tube and stored at -80ºC. At this point the pellet can be further 
treated to extract more protein but as I only required the membrane I omitted 
the remaining steps and discarded the pellet.  
2.1.11 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE allows the separation of protein samples bases solely on the size of 
the proteins. SDS plays a crucial role in insuring no factors but size effects 
migration through the gel by binding to the denatured protein, preventing the 
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formation of secondary or tertiary structure. The binding of SDS also imparts a 
slightly negative charge on the proteins removing any natural variation in charge 
that proteins have. Boiling the samples at 105ºC denatures the protein to allow 
comprehensive binding of SDS. β-mercaptoethanol is also added to the 
samples to ensure primary structures and also reduce disulphide bridges.  
Once the samples have been charged and linearised they can be ran through a 
polyacrylamide gel in a tank containing tris-glycine running buffer.  An electric 
current is run through the gel with the anode at the bottom, and cathode at the 
top. This causes the now negatively charged proteins to migrate down the gel. 
The gel is split into the “stacking gel” and the “resolving gel” the stacking gel is 
above the resolving gel and due to a lower percentage of acrylamide has a 
larger pore size. Movement through the part of gel is therefore due to current 
rather than size meaning large and small proteins migrate together. Proteins 
become trapped in the stacking gel between chloride ions (from the gel) which 
move faster and glycine (from the buffer) which moves slower, the glycine 
essentially then pushes the protein into a desired band at the top of the 
resolving gel.   The lower pH of the resolving gel then causes the glycine and 
chloride ions to move much faster through the gel, leaving the proteins to 
separate based on size. The resolving gel has smaller pores and so this retards 
the progression of larger proteins.  
Reagents:  
 Resolving gel; 375mM Tris pH 8, 0.1% (w/v) SDS, 12% (v/v) 
Acrylamide/Bis-acrylamide. 
 Stacking gel; 125mM Tris pH 6.8, 0.1% (w/v) SDS, 4% (v/v) 
Acrylamide/Bis-acrylamide. 
 Ammonium Persulphate (APS) 0.2% (w/v)   
 5x Laemmli Buffer: 625mM Tris pH 6.8, 50% (v/v) Glycerol, 10% (w/v) 
SDS, 5% (v/v) β mercaptoethanol, 0.025% Bromophenol blue.  
 Running buffer 25mM Tris, 192mM Glycine, 0.1% (w/v) SDS. 
 Tetramethylethylenediamine (TMED) 
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Method: Whole cell or membrane specific protein samples were mixed 4 parts 
to 1 in 5x laemmli buffer and boiled at 105ºC for 3 minutes. The SDS page gels 
where made in house and were set using 20μl TEMED and 60μl APS. Once set 
the gels were then loaded into a Bio-Rad Mini-PROTEAN Tetra cell tank with 
running buffer. Between 10-30µl of the SDS protein samples were then loaded 
into the gels along with 5µl of a pertained protein ladder (Thermo Fisher, 
Loughborough, UK), so the size of the proteins could be determined after 
Western blot. The gel was then ran at between 140-200V until the bromophenol 
blue had reached the bottom of the gel, this took approximately two hours. 
Western blot was then performed to visualise the protein.  
2.1.12 Western blot 
Background: Western blotting is a technique that allows the visualisation of 
specific proteins following SDS-PAGE. The proteins are transferred from the 
acrylamide gel to either polyvinylidene fluoride (PVDF) or nitrocellulose 
membrane. The transfer takes advantage of the negative charge imparted on 
the proteins by SDS. The membrane must be first activated, the gel and 
membrane are then held tightly together and an electric current causes the 
proteins to move onto the membrane.  The activated membrane has a high 
affinity for proteins, so to prevent any further proteins binding and leading to 
non-specific binding (from the antibody in later steps) it must first be blocked 
with milk. The membrane is then incubated with an antibody against the protein 
of interest. The excess is washed away and the membrane is then incubated 
with a secondary antibody against the primary antibody. This secondary 
antibody is conjugated to the horseradish peroxidase (HRP) enzyme, and 
enhanced chemiluminescence (ECL) can then allow visualisation of the protein. 
HRP can covert luminol to its oxidised form in the presence of hydrogen 
peroxide, this reaction produces light as a by-product, which can be detected on 
x-ray film in an imaging hood. The amount of protein present in the band will be 
directly relative to the amount of light observed. Meaning western blotting is a 
semi-quantitative method for a single band but cannot be directly compared to 
separate blots or different protein bands on the same blot.  
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Reagents:  
 Transfer Buffer: 39mM glycine, 48mM Tris-base, 0.0375 % (w/v) SDS 
and 20 % (v/v) methanol  
 Tris-buffered saline-Tween (TBS-T): 10mM Tris-HCl pH 7.4, 0.15M NaCl 
and 0.2 % (v/v) Tween-20 
 Non-fat dry milk (Marvel brand)  
 HRP-conjugated secondary antibody (Dako, Agilent Technologies, Santa 
Clara, USA) 
 ECL reagents 
 Bovine serum albumin (BSA) 
 PVDF or nitrocellulose membrane 
 Methanol 
Method: Transfer was performed using a semi-dry method throughout this 
project. 4 pieces of blotting paper were cut to the size of the gel being 
transferred; these were then placed into transfer buffer. The membrane was cut 
marginally smaller and activated by being placed in methanol, then moved to 
transfer buffer. A sandwich was made with the components: in order, two pieces 
of blotting paper, the membrane, the gel and then two more pieces of blotting 
paper. Any bubbles in the sandwich were removed with a roller. It was then 
secured and moved to electroblotter from BioRad (Hercules, USA). 
Electroblotting was undertaken at 80 mA per gel for 1.5 hours. The membrane 
was then washed three times in TBS-T before being left in 5% milk for 2 hours 
at room temperature. After which, the membrane was again washed three times 
in TBS-T for 5 minutes, before being left overnight at 4°C in primary antibody 
(table 2.2). The primary antibody was diluted to manufacturer-recommended 
concentration in 5% BSA in TBS-T with 0.02% sodium azide. The next morning 
the membrane was washed three times in TBS-T for 5 minutes. The relevant 
secondary antibody was then added at 1:2000 concentration, in 5% milk. The 
secondary antibody was left for 1 hour, then followed by three final wash steps 
with TBS-T for 5 minutes. The membranes were treated with the ECL  
reagents and visualised using a Gbox EF Gel Documentation System with 
Genesnap software (Syngene, Cambridge, UK). 
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2.1.13 Small interfering RNA (siRNA) transfection 
Background: 
siRNA transfection allows the short-term silencing of a specific gene of interest. 
It takes advantages of a process that is normally important in protecting the cell 
against viral infection. The silencing is mediated by double stranded (ds)RNA 
which is delivered intracellularly using lipid vesicles that can permeate the cell 
membrane. Once in the cell the dsRNA is cleaved by the enzyme 
endoribonuclease Dicer which leaves 21-23bp siRNAs. These in turn bind to the 
RNA-induced silencing complex (RISC). This is a ribonucleoprotein which 
incorporates the siRNA and uses it as a template to target mRNA. Once the 
target mRNA is found a protein in the RISC, called Argonaute, then activates 
and cleaves the mRNA. This can essentially silence the specific gene in a given 
cell population. After transfection, cells can be either harvested to test 
transfection efficiency, or treated further to test the effect gene silencing will 
have on the cells response to stimuli.  
Reagents:  
 Dharmacon ON-TARGET plus SMARTpools (Thermo Fisher, 
Loughborough, UK). 
Table 2.2 Antibodies used throughout this project. 
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 Dharmacon ON-TARGET plus Non-targeting pool control siRNA (Thermo 
Fisher, Loughborough, UK). 
 DharmaFECT Transfection reagent (Thermo Fisher, Loughborough, UK). 
 5x siRNA resuspension buffer (Thermo Fisher, Loughborough, UK). 
 Serum-containing medium: DMEM-F12, 10 % (w/v) FBS, 2mM L-
glutamine, 200IU/ml penicillin, 200µg/ml streptomycin. 
 Antibiotic- and serum-free medium: DMEM-F12, 2mM L-glutamine. 
 Serum-free medium: DMEM-F12, 2mM L-glutamine, 200IU/ml penicillin, 
200µg/ml streptomycin. 
 PBS 
 RNase-free water 
Method: SW1353 cells were cultures in 96 or 6 well plates until they had 
reached 50-70% confluency. siRNA including the non-targeting siRNA controls 
were made up at a final concentration of 100nM, from a 20µM stock, using 1x 
siRNA resuspension buffer, diluted in RNase-free water. DharmaFECT 
transfection reagent (0.2µl/well of 96-well plate or 3.2µl/well of 6-well plate) was 
added to antibiotic- and serum-free medium (10µl/well of a 96-well plate or 
160µl/well of a 6-well plate). In a separate container the volume of siRNA 
required for the desired transfection concentration was made up to 10µl/well (96 
well) or 160µl/well (6 well) with Anti-biotic and Serum-free medium. Both 
DharmaFECT and siRNA were left for 5 minutes, then combined and left for a 
further 20 minutes all at room temperature but under sterile conditions. 90µl/well 
(96 well) or 1440µl/well (6 well) of serum-containing medium was then added. 
Cells were washed and then 100µl/well (96 well) or 1600µl/well (6 well) of the 
final mixture was added to the cells and left for 24 hours. After which, they were 
washed with PBS, serum starved overnight and then subsequently harvested or 
further treated. 
2.1.14 Lentiviral transfection 
Background: lentivirus is a type of retrovirus that can lead to chronic and deadly 
diseases such as the Human Immunodeficiency Virus (HIV), which causes 
AIDS. All retroviruses have a single stranded RNA genome with reverse 
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transcriptase activity. Lentiviruses also have a viral envelope that helps to 
facilitate the incorporation of their vial genome into host DNA, allowing it to 
replicate within the host cell. Taking advantage of this system allows the 
transient overexpression of proteins in cell lines. Lentiviral vectors use a highly 
modified version of the HIV-1 virus. There are three generations of vectors the 
1st generation present a significant biosafety risk, the 2nd generation are much 
safer and sufficient for most experiments, but the 3rd generation has the 
maximal biosafety. This project uses a commercially available “ready to use” 
lentivirus from Vigene (Rockville, USA). It contains: C-terminal FLAG and Myc 
protein tags, a Woodchuck hepatitis virus post-transcriptional Regulatory 
Element (WPRE), a SV40 and CMV promotor region as well as ampicillin 
resistance. Figure 2.1 gives an overview of the plasmid. Hexadimethrine 
bromide (commercial brand name Polybrene) neutralises the affect that charge 
has on transduction, to increase efficacy.  
Reagents:  
 Polybrene (Sigma-Aldrich, Poole, UK). 
 HI-Serum-containing medium: DMEM-F12, 10 % (w/v) Heat-inactivated 
(HI)-FBS (made by heating FBS at 56°C for 30 minutes), 2mM L-
glutamine, 200IU/ml penicillin, 200µg/ml streptomycin. 
 Serum-free medium: DMEM-F12, 2mM L-glutamine, 200IU/ml penicillin, 
200µg/ml streptomycin. 
Method: SW1353 cells were cultures in 96 or 6 well plates until they had 
reached 50-60% confluency. 5µl of polybrene was added to 10ml of HI-Serum-
containing medium. 100µl/well (96 well) or 2ml/well (6 well) of this mixture was 
then transferred to a clean container. Lentivirus was then thawed slowly on ice 
and the relevant amount for the desired MOI added to the mixtures. Any 
remaining lentivirus was stored at 4ºC, as freeze-thawing vastly reduces 
potency. 100µl/well (96 well) or 2ml/well (6 well) was added to cells and they 
were incubated at 37°C for 24 or 48 hours. After which, they were washed with 
PBS, serum starved overnight and then subsequently harvested or further 
treated.  
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2.1.15 Adenovirus transfection  
Background: Adenoviruses are the largest non-enveloped viruses and contain 
double stranded DNA. They are able to replicate in the host cell’s nucleus using 
the cells own replication machinery. This means adenoviral DNA does not 
incorporate into the host genome. A replication deficient adenovirus is used for 
the transfection. This allows your gene of interested to be transfected into the 
cell with a high efficiency and then shuttled to the nucleus, where it will be 
overexpressed. As the gene cannot integrate into the genome it is lost during 
cell division, the high transfection efficiency will allow for this but it means cells 
should be at a higher seeding density than for siRNA or lentiviral transduction.  
The adenovirus used through this project was a gift from Prof Peter van der 
Kraan (Radboud, Nijmegen, Netherlands).  
Reagents: 
 Serum-containing medium: DMEM-F12, 10 % (w/v) FBS, 2mM L-
glutamine, 200IU/ml penicillin, 200µg/ml streptomycin. 
Figure 2.1 ALK1 lentiviral plasmid.  
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 Serum-free medium: DMEM-F12, 2mM L-glutamine, 200IU/ml penicillin, 
200µg/ml streptomycin. 
 PBS 
Method: SW1353 cells were cultures in 96 or 6 well plates until they had 
reached >70% confluency. Adenovirus was then thawed slowly on ice and the 
relevant amount for the desired concentration added to Serum-containing 
medium. The cells were washed with PBS. Then 100µl/well (96 well) or 1ml/well 
(6 well) of the adenovirus containing medium was added to the cells and left for 
24 or 48 hours.  After which, they were washed with PBS, serum starved 
overnight and then subsequently harvested or further treated. 
2.1.16 Live/dead viability/cytotoxicity assay 
Background: The LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian cells 
provides two probes that work simultaneously to stain a given population for 
alive and dead cells. Calcein-AM (Cal) is used to measure alive cells, it is a 
non-fluorescent precursor which can enter cells but only fluoresces (at 
excitation ~494 nm, emission ~517 nm) when cleaved by intracellular esterase, 
which is only present in live cells. Ethidium homodimer (Ethd) is used to 
measure the dead cells as it can only enter cells when they have damaged 
membranes. It then binds to nucleic acid, which results in a 40-fold increase in 
fluorescence (at excitation ~528 nm, emission ~617 nm). 
Reagents:  
 LIVE/DEAD® Viability/Cytotoxicity Kit 
 PBS 
 
Method: The assay usually requires that you test different concentrations of Cal 
and Ethd for your given cell type. However, our group has already done this for 
SW1353 cells so it was not necessary to replicate this. SW1353 cell were plated 
and treated under normal conditions until they would have ordinarily been 
harvested.  Prior to treatment both chemicals were removed from the freezer 
and warmed to room temperature. Cells were then washed with PBS. A solution 
of BPS was then made that contained Cal at 0.5µM and Ethd at 2.5µM. This 
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was then lightly vortexed to ensure mixing. 100µl/well of this mix was added to 
cells and left in a dark cupboard for 5 minutes. The mixture was then removed 
and the cells left in PBS. Each lane was then photographed on a Zeiss Axiovert 
200M inverted microscope (Carl Zeiss AG, Oberkochen, Germany) at the 
different wavelengths, as well as one image on bright field.  
Analysis: Using a representative area for each given well I counted the live and 
dead cells. I then added the values together to get the total cell count. I also 
counted all of the cells using the bright field image to confirm it matched the 
total cell count. After which, I divided the number of dead cells by the total cell 
count and multiplied this by 100 to get a percentage of cell death.  
2.1.17 Stable plasmid transfection 
Background: A stable cell lines is one that has incorporated a plasmid into its 
genome, resulting in a stable over-expression of a protein of interest. This 
plasmid will also include a gene for antibiotic resistance, which is used to select 
the cells that have successfully incorporated the plasmid. Culturing transfected 
cells in medium containing the antibiotic will result in the death of all cells not 
expressing the plasmid. The surviving cells can then be cultured as normal but 
in medium containing this antibiotic. This means that all surviving cells should 
be expressing your gene of interest, removing the variability between cells 
which is seen with a transient transfection. If for any reason the plasmid stops 
being expressed the antibiotic will ensure these cells die, so there is no chance 
of you continuing with cells that no longer express the plasmid. As the cells are 
all expressing the gene they can be treated in the same way as wild-type, 
allowing treatment to be done immediately.  
Reagents:  
 DMEM-F12, supplemented with 10% FBS and 2 mM L-glutamine but no 
antibiotics. 
 50mg/mL G418 in ddH2O, filtered with 0.22µm PES filter. 
 FuGene HD (Promega, Wisconsin, United States) 
 Serum-containing medium: DMEM-F12, 10 % (w/v) FBS, 2mM L-
glutamine, 200IU/ml penicillin, 200µg/ml streptomycin. 
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 Serum-free medium: DMEM-F12, 2mM L-glutamine, 200IU/ml penicillin, 
200µg/ml streptomycin. 
 Selective medium: DMEM-F12, 10 % (w/v) FBS, 2mM L-glutamine, 400 
µg/mL G418. 
 PCR clean up kit 
 Restriction enzymes and relevant buffers. 
Method: I used two different plasmids throughout this thesis, the first was 
mEmerald-ALK1-N-13 and was a gift from Michael Davidson (Addgene plasmid 
# 53981). The second was created in-house using the pcDNA3.1 plasmid 
(Thermo Fisher, Loughborough, UK). Both plasmids were selected for with the 
antibiotic G418. Prior to transfection the plasmid should be linearised. For this a 
100µL reaction was set up contain 10µg plasmid and 50 units of either MfeI or 
Pvu1 (depending on the plasmid) along with the relevant buffer, these were 
then incubated for 4 hours at 37°C. An ethidium bromide gel was used to 
confirm the digestion had been successful. The remaining product was then 
purified using a PCR clean up kit, as per the instructions. A 6 well plate was 
seeded with 200,000 SW1353 cells then incubated overnight in Serum-
containing medium. Plasmid DNA (2.75µg) was combined at a 1:3 ratio with 
8.25µL FuGene HD and 137.5µL of Serum-free medium. A control was also 
created that had water instead of the plasmid. These mixtures were vortexed at 
full speed for 5 seconds then left for 10 minutes at room temperature, before 
being added to the cells along with 4ml of Serum-containing medium. After 24 
hours the treatment medium was removed and replaced with Serum-containing 
medium overnight. The following day the medium was replaced with selective 
medium, this was then replaced every 2-3 days until the control cells were dead 
and the treated cells were fully confluent. Each well of the plate was then split 
and transferred to a T25 flask until confluent. They were then split and 
transferred to a T75 flask. After which, they could be treated the same as wild-
type SW1353 cells but incubated in selection medium instead of Serum-
containing medium. It is important to note that typically you need to test various 
concentrations of G418 for your specific cell type. However, this had already 
been done by our group for SW1353 cells. 
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2.1.18 Mini/maxi prep 
Background: QIAprep Spin Miniprep Kits are designed to isolate high-purity 
plasmid DNA. Allowing the extraction of high quality DNA from bacterial 
cultures. The mini-prep results in lower quantities of DNA but is cheaper, 
allowing you to reduce risk when testing if a plasmid is as desired. The Maxi-
prep then allows much higher quantities of DNA to be produced, allowing you to 
make sufficient plasmid DNA for regular transfection.   
Reagents  
 QIAprep Spin Miniprep Kit 
 QIAprep Spin Maxiprep Kit 
 QIAvac 24 Plus 
 Antibiotic containing Lysogeny broth (LB) medium, autoclaved to prevent 
any unintended growth, also containing Kanamycin at 50mg/ml. 
 DNase-free water. 
Method: Three 50ml mixtures where made containing: the LB medium with no 
bacteria, bacteria containing the plasmid of interest or bacteria resistant to an 
alternative antibiotic. Bacteria were transferred to the tubes by pressing the 
colony with a 20µL pipette tip and then moving the tip to the medium, all under 
sterile conditions. The tubes were then incubated at 37ºC overnight with 
agitation at 225-250 rpm in an orbital incubator. The following day only the 
bacteria containing the plasmid of interest should have grown.  
Mini-prep: This tube is spun at 5400xg for 10 minutes at 4ºC and the 
supernatant discarded. The pellet was then resuspended in 200µL P1 buffer 
and transferred to a 1.5ml microcentrifuge tube. 200µL P2 buffer was added 
and mixed by inverting gently. This was followed by adding 350µL P3 buffer and 
mixed by inverting gently. The tube was then spun at 17,900g for 10 minutes at 
4ºC. The QIAvac 24 Plus filtering system was then used on the lysates. Lysates 
were passed through the column and then the eluant was discarded. Endotoxin 
removal wash was then eluted through the column. This was then followed by 
buffer PE to wash. The DNA was then eluted into a clean 1.5ml microcentrifuge 
tube using DNase-free distilled water, extra time was taken to ensure the 
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column was completely dry. The eluted DNA could then be analysed on a 
Nanodrop ND 1000 spectrophotometer (Thermo Fisher, Loughborough, UK) to 
determine purity and concentration.  
Maxi-prep: All the bacteria containing medium was then added to 250ml of fresh 
LB medium and incubated at 37ºC overnight with agitation at 225-250 rpm in an 
orbital incubator. This tube was spun at 5400xg for 10 minutes at 4ºC and the 
supernatant discarded.  The pellet was then resuspended in 12ml resuspension 
buffer and vortexed until there were no clumps remaining. 12ml of lysis buffer 
was then added and inverted 3-5 times. After which, it was left for 3 minutes. I 
then added 12ml of neutralising solution and spun at 17,900g for 20 minutes at 
4ºC. The QIAvac 24 Plus filtering system was then used on the lysate, with 
larger columns than used from the Mini-prep. Lysates were passed through the 
column and then the eluant was discarded. Endotoxin removal wash was then 
eluted through the column. This was then followed by buffer PE to wash. The 
DNA was then eluted into a clean 1.5ml microcentrifuge tube using DNase-free 
distilled water, extra time was taken to make sure the column was completely 
dry. The eluted DNA was then run on a Nanodrop ND 1000 spectrophotometer 
to detect purity and concentration. Plasmids were then stored at -20ºC until use. 
2.1.19 Site directed mutagenesis 
Background: QuikChange site-directed mutagenesis from Agilent Technologies 
(California, USA) allows you to make single nucleotide changes. 
Oligonucleotides are used that have an almost identical sequence to the region 
of interest, but also contain the relevant mutation(s). These bind to the plasmid 
of interest and a high fidelity DNA polymerase can then replicate both plasmid 
strands. However, the ends of the plasmid cannot be joined leaving it with 
staggered nicks. DpnI endonuclease is added to the samples as it targets 
specifically methylated and hemi-methylated DNA resulting in it degrading the 
parental strand (without the mutation). The DNA must then be transformed into 
bacteria in order to fix the nicks. It can then be harvested from these cells at a 
much higher quantity and ready for transfection.  
Reagents:  
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 QuikChange site-directed mutagenesis kit 
 “Stellar” E. coli (Clontech, California, USA) 
 SOC medium  
 Oligonucleotide primers  
 DNase-free water  
 dNTPs, 2.5mM each 
 Kanamycin (50mg/ml) containing agarose plates 
Method: Created a 50µL reaction made up of 10x reaction buffer, 5-50ng 
plasmid, 125ng of forward and reverse primers, 0.5µL dNTP mix, 0.5µL 
PfuTurbo DNA polymerase and water. This mix was then added to a PCR block 
and run using the following cycle:  
1. Initial denaturation stage of 95ºC 30 seconds  
2. 12 cycles of 95ºC for 30 seconds then 55ºC for 1 minute and finally 68ºC 
for 7 minutes (I minute per kb of plasmid length).  
The samples were then transferred to ice for 2 minutes to cool the reaction. 
0.5µL of  20,000 units/ml DpnI was then added to the reactants and gently 
mixed. The samples were then transferred to a water bath at 37ºC, for 1 hour. 
During this I gently thawed “Stellar” E. coli on ice, 25µl was then transferred to 
two clean 1.5ml microcentrifuge tube. 1µl of water was added to 1 tube, and 1µl 
of treated DNA was added to the other. The tubes were then swirled to mix and 
left on ice for 30 minutes. The samples were then carefully placed in a water 
bath for 1 minute at 48ºC, then transferred to ice for 2 minutes. In sterile 
conditions 500µl of SOC medium was added to each tube and they were 
incubated at 37ºC for 1 hour with agitation at 225-250 rpm in an orbital 
incubator. The mixture was then spread on Kanamycin (50mg/ml) containing 
agarose plates and left for 16 hours at 37ºC. Any colonies could then be mini-
prepped and sent for sequencing to check the mutation was as desired. More 
information on specific gene changes and primers used will be given in chapter 
6.  
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2.1.20 Colony PCR 
Background: Colony PCR is a simple and quick method of determining if an 
insert has successfully incorporated into a plasmid. Cells are lysed to release 
the DNA, allowing plasmids to serve as templates for an amplification reaction. 
Primers can either flank the insert or copy the entire plasmid. The amplified 
DNA can then be run on a gel to determine if insert is present.  
Reagents: 
 Master mix per reaction: 0.3mM dNTPs, 0.5 µM of each forward and 
reverse primers, 1.5mM MgCl2, 0.25 units recombinant Taq polymerase 
(Thermo Fisher, Loughborough, UK) in the supplied buffer. 
 DNase-free water. 
Method: 10+ colonies were chosen from an antibiotic containing agar plate. The 
colonies were selected by pressing them with a 20µL pipette tip then moving 
that tip to an Eppendorf tube containing 100µL sterile water. The tube was then 
heated for 3 minutes at 98°C. 1µL of this DNA-containing water was then added 
to 9µL of master mix. The reactants were then transferred to a PCR block with 
cycling conditions:  
1. Initial denaturation stage of 94ºC 2 minutes  
2. 35 cycles of 94ºC for 45 seconds, 42ºC for 30 seconds and 72ºC for 90 
seconds  
3. Final elongation of 72ºC for 10 minutes             
The products of this cycling were then run on a1% agarose gel with ethidium 
bromide. If the primers were flanking the gene then any products showed that 
the insert was present. If the primers replicated the full plasmid then the DNA 
ladder would show the molecular weight, which will be higher if the insert is 
present. If the fragment was as expected the sample was then mini-prepped 
and sequenced. More information on specific gene changes and primers used 
will be given in chapter 6. 
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2.1.21 In-fusion cloning   
Background: In-Fusion Cloning Kits by Clontech (California, USA) are designed 
to allow fast cloning of a fragment, or fragments of DNA into a vector. Primers 
are designed that flank the gene of interest but leave overhangs of 15-bp that 
have known restriction enzyme sequences at the end. A restriction enzyme can 
then be used to cut your plasmid of interest leaving compatible ends of both 
your plasmid and gene fragment. The In-Fusion Enzyme then allows the DNA 
fragment to fuse into the plasmid efficiently and precisely by recognizing 15-bp 
overlaps at their ends. The resulting plasmid should be seamless with no 
unwanted base pairs so can be used immediately.  
Reagents:  
 In-Fusion cloning kit  
 “Stellar” E. coli (Clontech, California, USA) 
 Master mix per reaction: 0.2mM dNTPs, 0.5µM of forward and reverse 
primers and 0.5 units of Q5polymerase, in Q5 polymerase buffer 
 SOC medium.  
 PCR clean up kit. 
 DNase-free water.  
 Kanamycin (50mg/ml) containing agarose plates. 
 Restriction enzymes and relevant buffers. 
Method: Two mixes were made containing template DNA (1ng) and master mix, 
to a 25µL total volume. The reactants were then transferred to a PCR block with 
one of two cycling conditions 64ºC or 72ºC, as advised by the protocol:  
64ºC cycle: 
1. Initial denaturation stage of 98ºC 30 seconds  
2. 30 cycles of 98ºC for 10 seconds, 56ºC for 15 seconds and 64ºC for 15 
seconds  
3. Final elongation of 64ºC for 2 minutes 
72ºC cycle: 
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1. Initial denaturation stage of 98ºC 30 seconds  
2. 30 cycles of 98ºC for 10 seconds, 56ºC for 15 seconds and 72ºC for 15 
seconds  
3. Final elongation of 72ºC for 2 minutes 
The plasmid was then double digested with two restriction enzymes. 1µg of the 
plasmid was incubated for 4 hours at 37°C with 20 units of each restriction 
enzyme in 50µL reactions with relevant buffer (New England Biolabs, Ipswich, 
USA). The products were subsequently purified using a PCR clean up kit, as 
per instructions.  Both the products of the DNA fragments and cut plasmid were 
then run on a 1% agarose gel with ethidium bromide to verify both have worked. 
I found the 72ºC cycle samples gave a stronger signal so continued with them 
samples and discarded the samples from the 64ºC cycle. 50ng of cut plasmid 
and 100ng of insert were then incubated with the relevant In-Fusion kit 
component at 50°C for 15 minutes, in a 10µL reaction. During this Stellar” E. 
coli were gently thawed on ice. After which, 25µl were transferred to two clean 
1.5ml microcentrifuge tubes. In 1 tube 1µl of water was added and the other 1µl 
of treated DNA. The tubes were swirled to mix and then left on ice for 30 
minutes. The samples were then carefully placed in a water bath for 1 minute at 
48ºC then transferred to ice for 2 minutes. In sterile conditions 500µl of SOC 
medium was added to each tube and they were left at 37ºC for 1 hour with 
agitation at 225-250 rpm in an orbital incubator. The mixture was then spread 
on Kanamycin (50mg/ml) containing agarose plates and left for 16 hours at 
37ºC. Any colonies could then be mini-prepped and sent for sequencing to 
check the mutation was as desired. More information on specific gene changes 
and primers used will be given in chapter 6. 
2.1.22 Ethidium bromide gel  
Ethidium bromide gels are used to visualise DNA by utilising agarose gel 
electrophoresis to separate the samples by size. The gel contains ethidium 
bromide which can intercalate with DNA, allowing it to be visualised under UV-
light.  
Reagents: 
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 TAE buffer: 40mM Tris-base, 0.11% (v/v) Acetic acid, 1mM EDTA in 
ddH2O. 
 Ethidium bromide (10mg/mL). 
 Agarose. 
Method: A 1% agarose gel was made by adding 1g of agarose to 100ml of TAE 
buffer and dissolving in a microwave until boiling. This mixture is then allowed to 
cool before adding 1µL ethidium bromide in a hood. The solution was then 
added to a gel tray and left to solidify. The gel was then placed in a running tank 
that was full with TAE buffer and 1µL of ethidium bromide. Samples were 
loaded and the gel was run at 110V for approximately 30 minutes (until the dye 
in the DNA ladder reached the end of the gel). Gels were then visualised using 
a Gbox EF Gel Documentation System with Genesnap software (Syngene, 
Bangalore, India). 
2.1.23 Graph pad prism 
GraphPad Prism is commercial scientific 2D graphing and statistics software 
published by GraphPad Software, Inc. It has an intuitive interface that allows the 
plotting of graphs but also statistical analyses of all data. It was used for the 
plotting and statistical analysis of my experimental data.  
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2.2 Bioinformatics tools  
A range of bioinformatic tools have been used throughout this thesis. Making 
use of publically available microarray data helped to guide the initial 
experiments and has provided direction for future work. Sections 2.2.1 through 
to 2.2.5 explain the programs that were used to create a cytoscape network of 
OA, as described in 2.2.6. 
2.2.1GEO 
The gene expression omnibus (GEO) is a publically available international 
repository run by the National Center for Biotechnology Information (Ron Edgar 
et al. 2002). It archives and freely distributes microarray, next-generation 
sequencing, and other high-throughput functional genomic data sets. GEO 
stores and provides all details of the study, a link to any associated publications 
as well as raw data files, processed data, and descriptive metadata, which are 
indexed, cross-linked, and searchable. The database can be searched 
according to any property of the data for example: organism, cell type, 
treatment or disease.  
2.2.2 R 
R is a computational language used for statistical computing and graphics. 
Originally it was developed by Bell Laboratories (formerly AT&T, now Lucent 
Technologies) by John Chambers and colleagues (Team 2013). It is an open 
source software with a wide variety of statistically and graphical techniques. It 
also has a variety of “packages” that can be added to tailor it to your specific 
needs. It allows the incorporation, storage and manipulation of large data files 
making it ideal for manipulating microarray data. Some of the R packages were 
also useful for combining multiple microarray data files. Bioconductor is a 
package that I used regularly.  
2.2.2.1 Bioconductor 
An open source package designed to provide tools of the analysis and 
comprehension of high-throughput genomic data (Gentleman et al. 2004). It 
allows for data to be taken directly from GEO or imported from your own data 
files. It provides the “RMA” function which computes the RMA (Robust Multichip 
Average) expression measure described in (Irizarry et al. 2003), providing a 
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quick and uniform way to normalise microarray data. It also contains the 
function “ComBat” which allows user to correct for batch effects, when the 
reasons for the batch effects are known. The methodology used is described in 
(Johnson et al. 2007).  
2.2.3 ARACNE 
The Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNE) 
is a novel algorithm that uses mutual information (MI) to quantify interaction 
between genes (Margolin et al. 2006). This number quantifies the "amount of 
information" obtained about one random variable, through the other random 
variable. In this case the variable is gene expression and how much the change 
in one gene effects the expression of another. MI is scored between zero and 
one, with one being the highest. How the expression of one gene corresponds 
to another is used for your data to determine interactions and their MI values. 
The data processing inequality is then used to remove the majority of indirect 
candidate interactions that is inferred by co-expression methods. The algorithm 
provides a way of using microarray data to expose the functional mechanisms 
that underlie the cellular processes.  
2.2.4 Cytoscape 
Cytoscape is an open source software platform used primarily for the 
visualisation of molecular interaction networks, whilst also integrating gene 
expression profiles and other state data (Shannon et al. 2003). Cytoscape core 
distribution provides a basic set of features for data integration, analysis, and 
visualization. Allowing you to change how the network is visually presented as 
well as sorting the data by whatever value you have used to quantify 
interactions. For example when looking at MI you can sort the data so that any 
interactions with an MI lower than a set threshold are deleted. This helps to 
identify the strongest interactions in the data. Additional features can be added 
to Cytoscape, known as apps. Throughout this thesis I have used two 
“clusterMaker” and “PhenomeScape”. 
2.2.4.1 clusterMaker 
clusterMaker is an open source Cytoscape app that contains multiple different 
clustering algorithms, which allow you to locate distinct clusters of genes in your 
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network that interact with each other (Morris et al. 2011). These can then be 
presented as hierarchical groups of nodes that can be exported to other 
programs to determine the processes governed by this specific group of genes. 
Community clustering (GLay) was used as it is powerful tool that can quickly 
identify groups of genes that interact exclusively with each other (Su et al. 
2010). It then presents these clusters in a uniform order, with the largest cluster 
at the beginning followed by smaller clusters, leading to single genes at the end.   
2.2.5 DAVID 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) is 
an integrated biological knowledgebase that contains analytical tools for 
extracting biological meaning from gene lists (Huang et al. 2009). It requires a 
gene input list containing common identifiers, such as official gene symbols. 
The DAVID Bioinformatics Resources consists of five integrated, web-based 
functional annotation tool suites: the DAVID Gene Functional Classification 
Tool, the Functional Annotation Tool, the Gene ID Conversion Tool, the Gene 
Name Viewer and the DAVID NIAID Pathogen Genome Browser. I made use of 
the DAVID Gene Functional Classification Tool, which allows functional 
annotation clustering of a gene list based on enriched biological themes. This 
means by using pre-selected biological themes, such as GO term or KEGG 
pathways, the system can then look for terms that contain a significant number 
of your gene list. This provides an idea of biological functions your gene list 
could be responsible for.  
2.2.6 Creating a network of human OA  
To create a network overview of human OA I collected publically available OA 
microarray data from GEO. I searched GEO using the keyword “osteoarthritis” 
then selected the relevant affymetrix samples. Table 2.3 shows the samples 
that were used for the rest of the analysis of these I only used the diseased 
samples and got 50 samples overall from 5 different studies. The samples are 
not identical but they are close enough that I could consider them 
representative of the same disease.  The data was first imported into R and 
normalised using the RMA function, which is built into Bioconductor. R was then 
used to combine the data, change the gene names to “official gene names” and 
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take the average of any duplicate genes in the samples. The expression data 
from all the samples were tested using a principle component analysis (PCA) 
analysis, which is also built into Bioconductor. PCA tests for variably between 
samples and showed that the samples from the same experiment clustered 
together (Fig 2.2A). This is unsurprising as slight changes in the experimental 
technique as well as how the samples were processed most likely led to minor 
changes. ComBat was then used to remove these batch effects. It was run for 
all the samples under the assumption that the some changes could be the result 
of experimental variation between samples. Figure 2.2B shows a PCA after 
running ComBat for which the gene sets have a less clustered pattern.  
After batch corrections I put the samples through ARACNE which determined 
how all of the genes interact with each other and the strength of these 
interactions. ARACNE was run using the command line, by directing my 
combined data to the programme and setting a p value cut off. The following 
script was used “-i corrected-data.txt –p 1e5 –o outfile.adj –h C:\aracne “.The 
resulting data was then imported into Cytoscape and clustered with the GLay 
algorithm (clusterMaker) to provide an overview of OA as a network. Selecting 
any of these clusters gave me a gene list that could then be analysed using 
DAVID to determine the biological function of that cluster. The analysis of these 
clusters is shown in chapter 3. It is important to note that this analysis was run 
at the end of 2015 so any protein links established since then will not have been 
included in the analysis.  
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Number of 
samples 
Array type Tissue Reference 
19 Affymetrix Human Genome 
U133 Plus 2.0 Array 
synovial 
membrane 
(Q. Wang 
et al. 
2011) 
10 Affymetrix Human Genome 
U133A Array 
synovial 
membrane 
(Woetzel 
et al. 
2014) 
10 Affymetrix Human Genome 
U133A Array 
synovial tissue (Woetzel 
et al. 
2014) 
6 Affymetrix Human Genome 
U133A Array 
synovial 
membrane 
(Woetzel 
et al. 
2014) 
5 Affymetrix Human Genome 
U133 Plus 2.0 Array 
synovial biopsy 
samples 
(Toukap 
et al. 
2007) 
 
 
Table 2.3 Details of publically available microarray data for OA patients. 
Relevant details of all microarray samples combined to create the cytoscape OA 
network. Although three share the same reference, they were created by three 
separate groups that were collaborating for that publication.   
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Figure 2.2 ComBat removes the batch effects in combined microarray data. 
Principle component analysis (PCA) which separates the samples presented in table 
2.3 based on their variance.  A) PCA analysis on the samples, after they had been 
normalised and combined. B) PCA of the same samples after running ComBat to 
remove batch effects.  
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2.2.7 PhenomeScape 
PhenomeScape is an open source Cytoscape app that enables the 
identification of active sub-networks, by looking at groups of differentially 
expressed genes that are physically interacting (Soul et al. 2016).  What makes 
it unique is that it also links these sub-networks to human and animal disease, 
by using gene expression studies that show changes in genes leading to 
disease like phenotypes. There is an option to only look for phenotypes relevant 
to a disease of interest and in an animal of interest. 
PhenomeScape requires a protein-protein interaction (PPI) network for which I 
used the cytoscape network described in section 2.2.6. Manual selection of 
phenotypes of interested is then required. These phenotypes are taken from 
UberPheno (Köhler et al. 2013) and include human, mammalian and zebrafish 
studies. Finally PhenomeScape requires analysed expression data with gene 
symbols, fold change and P-values is required. There is an OA dataset built into 
cytoscape that I used for this analysis (S. L. Dunn et al. 2016). This expression 
dataset is linked to the original PPI network by gene symbols. PhenomeScape 
works by a two-step process as described in Soul et al. (2016) first ranking the 
protein-protein interactions based upon the phenotypes chosen. It then uses 
these genes and phenotypes as the starting points to find other closely related 
phenotypes, and also uses their known associations to aid the analysis. Activity 
scores are calculated based on the gene and phenotype interaction and high 
scoring groups of interacting proteins are identified as sub-networks. There is 
then a final test to make sure a sub-network of that size could not have that 
level of differential expression by chance. The networks also show the top 
enriched GO term associated with them genes to give an indication of the 
function of that sub-network. I ran the programme for human phenotype with the 
default parameters: network size (10),number of random networks (1000), 
minimum p value (0.05) and minimum size (4). More information on this 
analysis will be given in chapter 8.  
PhenomeScape contains zebrafish and mammalian phenotypes which were 
used in this study despite being linked to human diseases. This was because 
UberPheno have designed them to be comparable. To do this they used mouse 
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or zebrafish datasets to infer gene-phenotype interactions in there human 
orthologues, when human data was unavailable. This was justified in (Köhler et 
al. 2013).  
2.2.8 GSEA 
Gene Set Enrichment Analysis (GSEA) is a computation method used to 
determine if a gene list significantly up or down regulates a biological state, 
such as chromosomal modifications, pathway regulations or cell division 
(Subramanian et al. 2005). Taking microarray data sets and running them 
through the GSEA programme allows you to find process that are affected by 
their gene profiles. For example KEGG pathways have known genes that affect 
them, if a significant number of genes are upregulated in your profile the 
relevant KEGG pathway will appear in the output. The programme also takes 
into account the change in regulation when determining significance. So if one 
of the genes in the pathway is upregulated 2-fold it will carry more weight, 
compared to another upregulated 0.5-fold.  The GSEA programme also ranks 
the genes showing which genes are responsible for that pathway being 
significantly regulated and which are not. This gives you an idea of the 
biological processes that are occurring in your samples and which genes from 
your data are responsible for this. I have ran differentially expressed gene lists 
through GSEA to determine their biological function but also because it allows 
you to explore what genes are responsible for that function being significantly 
upregulated. This will be demonstrated in chapter 3.  
2.2.9 MeV 
Multiple Experiment Viewer (MeV) is an open source cloud based application 
that allows analysis, visualization, and stratification of large genomic data 
(Saeed et al. 2003). MeVs built in PCA function allows you to assess the 
variability between samples, from this you can see if any of the samples are 
outliers and need to be removed from the samples. Significance Analysis of 
Microarrays (SAM) analysis can also provide a list of differentially expressed 
genes between sets of samples. It also provides an estimate of the False 
Discovery Rate (FDR), allowing for the removal of genes that are most likely 
there by chance. How stringent this is, is not set and can be changed 
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accordingly. Its design has the advantage that before setting this value you can 
look at the distribution of your genes and so can alter to a level relevant for what 
you require. 
 MeV was used through this thesis for determining differential genes in any 
microarray data not present in table 2.3. The array data was initially normalised 
using the Bioconductor function RMA, this normalised data was then moved to 
MeV where the built in PCA allowed for outliers to be removed. PCA clusters 
each of patient samples so that if one sample does not cluster with others it can 
be removed from the analysis. The differentially expressed genes were then 
determined using SAM. Figure 2.3A shows an example of the distribution of the 
genes. Figure 2.3B shows the delta values from the same gene list. 0.622 is the 
highest value with an FDR less than 10%, so re-running the SAM with this delta 
value provides a list of differentially expressed genes.  
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Figure 2.3 Using MeV to determine differentially expressed genes. A) SAM 
analysis of an entire microarray gene list. It is intentionally set with a high delta value 
so only highly significantly enriched genes will be found. B) The delta values from 
the SAM analysis preformed in A. The black line indicates where the FDR becomes 
less than 10%. The delta value in the red circle gives the value where all genes 
underneath have a FDR less than 10%. Re-running SAM with this cut off will then 
result in a gene list where all significantly enriched genes have a less than 10% 
FDR.   
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2.3 Mathematical modeling tools 
2.3.1SBML 
All the models in my thesis were encoded in the Systems Biology Markup 
Language (SBML), a machine-readable format that is based on XML - (Hucka 
et al. 2003). SBML model are comprised of compartments, species and 
reactions. Compartments are what the reactions take place in for example 
nucleus. They have an initial volume that helps determine the speed of 
reactions. Species are what react, and are representative of proteins or 
complexes. The initial concentrations of species need to be set. Reactions refer 
to interactions between species (i.e. phosphorylation events), how these 
interact is via rate laws.  
2.3.2 COPASI    
Complex pathway simulator (COPASI) is a software application for simulation 
and analysis of biochemical networks and their dynamics (Stefan Hoops et al. 
2006).  It supports computational models in SBML format and allows time 
dependant simulations that can be deterministic, stochastic or a hybrid. The 
model is created in a graphical user interface (GUI) format which allows you to 
insert reactions and specify the rate laws. COPASI will then automatically 
convert the reactions into a set of differential equations. I created a model by 
modifying two previously published models in COPASI. I then combined the 
models and made any further modifications that were required in order to fit the 
model to experimental data. COPASI allows for the model to be run using a 
variety of different units. However as I was looking for patterns rather than exact 
concentrations I used particle numbers for the species concentrations. Particle 
number is normally depicted with the letter N and literally refers to the number 
of constituent particles in the system. COPASI has a number of built in tools for 
simulating and analysing models. I used the following tools to create and 
investigate the model:  
2.3.2.1 Model simulation  
Simulations involve solving the system of coupled differential equations that 
constitute the model. COPASI allows from the deterministic or stochastic 
simulation of the model. The deterministic simulations were run using the 
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simulation algorithm LSODA (Petzold 1983). Simulations were configured with 
parameters: Duration (1440), Interval Size (1), Relative Tolerance (1e-06), 
Absolute Tolerance (1e-12), Max Internal Steps (10000). Stochastic simulation 
were run using the direct method, which uses the Gillespie algorithm (Gillespie 
1976). Simulations were configured with the Max internal step set at 1000000, 
random seed was not used.  Simulations were run using COPASI version 4.20.  
2.3.2.2 Parameter scans 
Parameter scans allow the user to vary the value of a parameter or particle 
number of a species. The scan will increase the value or concentration from the 
minimum to the maximum values in a stepwise manner simulating the model at 
each increase. The minimum, maximum and number of simulations are set by 
the user. I used these parameter scans to alter the starting concentration of 
TGFβ in the model. This allowed me to compare simulation data to 
experimental data as explained in chapter 5.  
2.3.2.3 Extracting data 
Although COPASI offers a way to visualise the data generated within it, these 
are normally rudimentary with no way to generate high quality figures.  COPASI 
allows you to extract the data as a comma-separated values file that can then 
be moved to other programmes for visualisation.  
2.3.2.4 Events 
Events are state transitions of the model that require a condition to be triggered. 
They consist of two parts a trigger, such as a specific time, which signals for the 
event to take place. The second part is at least one assignment, which modifies 
the model; this is normally a change in concentration of one of the species. At 
the exact moment that the trigger changes from false to true the assignment will 
take effect. The assignment can affect multiple species in the model. It is also 
possible to have multiple events in the same simulation. Events were used to 
alter the concentration of species in the model after time zero. For example IL-
1+OSM rather than being present initial in the model, was introduced at 6 hours 
in the simulation shown in chapter 5.  
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2.3.2.5 Parameter estimations  
Background: The original choice of model variables can be determined from 
past literature, or if feasible measured experimentally. Unknown variables are 
normally estimated. However, parameter estimation provides a way of 
optimising the model to fit experimental data, by altering the parameters to allow 
the model to fit the data with reduced error.  The algorithms for parameter 
estimation work by measuring the distance between model observables and 
data measurements at given time points. They then compute a solution by 
assigning and changing parameter values that minimise the distance between 
model predictions and experimental results. How this is accomplished depends 
on the algorithm that is used.  These algorithms can be classified as either 
global or local. Global estimations aim to find the minimal distance by altering 
the parameter values over a large search space and once a lower minimum 
distance has been found the estimation starts to focus on these parameters. 
These algorithms can be very accurate as they search a large area. However, 
they also have a high demand on computational power and time. There is also 
a chance that they can focus on the wrong local minima, missing the optimum 
parameter values. Local algorithms focus on reducing the minimal distance, by 
finding new parameters close to the original starting values of the model. This 
has the advantage of being much faster but comes at the expense of excluding 
the majority of parameter sets. These algorithms are regularly used to improve 
a model that already has a reasonable fit to the data.  Both types of algorithms 
allow you to select which parameters can be estimated.  
Method: To parametrised my model I used a common technique of combining 
an initial global parameter scan followed by a local scan. I used the genetic 
algorithm for the global estimation. It works by randomly creating different 
parameter sets, the top ranking sets then progress to the next population being 
only marginally altered. The second population then contains the original sets 
combined with a new set of randomly assigned parameters, again the highest 
ranking parameter sets move on to the next generation. This is continued for a 
number of generations set at 1000. The amount of parameter sets that move 
through each generation is also set at 20. Once this has finished the highest 
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ranking parameter set is then further optimised using the local algorithm, Hook 
and Jeeves. This works by choosing parameters and randomly increasing or 
decreasing them, it then analyses if this positively impacts the models fit to the 
data if it does then the change remains, if not it is reversed. This is repeated for 
a number of iterations chosen were 50. For my model I was fitting MMP-13 data 
and since this gave a variable fold change, I instead fit to the percentage of 
repression. This was possible as the MMP-13 expression pattern under IL-
1+OSM treatment had already been established in the model I started with. 
Knowing this I then used my generated data to determine the level of repression 
necessary at each time point and created a file for which that was true. For 
example at 24 hours the molecular number for MMP-13 with IL-1+OSM 
treatment was 109. I knew from my data that when TGFβ was present this 
should be reduced 42%, so at 24 hours the value was 63. This was repeated for 
all known time points and the IL-1+OSM+TGFβ model was fit to that data.  
2.3.3 Model justification 
Throughout this thesis I have used COPASI to modified and expanded upon 
two previously published models (Wang Hui et al. 2014; Proctor et al. 2014) in 
order to assess how these systems interact during ageing. The models where 
simplified but to still fit the same profiles. They were simplified in ordered to 
reduce the computational burden. In order to achieve this some assumptions 
had to be made, which marginally changed the structures. These changes are 
shown in chapter 5 and, as explained there, the simulation profiles still match 
the output in the previous models. However, there were some simplifying 
assumptions still in place from the original models that should be mentioned. 
These were justified in the supplementary data in (Wang Hui et al. 2014) and 
the main text of (Proctor et al. 2014).  
The first model simplification is that TGFβ is not turned over and so it can only 
be added to the model in the initial conditions or via an event. This simplification 
was left in place as TGFβ can enter the system for a variety of reason and 
incorporating these into the model would have added significant complexity. 
Instead TGFβ is inactivated and activated in the model but never lost. Any 
active TGFβ that enters the system is then inactivated, in a process that 
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degrades ALK5 and SMAD7. ALK1 can also be degraded if TGFβ is bound to 
an ALK1/ALK5 heterodimer. Inactive TGFβ can then be activated by Integrin, a 
species in the model that can convert inactive TGFβ to active. MMP-2 could 
also activate TGFβ in the original model but this was removed as it had no 
effect on my combined model. It is known that TGFβ can be activated by many 
biological components such as plasmin, F-spondin or MMP-2/-9 (Yu and 
Stamenkovic 2000; Attur et al. 2009) as well natural detergents such as 
lysophosphatidylethanolamine (LPE) and lysophosphatidylcholine (LPC) (Gay 
et al. 2004). For simplification integrin is representative of all mechanisms of 
TGFβ activation. The TGFβ driven increase in MMP-13 mRNA is driven by 
RUNX2, which is activated by phospho-SMAD1 and inactivated by phospho-
SMAD2. This is a simplification as RUNX2 can be inactivated by other means 
(Jonason et al. 2009). However, as we are specifically interested in how TGFβ 
affects RUNX2, having just phospo-SMADs affecting its activation gives us an 
insight into how their effect on RUNX2 changes with age. It is also important to 
note that SMAD2 in the model represents both SMAD2/3, and SMAD1 
represents SMAD1/5/8.  
The model works through the assumption that IL-1+OSM-driven MMP-13 
expression is a result of c-Fos/c-Jun heterodimers and c-Jun homodimers. Our 
group has recently published that this may be a simplistic view as ATF3 
appears to be important in the upregulation (Chan et al. 2017). However, it is 
clear that c-Fos/c-Jun heterodimers have a significant effect on ATF3 
upregulation (Chan et al. 2017), so it is reasonable to assume that blocking c-
Fos/c-Jun in the way predicted in the model would have the same effects. The 
model also allowed TGFβ to affect the stability of MMP-13 mRNA. This was 
required for the model to fit experimental data. The justification behind including 
this instead of alternatives will be discussed in more detail in chapter 5.  
The combined model uses mass action kinetics excluding equations for 
homodimer formation, where mass action has been altered to allow for the fact 
that the initial molecule cannot bind to itself. Normally during heterodimerisation 
one molecule binds to another so the reaction can be determined as X*Y*k1. 
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Where X is the concentration of molecule X, Y is the concentration of molecule 
Y and k1 is the rate constant. However, during homodimerisation one X 
molecule cannot bind to itself so has to be X*(X-1)*k1, the minus one take into 
account that the second molecule is taken from the overall concentration not 
including the first. This reaction must also be time be halved to account for the 
fact that both molecules are from the same pool so becomes X*(X-1)*0.5*k1. An 
example is for c-Jun dimerization which has the 
equation:“k1*(cJun_P)*(cJun_P-1)*0.5”.  Only one compartment was used for 
the model. The complete list of species and reactions in the combined model 
can be seen in tables 2.4 and 2.5. 
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Species 
 
Description 
Initial amount 
(particle 
number) 
IL1  IL-1 100 
Jnk_p  Phosphorylated form of Jnk 0 
Jnk  Jnk 100 
IL1R  IL-1 receptor 100 
IL1RR  IL-1 bound to receptor 0 
IL1RR.int          
                                     
IL-1 bound to receptor and 
internalised 0 
cJun  c-Jun 100 
cJun_P  Phosphorylated form of c-Jun 0 
cJun_dimer  c-Jun dimer 0 
OSM  OSM 1000 
OSMR  OSM receptor 100 
OSMRR  OSM bound to receptor 0 
Jak1  Jak1 100 
Jak1_P  Phosphorylated form of Jak1 0 
Stat3_nuc  Stat3 in the nucleus 0 
cFos_mRNA c-Fos mRNA 0 
Stat3_cyt  Stat3 in the cytoplasm 75 
cFos  c-Fos 0 
p38  p38 100 
p38_P  Phosphorylated form of p38 0 
cFos_P  Phosphorylated form of c-Fos 0 
cFos_cJun  c-Fos/c-Jun heterodimer  0 
Block  
 
A dummy species to represent 
3 proteins (see chapter 5) 0 
MMP13_mRNA  MMP-13 mRNA 0 
Integrin  
 
 
Integrin but also representative 
of all mechanisms of TGFβ 
activation  0 
Source (fixed particle 
number) 
A fixed pool for the creation of 
new molecules 1 
Sink (fixed particle number) 
 
A fixed pool for the degradation 
of molecules  1 
Alk5  ALK5 500 
Tgfb_A  Active form of TGFβ  0 
Tgfb_I  Inactive form of TGFβ 200 
Alk5_dimer  ALK5 homodimer 0 
Alk1  ALK1 300 
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Alk1_Alk5  
 
ALK1/ALK5 heterodimer 
0 
Tgfb_Alk5_dimer  
 
Active TGFβ bound to an ALK5 
homodimer 0 
Smad7  SMAD7 0 
Tgfb_Alk5_dimer_Smad7  
Active TGFβ bound to an ALK5 
homodimer and SMAD7 0 
Tgfb_Alk1_Alk5  
 
Active TGFβ bound to an 
ALK1/ALK5 heterodimer 0 
Smad2  SMAD2 600 
Smad2_P  Phosphorylated form of SMAD2 0 
Smad2_P_Smad4 
  
Phosphorylated form of SMAD2 
bound to SMAD4 0 
Smad4  SMAD4 600 
Runx2_A  Active form of RUNX2 0 
Runx2_I  Inactive form of RUNX2 100 
Smad1  SMAD1 600 
Smad1_P  Phosphorylated form of SMAD1 0 
Smad1_P_Smad4 
  
Phosphorylated form of SMAD1 
bound to SMAD4 0 
Tgfb_Alk1_Alk5_Smad7 
  
Active TGFβ bound to an 
ALK1/ALK5 heterodimer and 
SMAD7 0 
JunB_mRNA  JunB mRNA 0 
JunB  JunB 0 
JunB_cJun  JunB bound to c-Jun 0 
Dummy 
  
A dummy species (see chapter 
5) 0 
Dummy_mRNA Dummy species mRNA 0 
A 
 
Protein needed to drive dummy 
production 100 
A_P 
 
Protein needed to drive dummy 
production phosphorylated 0 
Anti-TGF 
  
A antibody representative of 
1D11 (see chapter 7) 0 
   
Table 2.4 Model species. The names and initial amounts (particle 
numbers) of all species in my complete model, as well as description of 
what the species represents.  
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Reactions  Parameter values 
IL1  → sink  0.0134 s-1 
Jnk + IL1RR.int  → Jnk_P + IL1RR.int  0.0000707 mol-1 s-1 
Jnk_P  → jnk  0.00117 s-1 
IL1 + IL1R  → IL1RR  0.0000156 mol-1 s-1 
IL1RR  → IL1 + IL1R  0.000456 mol-1 s-1 
IL1RR  → IL1RR.int  0.000526 s-1 
IL1RR.int  → IL1RR  0.000109 s-1 
cJun + JNK_P  → cJun_P + JNK_P  0.000518 mol-1 s-1 
cJun_P  → cJun  0.0101 s-1 
2 * cJun_P  → cJun_dimer  0.0000346 mol-1 s-1 
cJun_dimer  → 2 * cJun_P  0.00598 s-1 
OSM + OSMR  → OSMRR  0.00000565 mol-1 s-1 
OSMRR  → OSM + OSMR   0.000146 s-1 
OSM  → Sink  0.0049 s-1 
Jak1 + OSMRR  → Jak1_P + OSMRR  0.0000115 mol-1 s-1 
Stat3_cyt + Jak1_P  → Stat3_nuc + 
Jak1_P  0.000255 mol-1 s-1 
Jak1_P  → Jak1  0.000113 s-1 
 Stat3_nuc   → Stat3_cyt   0.00517 s-1 
cFos_mRNA  → sink  0.00193 s-1 
Stat3_nuc  → Stat3_nuc + cFos_mrna  0.0373 mol-1 s-1 
Stat3_nuc + Jak1_P  → Jak1 + 
Stat3_nuc  0.00000252 mol-1 s-1 
cFos_mRNA  → cFos_mRNA + cFos  0.000638 s-1 
cFos  → sink  0.0000893 s-1 
p38 + IL1RR.int  → p38_p + IL1RR.int  0.000103 mol-1 s-1 
p38_p  → p38  0.000375 s-1 
p38_p + cFos  → p38_p + cFos_P  0.0000123 mol-1 s-1 
cFos_P  → cFos  0.0249 
cFos_P + cJun_P  → cFos_cJun  0.0000517 mol-1 s-1 
cFos_cJun  → cFos_P + cJun_P  0.0000381 s-1 
cJun_dimer  → cJun_dimer + Block  0.000209 s-1 
cFos_cJun  → cFos_cJun + Block  0.00418 s-1 
Block  → sink   0.0000182 s-1 
 
 
 
76 
 
 
Block + IL1RR.int  → Block + IL1R  0.000181 mol-1 s-1 
Jnk_P + Block  → Jnk + Block  0.000351332 mol-1 s-1 
Stat3_nuc + Block  → Stat3_cyt + 
Block  0.00291 mol-1 s-1 
cFos_P + Block  → cFos + Block  0.0000658 mol-1 s-1 
cJun_dimer  → MMP13_mRNA + 
cJun_dimer  0.00154 s-1 
cFos_cJun  → MMP13_mRNA + 
cFos_cJun  0.000475 s-1 
MMP13_mRNA  → Sink  0.00000348 s-1 
Source  → Integrin   0.000000226 mol s-1 
Integrin  → Sink  0.000509 s-1 
Source  → Alk5  0.00000259 mol s-1 
Tgfb_I + Integrin  → Tgfb_A + Integrin  0.000832 mol-1 s-1 
Tgfb_A  → Tgfb_I  0.0309 s-1 
2 * Alk5  → Alk5_dimer  0.000119 mol-1 s-1 
Alk5_dimer  → 2 * Alk5  0.000743 s-1 
Alk1 + Alk5  → Alk1_Alk5  0.0000765 mol-1 s-1 
Alk1_Alk5  → Alk1 + Alk5  0.0105 s-1 
Tgfb_A + Alk5_dimer  → 
Tgfb_Alk5_dimer  0.0000354 s-1 
Tgfb_Alk5_dimer  → Tgfb_A + 
Alk5_dimer  0.00000111 s-1 
Tgfb_Alk5_dimer + Smad7  → 
Tgfb_Alk5_dimer_Smad7  0.0000165 mol-1 s-1 
Tgfb_Alk5_dimer_Smad7  → 
Tgfb_Alk5_dimer + Smad7  0.00000164 s-1 
Tgfb_Alk5_dimer_Smad7  → Tgfb_I  0.0000206 s-1 
Tgfb_A + Alk1_Alk5  → 
Tgfb_Alk1_Alk5  0.00000477 mol-1 s-1 
Tgfb_Alk1_Alk5  → Tgfb_A + 
Alk1_Alk5  0.00000156 s-1 
Tgfb_Alk5_dimer + Smad2  → 
Tgfb_Alk5_dimer + Smad2_P  0.0000312 mol-1 s-1 
Smad2_P + Smad4  → 
Smad2_P_Smad4  0.000053 mol-1 s-1 
Smad2_P_Smad4  → Smad2_P + 
Smad4  0.0109 s-1 
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Smad2_P  → Smad2  0.0088 s-1 
Smad2_P_Smad4  → 
Smad2_P_Smad4 + Smad7  0.00000894 s-1 
Runx2_A + Smad2_P_Smad4  → 
Runx2_I + Smad2_P_Smad4  0.000717 mol-1 s-1 
Alk5  → Sink  0.000000345 s-1 
Tgfb_Alk1_Alk5 + Smad1  → 
Tgfb_Alk1_Alk5 + Smad1_P  0.0000169 mol-1 s-1 
Smad1_P  → Smad1  0.000217 
Smad1_P + Smad7  → Smad1 + 
Smad7  0.000377 mol-1 s-1 
Smad1_P + Smad4  → 
Smad1_P_Smad4  0.000047 mol-1 s-1 
Smad1_P_Smad4  → Smad1_P + 
Smad4  0.0177 s-1 
Runx2_I + Smad1_P_Smad4  → 
Runx2_A + Smad1_P_Smad4  0.00166 mol-1 s-1 
Runx2_A  → mmp13_mrna + Runx2_A  0.00000159 s-1 
Source  → Alk1  0.00000488 mol s-1 
Alk1  → Sink  0.000000017 s-1 
Tgfb_Alk1_Alk5 + Smad7  → 
Tgfb_Alk1_Alk5_Smad7  0.265 mol-1 s-1 
Tgfb_Alk1_Alk5_Smad7  → 
Tgfb_Alk1_Alk5 + Smad7  0.00076 s-1 
Tgfb_Alk1_Alk5_Smad7  → Tgfb_I  0.00000977 s-1 
Smad7  → Sink  0.00797 s-1 
Smad2_P_Smad4  → 
Smad2_P_Smad4 + JunB_mRNA  0.0000171 s-1 
JunB_mRNA  → JunB_mRNA + JunB  0.000852 s-1 
JunB_mRNA  → Sink  0.0000148 s-1 
JunB  → Sink  0.00924 s-1 
p38 + Smad1_P_Smad4  → p38_P + 
Smad1_P_Smad4  0.000019 mol-1 s-1 
JunB + cJun_dimer  → cJun_P + 
JunB_cJun  0.00000138 mol-1 s-1 
JunB + cJun_P  → JunB_cJun  0.000697 mol-1 s-1 
JunB_cJun  → JunB + cJun_P   0.0000337 s-1 
cFos_cJun + JunB  → JunB_cJun + 0.00000675 mol-1 s-1 
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cFos_P  
Smad2_P_Smad4  → 
Smad2_P_Smad4 + A_P  0.0000142 s-1 
A_P  → Dummy_mRNA + A_P  0.0000146 s-1 
Dummy_mRNA  → Dummy  0.0000154 s-1 
Dummy + mmp13_mrna  → Dummy  0.00000107 mol-1 s-1 
Dummy_mRNA  → sink  0.0000386 s-1 
Dummy  → sink  0.0000322 s-1 
A_P  → A  0.000379 s-1 
Runx2_A  → Runx2_I  0.001 s-1 
Alk1 + Anti-TGF  → Anti-TGF  0.000000549 mol-1 s-1 
Anti-TGF  → Sink  0.000035 s-1 
Tgfb_A + Anti-TGF → Anti-TGF  0.000000549 mol-1 s-1 
 
2.3.4 CellDesigner  
CellDesigner is a structured diagram editor for drawing gene-regulatory and 
biochemical networks (Funahashi et al. 2003). The programme has built in tools 
that allow you to display biological pathways with the systems biology graphical 
notation (SBGN) (Le Novere et al. 2009). SBGN is a visual language for 
systems biology and was designed to create a consistent and unambiguous 
standard notation for biological networks.  The diagrams are then stored in 
SBML, which means that the structure can be moved to other programmes. 
Also models designed in another programme can be moved to CellDesigner, 
though this normally results in a cluttered diagram that is difficult to rearrange. 
Throughout this thesis I have used CellDesigner for any model schematic. 
2.3.5 Matlab   
MATLAB is a proprietary programming language developed by MathWorks, 
primarily for numerical computing, but also has a wide range of additional tools 
(MathWorks Inc., Natick, MA, 2016). I used it for analysing and plotting the 
model output. The programme allows the import of large data files and the 
Table 2.5 Reactions and their rates in my complete model. The reactions 
and parameter values in my complete model.  
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construction of high quality figures. I wrote scripts to generate the plots, as this 
enabled me to re-use and adapt the scripts for different figures. So creating 
figure in Matlab is much more efficient than other tools such as Excel.  
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Chapter 3. Pathway selection in the context of inflammation/OA 
3.1 Introduction 
Although it is becoming more established, there is still some debate about the 
importance of inflammation in OA (Berenbaum 2013). Future research into 
inflammatory pathways in the context of OA will hopefully enable us to fully 
understand its role in development of disease. I chose five pathways; TGFβ, 
Wnt/β-catenin, IHH, PKC and Notch, all of which, as described in chapter 1, 
have established roles in inflammation-driven joint damage. Activating 
compounds were used to examine the affect these pathways had on the 
expression of MMP-13. The aim was to create computational models for all of 
the pathways. I could then examine how these pathways interact with each 
other as well as how they contribute to the inflammatory response in OA 
development. Building a model requires an area of focus to act as an anchor to 
base the model design around. MMP-13 was used as it is vital for cartilage 
degradation and all of the pathways have a reported effect on its expression.  
3.1.1 Chapter aims  
 
 Use bioinformatic tools to justify the selection of inflammatory pathways.  
 
 Look at the affect of activating the five pathways: TGFβ, Wnt/β-catenin, 
IHH, PKC and Notch, on both cell viability and the expression of MMP-
13, after 24 hours. Then explore in more detail any interesting 
observations made. 
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3.2 Results 
3.2.1 Bioinformatic analysis highlights Inflammations impotence in OA 
The development of OA is typically a result of many changes within the tissue. 
This makes it difficult to identify the major factor driving the progression of this 
disease. To address this I took microarray data from 50 OA samples (chapter 
2.2.6) and using a series of bioinformatic tools created a clustered Cytoscape 
network representative of OA in humans (Fig 3.1). DAVID analysis of the 
clusters allowed me to better understand the function of each cluster, of which 2 
of the top 6 clusters represented inflammation. Tight clustering means each 
node has multiple connections to other nodes, suggesting that there is a lot of 
crosstalk between the genes in that cluster. In the case of both inflammatory 
clusters there was an area of tightly clustered genes, suggesting many of these 
genes interact with each other. This highlighted the importance of inflammation 
in OA development, as well as the level of crosstalk between inflammatory 
genes (Fig 3.1).
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Figure 3.1 Top Cytoscape clusters in human OA. Affymetrix microarray data 
from 50 knee OA patients were collected from the GEO database, normalised, 
and the differentially expressed genes combined. ARACNE then inferred the 
interactions between these genes providing mutual information (MI) values that 
could be visualised using Cytoscape. The nodes (blue dots) represent 
differentially expressed genes and the edges are the MI values. Using 
clusterMaker these genes were then clustered based on MI values. DAVID 
analysis was then used to determine what each of the clusters represent. The 
six largest clusters are presented along with what they represent.  
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3.2.2 Assessing the toxicity of activator compounds 
In order to examine some of the pathways that appear important in OA 
development I obtained five activating compounds: sodium butyrate (SB), a 
Notch activator; Purmorphamine (Pur), a IHH activator; Bryostatin-1(Bro-1), a 
protein kinase C (PKC) activator; QS11, a Wnt/β-catenin activator; and an 
active form of TGFβ (Table 3.1). Figure 3.2 shows the effect all the compounds 
had on SW1353 cells at 24 hours. Only QS11 and SB have a significant effect 
on MMP13 expression at this time point (Fig 3.2). The variability of the response 
as shown by the standard deviations was high for both of these compounds (Fig 
3.2). This could be traced to the raw data where the average CT value for the 
loading control gene (18S rRNA) was higher with irregular variation in cells 
treated with some of the compounds, compared to control cells. For example 
the average CT for 18S in QS11-treated samples was 20.1±1.28 compared to 
18.1±0.47 in control. This showed there was less total mRNA and that the 
amount was highly variable, both of which was most likely a result of cell death.  
Concentrations at which to use these compounds were taken from published 
literature (Table.3.1). I used a live/dead assay to assess the toxicity. This assay 
allowed me to visualise the number of live cells against the level of dead cells. 
Taking a representative sample I then counted the cells and worked out the 
percentage of cell death. Fig ure 3.3 shows an example of the live/dead assay 
for four concentrations of SB. It was clear that there were substantially more live 
cells at 1mM than the original 20mM concentration. 
Quantifying this cell death allowed me to alter the original concentrations of all 
the compounds so that there was a similar level of cell death to the control cells. 
Fig ure 3.4A shows this specifically for the quantifications of SB and this same 
process was applied to all compounds (data not shown). Fig ure 3.4B shows the 
cell death of the compounds at the corrected concentrations (Table.3.1). I found 
that Pur and Bro-1 were non-toxic at 0.5μM and 20nM respectively, whilst SB 
had to be 1nM (Table.3.1). All other compounds remained at their original 
concentrations. It is also worth noting that DMSO alone did not seem to induce 
additional cell death, so it is the compounds themselves that were mediating the 
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observed effects (Fig 3.4B). TGFβ was the only compound that increased cell 
viability, reducing the 14.9% cell death seen in control cells to 6.7% (Fig 3.4B).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Pathway 
Activators  
Activated Pathway Original 
Concentration 
Corrected 
Concentrations  
Sodium butyrate 
(SB) 
Notch 20mM 1mM 
QS11 Wnt/β-catenin 2.5μM 2.5μM 
Purmorphamine  
(Pur) 
Indian hedgehog 4μM 0.5μM 
TGFβ TGFβ 0.15μM 0.15μM 
Bryostatin-1 (Bro-1) Protein kinase C 100nM 20nM 
Table 3.1 The concentration used for activator compounds before and after 
cell viability adjustments.    
Figure 3.2 Effect of activating compounds on MMP-13 expression after 24 hours 
treatment. SW1353 cells were stimulated for 24 hours with SB (20mM), QS11 
(2.5μM), Pur (4μM), TGFβ (0.15 μM), Bro-1 (100nM), or DMSO as a vehicle control. 
qPCR was then performed on the isolated mRNA to measure MMP-13 expression. 
Data are presented as fold change relative to control (mean ± SD, n=6). Statistics 
calculated using unpaired Student’s t-test, where * p < 0.05; ** p < 0.01.  
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Figure 3.3 Exploration of cell death after 24 hour Sodium butyrate treatment. 
SW1353 cells were serum starved overnight and then treated with SB for 24 hours at 
20mM, 10nM, 5nM, 1nM. Calcein-AM stains only live cells, whereas EthD-1 stains only 
dead cells. The Calcein-AM and EthD-1 images are both taken from the same sample 
on the same field of view but under different fluorescent filters. Data are representative 
of two experiments using separate SW1353 cell populations.    
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Figure 3.4 Percentage of cell death in SW1353 cells after 24h stimulation. 
SW1353 cells were stimulated for 24 hours with A) SB at 20mM, 10nM, 5nM, 1nM 
or DMSO as a vehicle control. B) SB (1mM), QS11 (2.5μM), Pur (0.5μM), TGFβ 
(0.15 μM), Bro-1 (20nM) or DMSO. Live/dead assays were performed to quantify 
the number of alive and dead cells in a population after treatment. Data are 
presented as number of dead cells divided by total cell count x 100, defined as 
percentage cell death. Data are representative of two experiments using separate 
SW1353 cell populations.    
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3.2.3 Exploring the effect of activating specific pathways   
Once a non-toxic concentration had been established, I re-tested the effects of 
the compounds at 24 hours. IL-1 and OSM were also included in these 
experiments, as our group has previously explored their potent upregulation of 
MMP-13 in detail and so would provide a reference point for the potency of the 
various stimuli. The ability of TGFβ to protect against cell death (Fig 3.4B) 
highlighted some work done previously by our group, which showed TGFβ 
could protect against inflammatory stimuli (Hui et al. 2003; Hui et al. 2000). This 
work had not yet been followed up by our group and repression had only been 
previously shown in Northern blots. Therefore I also included IL-1+OSM+TGFβ 
to better quantify the levels of repression of MMP-13 mRNA.  
In this second experiment QS11 lost the upregulation of MMP-13 (Fig 3.5) that 
was previously seen (Fig 3.2). A potent effect was seen by IL-1+OSM and this 
was significantly repressed by TGFβ addition (Fig 3.5A). Pur appeared to 
upregulate MMP-13 but this effect was not significant. Only SB and Bro-1 
compounds had a significant effect on MMP-13 expression (Fig 3.5B). This 
effect was similar to that of IL-1 alone (Fig 3.5B).  
If Bro-1 was activating PKC I would have expected a more significant increase 
in MMP-13 than was seen (Fig 3.5B). The small increase contradicted work 
performed earlier by our lab and others on PKC (Litherland et al. 2010). Re-
evaluating when to look at PKC activation suggested it may have a stronger 
effect over a shorter time scale (6 hours) and at different concentrations. When 
run for 6 hours at various concentrations Bro-1 caused a much more potent 
increase in MMP-13 expression (Fig 3.6A). The expression of MMP-13 varied 
considerably across the concentrations, with a large standard deviation on 
many of the samples (Fig 3.6A). There was a prodigious increase in MMP-1 
expression which was also considerably less variable, although it did appear to 
peak at 10 and 30nM above all other concentrations (Fig 3.6B).  
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Figure 3.66 MMP-1/-13 expression after 6 hours of Bryostatin-1 treatment. 
SW1353 cells were stimulated with Bro-1 for 6 hours at concentrations ranging 
from 10-100nM. qPCR was then performed on the isolated mRNA to measure A) 
MMP-13 expression B) MMP-1 expression. Data are presented as fold change 
relative to control (mean ± SD, n=4-6) except 80nM where N=2. Statistics 
calculated using unpaired Student’s t-test, where *** p < 0.001. 
 
Figure 3.55 MMP-13 expression at 24 hours after treatment with various 
activating compounds. SW1353 cells were stimulated for 24 hours with SB 
(1mM), QS11 (2.5μM), Pur (0.5μM), TGFβ (0.15 μM), Bro-1 (20nM), IL-1 
(0.5ng/ml), OSM (10ng/ml) or DMSO as a vehicle control. qPCR was then 
performed on the isolated mRNA to measure MMP-13 expression. A) Data shown 
for all conditions B) Data from the same experiment with IL-1+OSM and IL-
1+OSM+TGFβ excluded to aid the visualisation of smaller fold changes. Data are 
presented as fold change relative to control (mean ± SD, n=5-6). Statistics 
calculated using unpaired Student’s t-test, where * p < 0.05; ** p < 0.01.  
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3.2.4 Protective effect of TGFβ 
I initially wanted to confirm that TGFβ-mediated repression of MMP-1/-13 in 
SW1353 cells treated with IL-1+OSM. Preliminary experiments looked at the 
effects of OSM, IL-1 and TGFβ on MMP-1/-13 over a range of time scales (Fig 
3.7 and 3.8). These determined that it took IL-1+OSM at least 3 hours to have a 
significant effect on MMP-1/-13 expression (Fig 3.7 and 3.8). TGFβ appeared to 
have little or no effect on MMP-1/-13 expression prior to 24 hours. However, at 
24 hours it appeared to repress the effect of IL-1+OSM (Fig 3.7 and 3.8). Initial 
studies also showed that the fold change expression of MMP-13 could vary 
markedly between experiments with fold changes around 150 (Fig 3.7A) being 
closer to 3000 in the repeat experiment (Fig 3.7B). The fold change variability 
was reduced for MMP-1, despite being between 80 (Fig 3.8A) and 300 fold (Fig 
3.8B). This was a result of low basal levels of MMP-13, meaning that control 
samples had a high CT value. This means even marginal differences in either 
control or treated samples could equate to large variations in fold change. This 
was less of an issue for MMP-1 as its basal expression was higher.  I also 
confirmed that OSM and TGFβ alone had no noticeable effect on MMP-1/-13 
expression and that the effect of IL-1 alone was also reduced, when compared 
to IL-1+OSM. Therefore I could exclude TGFβ and OSM alone from future 
experiments. In order to generate significant robust data I looked at the time 
when repression seemed the most potent and matched previous experimental 
data, 24 hours (Hui et al. 2000).  
  
 
 
  
Figure 3.7 Time course of MMP-13 expression across a range of stimulations. SW1353 cells stimulated with varying 
combinations of IL-1 (0.5ng/ml), OSM (10ng/ml) and TGFβ (0.15ng/ml) for 1, 3, 6 and 24 hours. qPCR was then performed on the 
isolated mRNA to measure MMP-13 expression. A) and B) Show the expression across two independent experiments. Data are 
presented as fold change relative to control (mean ± SD, n=3-4). Statistics calculated using unpaired Student’s t-test, where* p < 
0.05. 
 
Figure 3.8 Time course of MMP-1 expression across a range of stimulations. SW1353 cells were stimulated with varying 
combinations of IL-1 (0.5ng/ml), OSM (10ng/ml) and TGFβ (0.15ng/ml) for 1, 3, 6 and 24 hours. qPCR was then performed on the 
isolated mRNA to measure MMP-1 expression. A) and B) Show the expression across two independent experiments. Data are 
presented as fold change relative to control (mean ± SD, n=3-4). Statistics calculated using unpaired Student’s t-test, where*** p < 
0.001 
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Increasing the n number allowed me to confirm that there was a significant 
down regulation of MMP-1/-13 in IL-1+OSM+TGFβ treated cells, when 
compared to IL-1+OSM alone (Fig 3.9A and 3.10A). As in the first two 
experiments (Fig  3.7 and 3.8) fold changes varied considerably. To address 
this I used percentage of repression to provide a robust way of examining the 
effect of TGFβ, by calculating the ΔΔCT values relative to the IL-1+OSM 
samples, rather than the control. This allowed pooling of samples from multiple 
experiments to calculate the average amount of repression mediated by TGFβ. 
Pooling data this way showed highly significant repression for both MMP-1/-13 
(Fig 3.9B and 3.10B). 
Figure 3.9 Effect of TGFβ on IL-1+OSM induced MMP-13 expression. SW1353 cells were stimulated with IL-1 (0.5ng/ml), 
OSM (10ng/ml) and IL-1+OSM±TGFβ (0.15ng/ml) for 24 hours. qPCR was then performed on the isolated mRNA to 
measure MMP-13 expression. Data are presented as fold change relative to control (A) or IL-1+OSM (B) (mean ± SEM). A) 
A lone experiment, n=5-6. Representative of 4 independent experiments on separate SW1353 cell populations. B) Data 
pooled from 4 independent experiments at 24 hours, n=14. Statistics calculated using unpaired Student’s t-test, where * p < 
0.05; *** p < 0.001 
 
  
 
 
 
 
 
Figure 3.10 Effect of TGFβ on IL-1+OSM induced MMP-1 expression. SW1353 cells were stimulated with IL-1 (0.5ng/ml), 
OSM (10ng/ml) and IL-1+OSM±TGFβ (0.15ng/ml) for 24 hours. qPCR was then performed on the isolated mRNA to measure 
MMP-1 expression. Data are presented as fold change relative to control (A) or IL-1+OSM (B) (mean ± SEM). A) A single 
experiment, n=4-6. Representative of 3 independent experiments on separate SW1353 cell populations. B) Data pooled from 
3 independent experiments at 24 hours, n=10-13. Statistics calculated using unpaired Student’s t-test, where * p < 0.05; *** p 
< 0.001 
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3.2.5 Bioinformatic validation of TGFβ selection 
Publically available microarray data provided an opportunity to look at mRNA 
expression data from SRT/ort mice, a model of spontaneous OA development 
(Poulet et al. 2012). Cartilage was taken from the mice at 8, 16 and 40 weeks 
(Poulet et al. 2012). I took the genes with significant enrichment and using gene 
set enrichment analysis (GSEA) identified the most significantly enriched KEGG 
pathways. At 8 and 16 weeks there were no significantly upregulated KEGG 
pathways, whilst at 40 weeks there were 7 positively regulated and 22 
negatively regulated. Exploring these pathways identified a potential role for IL-
1, OSM and TGFβ in OA development. Looking in more depth at the specific 
pathway “KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION” (Fig 
3.11), it contained 17 core enriched receptors some of which have a role in 
inflammatory signalling. IL-1 (IL1A and IL1B), OSM (OSMR) and TGFβ 
(ACVRL1) receptors were all shown to have increased expression in these 
older mice (Fig 3.11).   
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Figure 3.11 Key KEGG processes in Srt/ort mice. Data presented are publically 
available Affymetrix microarray data. Articular cartilage was extracted from STR/ort and 
CBA mice at 8, 18 and 40 weeks. The differentially expressed genes, from the STR/ort 
mice, were run using GSEA to determine their importance in KEGG process. Based on 
significant enrichment scores only 40 weeks had any enriched KEGG pathways. The 7 
positively regulated pathways are shown here, the specific pathway 
“KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INERACTION” has been expanded to 
visualise the genes that have led to its enrichment. Core enriched genes are a subset of 
genes that contributes most to the enrichment result, of these the IL-1, OSM and TGFβ 
(ACVRL1) receptors are highlighted in red. FDR is the false discovery rate and is the 
estimated probability that a gene set represents a false positive finding. An FDR of 0.1 
represents a 1% chance the result is a false positive.  
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3.3 Discussion  
Bioinformatic analysis confirmed the importance of inflammation in OA 
development and also highlighted how important the interactions between 
inflammatory genes are. As a result I looked at the effect all five pathways had 
on MMP-13 expression. My initial aim was to build a computational model for all 
five pathways and then asses how they interacted with each other to modulate 
MMP-13, or more widely inflammation-driven OA development. However, it 
became clear that this was overly ambitious and instead I used the data I to 
choose one pathway to progress with further.  
3.3.1 Activating compounds  
The limitation of the live/dead assay is that it requires manual selection of the 
image and cell counting, leaving both open to human error. However, this 
approach also allowed close examination of the changes between 
concentrations. The only viable alternative was a Toxilight assay which I found 
to be variable with decreased sensitivity to the live/dead assay. 
 
One concern of altering the concentration was that activation of the pathways 
themselves may have led to cell death, so altering the concentration would only 
serve to prevent their activation. It is also possible that the activating 
compounds must be at a toxic concentration in order to activate their respective 
pathways. However, if either of these situations were correct they would not be 
an ideal pathway for further study. 
 
QS11, despite not being toxic, had a variable effect on MMP-13, possibly 
because the concentration was sufficient to initiate signalling in some cells but 
not all. Bro-1 led to a significant increase in MMP-1/-13 expression at 6 hours 
despite having little effect at 24 hours. This finding was intriguing as PKC 
signalling effects MMP-1 in a more robust manner than MMP-13. This was 
difficult to explain as no work performed by our group or others has shown this 
phenomenon. It also highlighted that 24 hours may not be the optimal time point 
for all the compounds. However, 24 hours was chosen because it was a 
significant period of time for slow acting pathways to have an effect but not so 
long that you would lose an early effect.  
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Neither SB nor Pur had a prominent effect on MMP-13 expression.  Whether 
this is due to the activating compounds used, the time point, or that Notch/IHH 
signalling does not have a strong effect in SW1353 cells, is unclear. The 
subsequent work into Bro-1 demonstrated that in order to fully comprehend the 
action of all the different activators I would need to examine more conditions. 
Further studies into all of these pathways would undoubtedly have its uses but 
time was a limiting factor and exploring all of them would have been impossible.  
3.3.2 TGFβ selection 
The TGFβ-mediated increase in cell viability was unsurprising given the role of 
TGFβ in maintaining chondrocyte homeostasis and preventing hypertrophy 
(Blom et al. 2004; Blaney Davidson et al. 2007). Regardless, to see such a 
pronounced effect in cell culture at only 24 hours was interesting. It also led me 
back to work done previously by our group that showed TGFβ can inhibit pro-
inflammatory responses, whether this be IL-1+OSM or OSM+TNFα (Hui et al. 
2003; Hui et al. 2000). This work showed that TGFβ could block collagen 
release, and that this effect was most likely mediated by reducing the effect pro-
inflammatory stimuli had on MMP-1/-13 expression (Hui et al. 2000). This 
reduction in MMP-1/-13 expression was shown in bovine cartilage by Northern 
blot (a semi quantitative technique) (Hui et al. 2000). qPCR as a quantitative 
technique allowed me to more accurately show the levels of repression 
mediated by TGFβ. This improved level of quantification was useful for model 
construction.  
At this point TGFβ or PKC signalling seemed the most reasonable pathways to 
progress with, both showing interesting effects on MMP-13 expression that 
could be built upon. TGFβ was chosen because exploring the microarray data 
from STR/ort mice identified it had a role in the development of spontaneous 
OA. This led to research also carried out on the STR/ort mice by Blaney 
Davidson et al. (2009). They showed that, with age, TGFβ signalling moved 
from its previously protective effects towards damaging effects in cartilage. This 
is mediated through a move from ALK5 receptor signalling towards ALK1 
signalling. How the protective effect of TGFβ against pro-inflammatory stimuli 
changed with age has not previously been explored. Losing the potent 
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protective effect against cell death I have seen, as well as potentially altering 
the protective effect of TGFβ against inflammation with age, could conceivably 
be key in OA development. Looking at mRNA expression in these mice allowed 
me to validate the role of ALK1. I found that not only ALK1 but also IL-1 and 
OSM receptors have core enrichment at 40 weeks in these mice. The KEGG 
pathway that was present represented cytokine receptor interactions suggesting 
there is increased signalling through these receptors in these mice. This was 
not seen in the younger mice, suggesting that this increased signalling may be 
one of the factors that drive OA development. I also had access to two 
computational models; a model of age-related changes in molecular pathways 
which included a TGFβ signalling component (W. Hui et al. 2014) and a model 
of IL-1+OSM signalling (Proctor et al. 2014). These provided a framework on 
which to base the direction of the work, expanding and combining these models 
to better understand the effects of TGFβ on inflammation with age.   
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3.3.3 Summary  
 Through this chapter I explored 5 different biological pathways (Notch, 
IHH, PKC, Wnt/β-catenin and TGFβ) that may be important in OA 
development by examining their effect on cell viability and MMP-13 
expression at 24 hours.  
 
 Notch activation with SB initially induced cell death but this was elevated 
by reducing the concentration. Notch activation was able to induce 
increased  MMP-13 expression at 24 hours.  
 
 Neither WNT/ β-catenin or IHH activation had a significant effect on 
MMP-13 expression.  
 
 Activating PKC significantly upregulated MMP-1/-13 at 6 hours. This 
upregulation was still seen at 24 hours, for MMP-13, but was greatly 
reduced. 
 
 PKC activation-mediated MMP-1 upregulation more robustly than MMP-
13, at 24 hours.  
 
 TGFβ was the only pathway that could protect against cell death in 
SW1353 cells. 
 
 TGFβ represses the IL-1+OSM-driven upregulation of MMP-1/-13 mRNA 
at 24 hours.  
 
 Bioinformatic analysis demonstrated the importance of inflammation in 
OA. It also showed increased IL-1, OSM and TGFβ receptor activation in 
end stage OA for SRT/ort mice. 
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Chapter 4. Exploring the TGFβ signalling pathway 
4.1 Synopsis 
The previous chapter identified the need to focus on one pathway to study using 
a computational approach. It showed how the first step in building a model is to 
find out what is already known about the pathway and then ensure you have a 
model that can match previous data. Once this has been established you can 
identify an area to explore. I chose TGFβ as I matched SW1353 data to what 
was seen previously but also located an unexplored area; looking at how the 
effect of TGFβ on a pro-inflammatory stimulus changes with age. Before 
continuing with the construction of the model, I wanted to examine the pathway 
closer. Throughout this chapter I will present the current literature around the 
role of TGFβ in OA. I will then expand on this experimentally, by exploring the 
time scale by which TGFβ mediates its effect on IL-1+OSM-driven MMP-1/-13 
expression. I will then identify the importance of the ALK5 receptor in this 
repression. It is worth noting that the TGFβ pathway is incredibly complex and it 
was not possible to explore all aspects of the pathway in one model.  
4.2 Introduction  
4.2.1 TGFβ 
Originally discovered in 1978 as a growth factor in rat kidney fibroblasts, that 
could lead to malignant transformation of cells, TGFβ was called sarcoma 
growth factor (SGF) (de Larco and Todaro 1978). It later became apparent that 
SGF was comprised of two separate factors, which were renamed transforming 
growth factor (TGF) α and β (Roberts et al. 1981). TGFβ was then examined 
further discovering that it could inhibit cell growth (Roberts et al. 1985). The 
same group subsequently showed it could also lead to growth and proliferation 
of chondrocytes, demonstrating the opposing roles of TGFβ (Roberts et al. 
1986).  
The complex nature of OA is highlighted by TGFβ, a growth factor with a lot of 
therapeutic potential due to its pleiotropic role in disease progression. It has 
varying effects depending on not only the type of tissue but the age and 
environment surrounding the tissue. There are three TGFβ isoforms: TGFβ1, 2 
and 3, all of which are identical in almost all biological properties (Panoulas et 
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al. 2009). All three isoforms of TGFβ are expressed in chondrocytes during 
differentiation. TGFβ 1 and 2 have continuous expression in healthy adult 
chondrocytes, Baugé et al. (2014) highlighting the role they have in maintaining 
homeostasis. Despite this, chondrocytes can still secrete all three isoforms 
under the right stimuli (Villiger and Lotz 1992). All isoforms appear to have a 
role in the development of OA, with removal of TGFβ signalling via the TGFβ 
receptor type 2 (TGFBR2) receptor having both positive and negative effects on 
OA development (Scharstuhl, Glansbeek, et al. 2002). Equine cartilage has 
shown that TGFβ1 is the most abundant isoform in cartilage and all three 
isoforms are decreased with age. Mice deficient in any isoform have embryonic 
lethality. For example TGFβ1-deficiency resulting in a diffuse and lethal 
inflammation in mice (Dunker and Krieglstein 2000). This inflammatory 
phenotype is particularly relevant as TGFβ1 has been shown to oppose the 
effects of inflammatory mediators; our group demonstrating this for IL-1+OSM 
and TNF-α (Hui et al. 2003; Hui et al. 2000; W. Hui et al. 2014). I chose TGFβ1 
because of its prominent role in protecting against inflammation and in particular 
how this might change with age (Hui et al. 2000).  It was also chosen as a result 
of the research done previously by the group which provided me with a wealth 
of information from which to plan experiments. It is also the best characterised 
in the literature and has a prominent role in the development of OA (Fang et al. 
2016).  
4.2.2 TGFβ activation  
TGFβ is secreted into the synovial joint in an inactive form and must first be 
activated in order to have an effect. Directly after synthesis TGFβ binds to 
latency associated peptide (LAP) to create a complex that can then interact with 
its binding partner latent TGFβ binding protein-1 (LTBP1). This creates a latent 
form of TGFβ that can be secreted into the various tissues (Pedrozo et al. 
1998). In this form it cannot bind to any TGFβ receptor, so in order to have an 
effect it must be activated by a two-step process; first removing it from LTBP1, 
then cleaving LAP to form the active TGFβ. Both of these events can be 
mediated by plasmin, F-spondin or MMP-2/-9 (Yu and Stamenkovic 2000; Attur 
et al. 2009), as well natural detergents such as lysophosphatidylethanolamine 
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(LPE) and lysophosphatidylcholine (LPC). Both LPC and LPE can release 
TGFβ from LTBP1 but cannot directly remove LAP, instead they promote the 
activation of proteases to form active TGFβ (Gay et al. 2004). Many other 
proteins and substances have been linked to TGFβ indicating that the activation 
of the TGFβ pathway is complex and not yet fully understood.  
4.2.3 TGFβ signalling 
Once activated TGFβ can signal through the SMAD-dependent (canonical) or 
SMAD-independent (non-canonical) pathways.  The non-canonical pathways, 
active TGFβ interacts with a number of other important biochemical pathways. 
Using a variety of MAP kinases it can interact with ERK (Hartsough and Mulder 
1995), p38 kinase (A. Nakao et al. 1997), or Rho-like GTPase (Bhowmick et al. 
2001) signalling pathways, amongst many others, which potentially could help 
to contribute to the development of OA. An example of this is its interaction with 
Wnt/β-Catenin. Dong et al, (2005) showed that TGFβ could inhibit all of the Wnt 
proteins. However, the most important interaction is with β-Catenin, regulating 
its ability to cause chondrocyte differentiation, with TGFβ removal resulting in 
excess differentiation (Dong et al. 2005).  
4.2.3.1 Canonical pathway 
The canonical TGFβ pathway is important to study as it can have either 
catabolic or anabolic effects depending on which of its receptors it activates (Fig 
1.6). TGFβ can signal through two receptors in cartilage; either Activin A 
Receptor Like Type 1 (ACVRL1 or ALK1) or TGFβ receptor 1 (ALK5). Which of 
these receptors it binds to leads to different downstream effects. ALK1 is the 
preferential binding partner, but TGFβ predominantly signals through ALK5 due 
to its abundance (van der Kraan et al. 2012). ALK5 binding leads to SMAD2/3 
phosphorylation, which in turn blocks terminal differentiation, chondrocyte 
hypertrophy and also stimulates the production of matrix components (Blaney 
Davidson et al. 2009) (Fig 4.1).  Problems arise if the balance is switched 
towards ALK1 signalling which causes increased SMAD1/5/8 phosphorylation. 
This has the exact opposite effect of ALK5 signalling leading to chondrocyte 
hypertrophy, terminal differentiation and matrix breakdown by MMPs such as 
 
 
 
104 
 
 
MMP-13 (Blaney Davidson et al., 2009). As mentioned in chapter 3, this change 
in ALK1/ALK5 has been shown to correspond with the development of 
spontaneous OA in the STR/ort mouse model (Blaney Davidson et al. 2009) but 
these results have also been seen in guinea pigs (Zhao et al. 2016).  
In order to have an effect, phosphorylated SMAD2/3 and 1/5/8 must bind to 
SMAD4, also known as the co-SMAD (Massaous and Hata 1997). SMAD4 is 
constantly shuttling between the cytoplasm and nucleus, both in unstimulated 
and ligand-stimulated cells (Bernhard Schmierer et al. 2008). Once bound 
SMAD4 can translocate the phosphorylated SMADs to the nucleus (Massaous 
and Hata 1997). When in the nucleus the SMADs are released from SMAD4 
and function as transcription factors to mediate their effects. The inhibitor I-
SMADs 6/7 regulate TGFβ signalling at two levels, targeting the receptors to 
stop signalling but also competing with SMAD4 to reduce the impact of SMAD 
signalling (Atsuhito Nakao et al. 1997; Imamura 1997). SMAD7 is a major 
regulator for SMAD2/3 signalling but it does have a smaller role in regulating 
SMAD1/5/8 (Hayashi et al. 1997). It binds to activated TGFβ receptors 
preventing them from phosphorylating SMAD proteins (Hayashi et al. 1997). It 
also has a key role in TGFβ receptor ubiquitination and destruction via 
interactions with the Smurf proteins (Kavsak et al. 2000). Smurf 2 can bind to 
SMAD7 to shuttle the receptors to the cytoplasm. Once there the Smurf-SMAD7 
complex can target the receptor for destruction (Kavsak et al. 2000). SMAD6 is 
the primary regulator of SMAD1/5/8 signalling (Imamura 1997). SMAD6 
competes with SMAD4 for interaction with receptor activated SMADs. For 
example binding to phospho-SMAD1 creates a SMAD1 - 6 complex that can no 
longer be shuttled to the nucleus (Hata et al. 1998). The activity of both I-
SMADs is regulated at many levels. TGFβ induces the expression of SMAD7 
(Atsuhito Nakao et al. 1997), whilst BMP signalling seems to induce SMAD6 
(Afrakhte et al. 1998). SMAD7 is also present in the nucleus but moves to the 
cytoplasm in response to TGFβ signalling (Itoh et al. 1998). Both I-SMADs can 
also be induced by other signals that effect TGFβ signalling such as IL-1 (Bitzer 
et al. 2000).   
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TGF beta receptor 2 (TGFBR2) is required to mediate TGFβs effect; two 
TGFBR2 molecules form a homodimer that forms a complex with TGFβ and 
either of its type 1 receptors (Bierie and Moses 2006). This complex can be 
comprised of TGFBR2 homodimers, TGFβ and a homodimer of ALK5 leading to 
SMAD2/3 phosphorylation, or the heterodimer of ALK5/ALK1 which leads to 
SMAD1/5/8 phosphorylation (M. J. Goumans et al. 2003). ALK1 cannot mediate 
its effect without ALK5 (M. J. Goumans et al. 2003).  Endoglin may also play a 
role in mediating ALK1 signalling by facilitating its binding to TGFBR2; although 
it is not yet clear to what extent it is required (Finnson et al. 2010). Which type 1 
receptor TGFβ is signalling through can be determined by gene specific 
expression patterns. Goumans et al. (2002) showed that plasminogen activator 
inhibitor-1 (PAI1) is a downstream target of ALK5 and that inhibitor of DNA 
Binding 1 (ID1) is downstream of ALK1; both can be upregulated by TGFβ. 
During TGFβ treatment, when ALK1 was removed, there was no change in ID1 
expression whilst, when ALK5 was removed, PAI1 was unchanged. 
Constitutively active forms of ALK1 and ALK5 also upregulated ID1 and PAI1 
exclusively (Goumans et al. 2002). ALK1 signalling inhibits downstream ALK5 
signalling; meaning that when ALK1 starts to become the dominant receptor 
SMAD2/3 phosphorylation becomes less abundant, whereas ALK5 downstream 
signalling has no direct effect on SMAD1/5/8 phosphorylation (M. J. Goumans 
et al. 2003).  
Figure 4.1 summarises TGFβ signalling through both type 1 receptors. The 
pluripotent effect of TGFβ here is interesting as the joint produces a large 
amount of it in response to damage, or in the event of inflammation, due to its 
protective effect mentioned earlier. If the tissue has changed to ALK1 signalling 
then this previously beneficial response will now lead to even greater damage. 
High levels of TGFβ are seen in osteoarthritic joints (Schlaak et al. 1996), and 
this could be a major source of damage if TGFβ is signalling through ALK1. 
Identifying the causes of this change from ALK5 to ALK1 signalling could 
potentially be of great benefit as a therapeutic target, as reversing this change 
would not only prevent damage but restore a previously protective pathway.    
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4.2.4 TGFβ and cartilage  
It has been demonstrated that TGFβ is required for normal cartilage 
development and is crucial for maintaining articular chondrocyte homeostasis in 
synovial joints (Blaney Davidson et al. 2007). Cartilage maintenance, as 
discussed in chapter 1.1.2.3, is mediated by many biological pathways. Figure 
4.2 highlights the central role of TGFβ in cartilage maintenance. Loss of TGFβ 
Figure 4.1 An overview of TGFβ signalling pathway in chondrocytes. 
Depending on which of the two type I receptors TGFβ binds to determines the 
downstream effect. Binding to ALK1 starts a series of reactions that result in matrix 
breakdown, chondrocyte hypertrophy and terminal differentiation. Conversely, 
binding to ALK5 produces the opposite effect. Both ALK1 and ALK5 are in dimers 
with ALK5 but this has been omitted for simplicity.  
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signalling in cartilage induces chondrocyte hypertrophy, ultimately resulting in 
cartilage degeneration (Hiramatsu et al. 2011). Furthermore, in mice, when 
tissue is aged TGFβ has the opposite effect on cartilage development (Blaney 
Davidson et al. 2009) (Fig 4.1). High levels of TGFβ in the synovial fluid of OA 
patients indicated it may also affect synovial fibroblasts (Blom et al. 2004). 
Further studies have confirmed this, with constitutively active TGFβ injections 
into the synovial fluid leading to synovial fibrosis whilst also increasing 
production of pro-inflammatory cytokines such as IL-1 and TNF-α (Scanzello 
and Goldring 2012).  
TGFβ has a potent anti-inflammatory effect and has been shown to protect 
against the synergistic effects of OSM with pro-inflammatory cytokines. It can 
reduce collagen release by both TNF-α + OSM and IL-1+OSM (Hui et al. 2003; 
Hui et al. 2000). In the case of IL-1+OSM, TGFβ reduced collagen release by 
≥80%. This effect was most likely mediated by reducing the downstream effects 
of IL-1 and OSM on MMP-1/-13 mRNA production (Hui et al. 2000). Both MMP-
1/-13 mRNA was significantly downregulated at 24, 48 and 72 hours. How 
TGFβ leads to this reduction is currently unknown.  TGFβ can also increase 
expression of TIMPs and PAI1, both of which have been reported to target 
cartilage destructive enzymes to reduce damage (Campbell et al. 1994; Blaney 
Davidson et al. 2007).Whether or not the protective effect of TGFβ against 
inflammatory stimuli remains in aged organisms is yet to be examined. 
However, I hypothesised that this effect will either be removed or reversed with 
TGFβ, leading to increased damage by further upregulation of MMP-13 and 
possibly MMP-1. 
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4.2.5 TGFβ and bone 
TGFβ has a relatively minor role in bone compared to cartilage but despite this 
proper maintenance of its expression is vital for bone health.  TGFβ is released 
by osteoclasts when they degrade old or damaged bone, allowing it to direct 
mesenchymal stem cells (MSC) to the resorption site. MSCs can then form 
osteoblasts leading to new bone synthesis as well as inactivating TGFβ (G. 
Zhen and X. Cao 2014). This process is summarised in Figure 4.3. As TGFβ 
has a relatively minor role, excess TGFβ in bone is easier to characterise than 
in cartilage as it appears to only have negative effects (G. Zhen and X. Cao 
2014). TGFβ is regularly found to be upregulated in OA bone, from both animal 
and human tissues. Osteoblast cells that constitutively expressed active TGFβ 
in transgenic mice lead to abnormal subchondral bone structure and eventually 
Figure 4.2 Interaction of cartilage maintenance pathways. Adapted from Mariani et al. 
(2014) it shows a schematic overview of how multiple pathways interact with TGFβ to 
maintain cartilage homeostasis. 
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degradation of cartilage (Tang et al. 2009). The increased levels of TGFβ result 
in increased bone thickness which reduces the bones ability to react to 
mechanical loading (G. Zhen et al. 2013).  Subchondral bone also begins to 
form osteophytes which lead directly to pain in patients and cartilage destruction 
(van Beuningen et al. 2000).  
4.2.6 Changing role of TGFβ with age  
Age has been suggested as the major driving factor for conversion of ALK5 to 
ALK1 signalling. ALK5 levels decrease with age whilst ALK1 levels stay 
relatively constant (Blaney Davidson et al. 2009). This emphasises how 
dysregulation can occur in an ageing system (Blaney Davidson et al. 2009). 
How exactly ageing leads to increased ALK5 degradation is unknown. What is 
known is that SMAD7 targets ALK5 for ubiquitination by Smurf 1 and 2 proteins 
followed by proteolytic destruction (Yan et al. 2009). It may be that as TGFβ 
signalling is persistently stimulated over a person’s life, ALK5 is slowly depleted 
until ALK1 becomes the most dominant type 1 receptor. It appears ALK1 is not 
targeted in this same manner since its signalling is predominantly regulated by 
SMAD6 (König et al. 2005). This change can also be mediated by crosstalk with 
other pathways. Wnt signalling, for example, has been shown to affect the 
expression of a number of proteins downstream that can skew TGFβ signalling 
towards the catabolic ALK1 pathway (Martijn H. van den Bosch et al. 2014). As 
shown earlier, Wnt signalling can also be affected by non-canonical TGFβ 
signalling, indicating a level of crosstalk between these pathways and 
highlighting the complexity of TGFβ.   
4.2.6.1 Pro-inflammatory interactions with TGFβ signalling 
Particularly interesting is how this change in the ALK5/ALK1 ratio affects the 
ability of TGFβ to protect against the damaging effect of inflammation, in 
particular the pro-inflammatory stimulus IL-1 and OSM. Looking at the pathway 
suggests that it is an ALK5-dependent effect, due primarily to the reduction 
shown in MMP-13 when TGFβ was present, compared to IL-1+OSM alone. This 
is unlikely to be an ALK1-mediated effect as it can lead to an upregulation of 
MMP-13 independently. It has been demonstrated previously that TGFβ can 
protect against the damaging effect of IL-1 in murine models (Scharstuhl, van 
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Beuningen, et al. 2002; Kuruvilla et al. 1991).  Our group have shown that this 
effect also extends to IL-1+OSM but how this effect is mediated is not currently 
understood (Hui et al. 2000).   
 
 
Figure 4.3 The role of TGFβ in new bone formation. TGFβ is released and 
becomes activated by osteoclasts during the removal of old or damaged bone. 
TGFβ can then recruit mesenchymal stem cells (MSC) to the site. MSCs can then 
differentiate into osteoblasts and form new bone. TGFβ is inactivated during new 
bone formation. Adapted from (G. Zhen and X. Cao 2014) 
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4.2.7 Importance of TGFβ in OA  
Given the role of TGFβ in almost all facets of cartilage biology, it is unsurprising 
that there is a large body of evidence showing changes in the TGFβ pathway 
culminate in a diseased phenotype. Multiple genetic studies have highlighted 
this, such as a genetic variant in asporin (ASPN) resulting in an extra aspartic 
acid which has been shown across several studies to correlate with a 
susceptibility to OA in Asian, Spanish and Caucasian populations (Shen et al. 
2014). This change causes asporin to be a stronger regulator of TGFβ 
signalling, with a reduction in signalling leading to a higher OA risk (Kizawa et 
al. 2005). Another study has shown a polymorphism in the TGFβ signal region 
(T29 to C), or a mutation in TGFβ by Camurati–Engelmann disease, can 
increase OA prevalence by increasing TGFβ activity (Kinoshita et al. 2000). In 
addition, a single nucleotide change in the TGFβ downstream target Smad3 has 
also been linked to the incidence of hip and knee OA in a European patient 
cohort (Valdes et al. 2010).  
Microarray studies have consistently shown the importance of TGFβ in OA, with 
its continued functionality being important in preventing OA. They have also 
identified how specific changes can be the cause of OA. Olex et al. (2014) 
induced OA in mice then looked at OA development as a whole across a range 
of time points (2, 4, 8 and 16 weeks post induction). They identified TGFβ as 
one of the key pathways at all the time points except week 8. Although they 
could not identify if it was being up or down regulated in their study, they 
showed it was important in OA development. They did this by identifying 
clusters essential for biological functions that changed during OA, and TGFβ 
was central for a high proportion of these clusters. The importance of TGFβ is 
something shown by many microarray studies. Finnson et al. (2012) reviewed 
the importance of TGFβ in OA and created a table that incorporates many large 
screen OA studies. Table 4.1 summarises the relevant points which makes it 
clear how components of the TGFβ pathway can be central in OA development. 
Olex et al. (2014) explained how TGFβ signalling changes is not obvious, as 
some studies show a downregulation of TGFβ whilst others show it is 
upregulated. This discrepancy in TGFβ could be a result of many things such as 
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the age of the tissue, if it is an inflammatory driven OA, an injury driven OA or a 
variety of other reasons. From table 4.1 what is also obvious is that, when 
present, ALK5 is downregulated. ALK1 can be up or down regulated, but it is 
always the case that the ALK1/ALK5 ratio is increased (Finnson et al. 2012). 
SMAD2 is also always downregulated and SMAD3 is also altered but not as 
clearly (Finnson et al. 2012). ALK1 becoming dominant indicates that the move 
of TGFβ from SMAD2/3 to SMAD1/5/8 clearly plays a role in development of 
many OA phenotypes. Unfortunately, SMAD1/5/8 was not explored and so not 
present in the table.  
More targeted studies can also highlight how important TGFβ is for OA. Two 
studies looking specifically at the role of clock genes BMAL1 and NR1D1 in OA 
development did microarrays to identify the most important pathways (M. Dudek 
et al. 2016; Akagi et al. 2017). In both cases TGFβ was identified as one of the 
most significant upstream regulators. M. Dudek et al. (2016) showed that ALK1 
expression was cyclic through the day and altering BMAL1 could result in a 
change in ALK1/ALK5 ratio, resulting in a significant downregulation of SMAD2 
phosphorylation. This suggests that TGFβ is once again having a negative 
effect on OA progression by moving from signalling through ALK5 to primarily 
ALK1 signalling.  
Targeting TGFβ to treat OA is a promising avenue but it is complicated because 
of the varying roles it can have in OA development. Lee et al. (2001) used gene 
therapy to produce fibroblasts expressing active TGFβ, then injected these into 
the knee joints of rabbits with induced cartilage damage. They showed that after 
4-6 weeks the cartilage had been repaired in these mice (Lee et al. 2001). They 
later showed that radiation treated versions of the same fibroblasts injected into 
mice could still repair the cartilage (Song et al. 2004): the advantage being the 
injected fibroblasts die rapidly so do not linger and result in any negative 
changes later.  Blocking of TGFβ (either directly or indirectly by overexpressing 
Smad7) significantly attenuated TGFβ induced synovial fibrosis in murine 
experimental OA models, whilst Blaney Davidson et al. (2006), demonstrated 
that they could reverse cartilage damage caused by IL-1 with the addition of a 
constitutively active form of TGFβ (Blaney Davidson et al. 2006)). However, in 
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order to avoid synovial fibrosis they needed to co-express a constitutively active 
form of Smad7. This despite alleviating synovial fibrosis, unfortunately failed to 
reduce osteophyte formation in the surrounding bone tissues. Nevertheless, 
these studies showed that with a better understanding of its function, TGFβ 
could serve well as a therapeutic target in the future, helping to reverse 
cartilage destruction in OA patients. Conversely, Chen et al. (2015) argued that 
inhibition of TGFβ rather than activation should be considered for treatment.  
They looked at blocking TGFβ due to studies that showed it was upregulated in 
OA (Pombo-Suarez et al. 2009). To do this they made conditional knockout 
TGFBR2 mice. Mice deficient in TGFBR2 are embryonic lethal, but their mice 
could have the deletion induced later in development. They found that mice 
deficient in TGFBR2 were protected from degradation in the knee, delaying OA 
development after DMM surgery by up to 6 weeks (Chen et al. 2015). To further 
confirm this they used inhibitors of TBFBR2 in wild type mice and found a 
similar result. The same group later used these mice to confirm TGFβ was low 
in cartilage of wild type mice pre DMM surgery. TGFβ then increased during the 
early stages of OA, with phosphorylated SMAD2/3 levels following the same 
pattern (Fang et al. 2017). They argue that previous studies have proven TGFβ 
is required for the development of joints, and if TGFBR2 or SMAD3 is removed 
early, the mice develop OA phenotypes. Despite this TGFBR2 removal in adult 
cartilage protects against cartilage damage, possibly because TGFβ is required 
for joint development but no longer essential once formed (Fang et al. 2017). 
Alternatively, they suggest TGFβ may work in a dose-dependent manner, as 
above or below a certain threshold it will lead to damage (Fang et al. 2017). 
They argue all their data confirm that inhibition of TGFβ should be used for 
treatment. Taken in context with the other studies that show the positive effects 
of overexpressing TGFβ, I would argue that neither blocking nor activating 
TGFβ will provide the answer. Instead a better understanding of the pathway 
will allow us to assess what changes occur in TGFβ signalling during cartilage 
degradation. Therapeutic targets may then arise from normalising the TGFβ 
response to what it was before the onset of OA. 
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Table 4.1 How TGFβ signalling components are altered during OA development. 
Looking across multiple animal and human studies with a range of different technique, 
shows how the expression of TGFβ1, ALK1/5 and SMAD2/3 change as OA develops. 
Abbreviations are as follows; IHC, immunohistochemistry; ACLT, anterior cruciate 
ligament transection; PCLT, posterior cruciate ligament transection; MT, meniscal tear; 
DMM, destabilization of the medial meniscus; CIA, collagenase-induced arthritis; 
PM/PST, partial meniscectomy/post-surgical training; SNP, single nucleotide  
polymorphism. Data taken from (Finnson et al. 2012) 
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4.2.8 TGFβ specific modelling  
Expanding on already developed models can be beneficial for increasing 
understanding of a system. Knowledge of TGFβ signalling has been improved 
greatly by this concept. Vilar et al. (2006) developed a concise model to 
represent the TGFβ signalling pathway. This model highlighted that receptors 
were not simply transducers of signals but key modulators of a downstream 
TGFβ response; their “constitutive-to-induced degradation ratio” being key for 
matching observed signalling responses (Vilar et al. 2006). Shortly after B. 
Schmierer et al. (2008) created two models, retention only (RO) and an 
alternative retention/enhanced complex import (ROCI) model. Attempting to 
match both of these models to their experimental data provided insight into the 
importance of SMAD-phosphorylation and nucleocytoplasmic dynamics. The 
RO could not fit their four datasets, whereas the ROCI model could be altered 
to replicate them all. This highlighted the importance of correct SMAD-dynamics 
(B. Schmierer et al. 2008). Zi et al. (2011) realised the importance of both 
component dynamics (receptors and SMADs) and so created a more 
comprehensive model that took elements from both models as well as including 
TGFβ depletion and ligand dynamics. This model better matched the switch like 
behaviour of TGFβ over longer time scales that previous models could not 
replicate. It also showed how signalling changed with varying 
concentration/volumes of TGFβ present, concluding that receptors react to 
molecule numbers rather than absolute concentrations (Zi et al. 2011). Wegner 
et al. (2012) expanded on elements of all these previous models to include 
more detailed negative and positive feedback mechanisms. SMAD7 and 
SMURF2 have the largest effect on dynamics (Wegner et al. 2012). TGFβ is 
known to signal through two type 1 receptors to cause the downstream 
phosphorylation of either SMAD2/3 or SMAD1/5/8. The previous models had 
only looked at SMAD2 dynamics until Nicklas and Saiz (2013) created a model 
that examined both SMAD2/3 and 1/5/8 signalling. They wanted to examine 
how TGFβ can have distinctly different results across multiple cell lines. They 
succeeded in matching experimental data from human keratinocyte (HaCaT), 
bovine aortic endothelial (BAEC) and mouse mesenchymal (C2C12) cell lines to 
the same model. The model demonstrated how concentrations of the species in 
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the model could explain the differing response across cell lines under identical 
experimental conditions, without the pathway structure changing (Nicklas and 
Saiz 2013). This is particularly interesting for ageing as it demonstrates that 
although the TGFβ response has changed, the pathway may be identical and 
the changes in receptors/ligands may be resulting in the altered response. 
Therefore if we can better understand how they are changing, restoring the 
pathway to its original response may be possible. 
 
4.2.9 Chapter aims  
 
 Expand on the work from the previous chapter to look at TGFβ-mediated 
repression in detail across 4 time points: 6, 12, 24 and 48 hours.  
 
 Determine the importance of ALK5 in TGFβ-mediated protection against 
IL-1+OSM-driven MMP-1/-13 expression.   
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4.3 Results 
4.3.1 TGFβ-mediated repression is robust. 
In the previous chapter the concentration of TGFβ was 0.15ng/ml. However, the 
literature examined suggested a higher concentration was generally used. 
Having data that reflected the literature was important in model construction, so 
the concentration was increased accordingly. Screening a range of 
concentrations showed that repression was robust, as significant repression of 
both MMP-1/-13 was seen at 24 hours irrespective of the concentration (Fig 
4.4). After the screen I continued with the concentration 10ng/ml as this is more 
commonly seen in the literature.  
After changing the concentration I looked at the effect TGFβ had on IL-1+OSM 
treatment across four time points. MMP-1/-13 followed a similar pattern for IL-
1+OSM treatment, with expression increasing between 6 to 24 hours, then 
decreasing at 48 hours (Fig 4.5A and 4.6A). One noticeable difference was 
MMP-13 had a sharp increase between 12 and 24 hours, whilst MMP-1 was 
relatively constant across the two time points (Fig 4.5A and 4.6A).  
In order to accurately determine the percentage of repression mediated by 
TGFβ I repeated all of the individual time points (6, 12, 24 and 48) across a 
multitude of experiments. I then pooled all of these results (Fig 4.5B and 4.6B). 
The pattern seen was similar for MMP-1/-13, taking an excess of 12 hours for 
TGFβ to have an effect. Significant repression was seen at 24 hours and for 
MMP-13 this repression was increased by 48 hours (Fig 4.5B). However, this 
was not seen for MMP-1 with repression still highly significant but similar to that 
at 24 hours (Fig 4.6B).   
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Figure 4.4 Various concentrations of TGFβ repress IL-1+OSM-induced MMP 
expression at 24 hours. SW1353 cells were stimulated for 24 hours with IL-1 
(0.5ng/ml) +OSM (10ng/ml) ±TGFβ at concentrations ranging from 0.15ng to 
10ng. qPCR was performed on the isolated mRNA to measure A) MMP-13 
expression B) MMP-1 expression. Data are presented as mean fold change 
relative to control ± SEM, N = 5-6. Statistics calculated using unpaired Student’s 
t-test, where ** p < 0.01; *** p < 0.001.  
 
Figure 4.5 Effect of TGFβ on IL-1+OSM induced MMP-13 expression. SW1353 cells were stimulated with IL-1 (0.5ng/ml), 
OSM (10ng/ml) and IL-1+OSM±TGFβ (0.15ng/ml (B) (10ng/ml (A and B)). qPCR was then performed on the isolated mRNA 
to measure MMP-13 expression. Data are presented as fold change relative to control (A) or IL-1+OSM (B) (mean ± SEM). 
A) A single experiment showing cells treated for 6, 12, 24 and 48 hours with IL-1+OSM±TGFβ, n=5-6. B) Pooled data from 
experiments at 6, 12, 24 and 48 hours in cells stimulated with IL-1+OSM±TGFβ treatment. At 6h n=35 from 7 experiments; 
12h n=39-45, across 7 experiments; 24h n= 42-48, across 10 experiments and 48h n=47 across 7 experiments. Statistics 
calculated using unpaired Student’s t-test, where ** p < 0.01; *** p < 0.001 
 
Figure 4.6 Effect of TGFβ on IL-1+OSM induced MMP-1 expression. SW1353 cells were stimulated with IL-1 (0.5ng/ml), 
OSM (10ng/ml) and IL-1+OSM±TGFβ (0.15ng/ml (B) or 10ng/ml (A and B)). qPCR was then performed on the isolated mRNA 
to measure MMP-1 expression. Data are presented as fold change relative to control (A) or IL-1+OSM (B) (mean ± SEM). A) A 
lone experiment showing cells treated for 6, 12, 24 and 48 hours with IL-1+OSM±TGFβ, n=4-6. B) Pooled data from 
experiments at 6, 12, 24 and 48 hours in cells stimulated with IL-1+OSM±TGFβ treatment. At 6h n=28-31 from 5 experiments; 
12h n=33-38 from 6 experiments; 24h n=20-21 from 5 experiments and 48h n=27-28 from 5 experiments. Statistics calculated 
using unpaired Student’s t-test, where * p < 0.05; ** p < 0.01; *** p < 0.001 
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4.3.2 Importance of ALK5 in protection 
The literature suggested ALK5 may have an important role in TGFβ-mediated 
repression of IL-1+OSM-mediated MMP-1/-13 expression. Therefore I 
measured the basal level of expression of ALK1 and ALK5 in SW1353 cells. I 
used the universal probe library. Therefore, it was necessary to test primer 
efficiency before comparing the basal expression. This was done as described 
in chapter 2.1.8 briefly, samples were diluted and the CT values of ALK5/ALK1 
were measured relative to the dilution; from this I could ascertain how accurate 
the primers were at determining quantity and alter CT accordingly. Comparing 
the altered CTs showed the expression of ALK5 was approximately 19 fold 
higher than ALK1 (Fig 4.7A). Comparing the expression of PAI1 (downstream of 
ALK5) and ID1 (downstream of ALK1) after 2 hours TGFβ treatment, showed 
that PAI1 was significantly upregulated (Fig 4.7B) whilst ID1 mRNA remained 
constant (Fig 4.7C). All of these data suggested that SW1353 cells signal 
almost exclusively through ALK5 (Fig 4.7).  
 
 
Figure 4.7 Level of ALK5 mRNA relative to ALK1 leading to downstream 
expression of TGFβ specific genes after 2h treatment. A) SW1353 cells were serum 
starved overnight then harvested without stimulation. qPCR was then performed on the 
isolated mRNA to measure expression of ALK1 and ALK5. The data are presented as 
fold change relative to ALK1± SEM, N=10. B and C) SW1353 cells were stimulated for 2 
hours with TGFβ (10ng/ml). qPCR was performed on the isolated mRNA to measure A) 
PAI1 expression B) ID1 expression. Data are presented as mean fold change relative to 
control ± SEM, N = 4-6. Statistics calculated using unpaired Student’s t-test, where ** p 
< 0.01. 
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As ALK5 appeared to be the dominant receptor, I explored how removing it from 
the system would affect TGFβ-mediated repression of MMP-13. ALK5 siRNA 
(siALK5) significantly reduced ALK5 expression at both the mRNA and protein 
levels (Fig 4.8A and B). At the mRNA level there was approximately 95% less 
ALK5 mRNA at 100 and 50nM (Fig 4.8A), whilst no significant change was seen 
with a non-targeting siRNA (siCON). This reflected in the protein where no 
ALK5 signal could be seen in samples treated with 50nM siALK5 (Fig 4.8B). 
This reduction in ALK5 does not seem to affect ALK1 protein expression (Fig 
4.8B). Non-targeting siRNA transfection resulted in repression similar to that 
seen previously (Fig 4.5, Fig 4.9), while siRNA against ALK5 completely 
removed the protective effect that TGFβ had on the IL-1+OSM stimulus (Fig 
4.9). It is worth noting that removing ALK5 did not result in a significant increase 
of MMP-13 in IL-1+OSM+TGFβ samples.  
 
  
Figure 4.8 Potency of ALK5 siRNA on SW1353 cells. SW1353 cells were 
harvested following 24 hour treatment with a non-targeting siRNA (siCON) or a 
siRNA specific to ALK5 (siALK5), at concentrations ranging from 20nM to100nM (B 
= 50nM). A) qPCR was then performed on the isolated mRNA to measure 
expression of ALK5. Data are presented as mean ALK-5 fold change relative to 
control ± SEM, N=5-6 Statistics calculated using unpaired Student’s t-test, where 
*** p < 0.001. B) Whole cell lysates were ran on SDS page gels and then Western 
blots for ALK1, ALK5 and GAPDH were performed.  Data are representative of N=2 
independent experiments on separate SW1353 cell populations.  
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Exploring how ALK5 removal affected MMP-1 was more problematic than 
looking at MMP-13, as for some unidentified reason the siRNA transfection 
procedure appeared to affect MMP-1 expression (Fig 4.10). Figure 4.10 shows 
MMP-1/-13 gene expression across the same experiment. MMP-13 showed 
significant repression in both the control and siCON samples that was lost in 
siALK5 treated samples (Fig 4.10A). MMP-1 showed repression in the control 
samples as expected (Fig 4.10B) but not in either siCON or siALK5 samples, 
where there appeared to be a significant increase in MMP-1 expression when 
TGFβ was present (Fig 4.10B). This was also seen in two other experiments 
(data not shown).
Figure 4.9 Effect of ALK5 silencing on TGFβ-mediated MMP-13 repression 
at 24h. SW1353 cells were stimulated for 24 hours with IL-1 (0.5ng/ml) +OSM 
(10ng/ml) ±TGFβ (10ng/ml), following 24 hour treatment with serum free media 
or 50nM of a non-targeting siRNA (siCON) or a siRNA specific to ALK5 
(siALK5). qPCR was then performed on the isolated mRNA to measure 
expression of MMP-13. Data are presented as mean fold change relative to 
control (A) or IL-1+OSM (B) ± SEM A) A lone experiment at 24 hours, N=5-6. 
Representative of N=6 independent experiments on separate SW1353 cell 
populations. B) Pooled data from multiple experiments, N= 32-34, across 6 
experiment, except for IL-1+OSM+TGFβ with neither siRNA where N= 18 
across 3 experiments. Statistics calculated using unpaired Student’s t-test, 
where ** p < 0.01; *** p < 0.001.  
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Figure 4.10 Effect of siRNA transfection on TGFβ-mediated MMP repression. 
SW1353 cells were stimulated for 24 hours with IL-1 (0.5ng/ml) +OSM (10ng/ml) 
±TGFβ (10ng/ml), following 24 hour treatment with serum free media or 50nM of a 
non-targeting siRNA (siCON) or a siRNA specific to ALK5 (siALK5). qPCR was then 
performed on the isolated mRNA to measure A) MMP-13 expression B) MMP-1 
expression. Data are presented as mean fold change relative to control ± SEM. N=5-
6, representative of N=3 independent experiments on separate SW1353 cell 
populations. Statistics calculated using unpaired Student’s t-test, where * p < 0.05; ** 
p < 0.0; *** p < 0.001. 
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4.4 Discussion  
To build a model of TGFβ I required a detailed understanding of how TGFβ 
mediates its effect on IL-1+OSM over a period of time. TGFβ needs 12 hours to 
mediate a repressive effect suggesting de novo synthesis is required, as the 
time delay provides sufficient time for the relevant protein, or proteins, to be 
transcribed and activated accordingly. The relevant protein, or proteins, are 
then present at 24 hours resulting in a robust repression across a range of 
concentrations (0.15ng – 10ng), with this repression being increased at 48 
hours. Studies have demonstrated the protective effect of TGFβ on 
chondrocytes is mediated through ALK5 (van Caam et al. 2015), and these 
effects may be lost as ALK1 becomes dominant.  
Comparing their basal expression showed that ALK5 mRNA was 19 fold higher 
than that of ALK1, which is representative of what is normally found in young 
tissues (Blaney Davidson et al. 2009). It is documented that mRNA does not 
always correspond to protein expression (Vogel and Marcotte 2012) and 
downstream effects. It was not possible to compare the relative levels of ALK1 
and ALK5 expression using a semi-quantitative approach such as Western blot. 
Instead I examined two proteins directly downstream of ALK1 (ID1) or ALK5 
(PAI1) at two hours. This time point was chosen as it has been used to compare 
expression in cartilage tissue previously (Madej et al. 2013), and is a time when 
both genes can be upregulated depending on receptor composition. PAI1 
showed increased expression whilst ID1 was unchanged confirming that TGFβ 
is signalling through ALK5.  
This did not confirm that ALK5 was responsible for the repressive effect of 
TGFβ against IL-1+OSM, as TGFβ activates a range of different responses 
through non-canonical pathways (Zhang 2009). Removing ALK5 from the 
system allowed me to verify its role in TGFβ-mediated repression of MMP-13. 
This could not be verified for MMP-1 as siCON altered the effect of TGFβ on IL-
1+OSM. Off-target effects are known to occur during transfection (Baum et al. 
2010). Non-targeting siRNAs are designed as negative controls as they 
undergo the same transfection protocols but should not target any genes. The 
siRNA used (ON-TARGET plus) is designed to minimise off-target effects, but in 
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the case of MMP-1 the effects seen appear to be a result of off-target effects. 
To explore the effect of ALK5 silencing on MMP-1 an alternative system would 
need to be used.  I considered using a clustered regularly interspaced short 
palindromic repeats (CRISPR)-cas9 system to remove ALK5 without the off 
target effects. Unfortunately, the reagents to remove ALK5 were not 
commercially available so the primers for the system would have had to be 
designed, which can be a very time consuming process.  Since I have a system 
that can remove ALK5 and appears to have no off target effects for MMP-13, I 
progressed without MMP-1. Another reason for this decision was the repression 
patterns of MMP-1/-13 at 24 and 48 hours. MMP-13 had greater repression at 
48 hours in the IL-1+OSM+TGFβ treatment than 24 hours, whilst MMP-1 has 
similar levels of repression at both 24 and 48 hours. This means that the model 
would have needed increased complexity to explain how both genes could be 
repressed, but in subtly different ways. Reducing complexity where possible is 
important for model design and as both are MMPs and MMP-13 is regarded as 
the most important in OA development I decided to progress with MMP-13, with 
the scope to return to MMP-1.  
4.4.1 Pro-inflammatory interactions with TGFβ signalling 
Although this work showed ALK5 was required for TGFβ-mediated repression, it 
was not clear how ALK5 enabled these effects. There are numerous 
interactions between these three factors (TGFβ, IL-1 and OSM) that could be 
responsible for the effect that is seen. TGFβ induction of JunB is mediated by 
the ALK5 pathway; once transcribed it has been shown to interact with c-Jun, 
an important component of the activator protein 1 (AP1) complex that controls 
upregulation of both MMP-1 and -13 (Ponticos et al. 2009). JunB upregulation 
may cause competitive inhibition of the AP1 complex that limits the production 
of these key matrix-degrading enzymes. There are also reports that Smad3 can 
bind to, and inhibit the AP1 sites directly leaving fewer sites available for the 
activated AP1 complex to bind to and induce expression of the MMPs (Zhang et 
al. 1998).)Chen et al. (2012) showed Smad3 helped to maintain the balance of 
cartilage synthesis by inducing Collagen II expression whilst repressing Runx-2 
inducible MMP-13 expression. They suggest this effect was through the actions 
of Histone deacetylase 4 (HDAC4), which is known to bind to and repress the 
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MMP-13 promoter (E. Shimizu et al. 2010). This protective effect has been 
questioned by other reports claiming the opposite is true and HDAC4 is 
responsible for an increase in MMP-13 (Lu et al. 2014; Queirolo et al. 2016). 
The protective effect may also be a result of upregulation of proteins such as 
TIMPs, which counteract the effects of MMP-1/-13 (Leivonen et al. 2013).  It is 
also possible that TGFβ could interact with the receptors that mediate the IL-1 
and OSM response.  
4.4.2 Age-related changes to pro-inflammatory TGFβ interactions  
Cartilage in older mice has a reduced ability to repair after treatment with IL-1 
and changes in TGFβ signalling appear to have a key role in this change 
(Davidson et al. 2005). If we assume, based on the evidence, that the protective 
effect against pro-inflammatory stimuli shown by TGFβ is mediated entirely by 
an ALK5-dependent response, then what happens when it signals through 
ALK1 could potentially be very interesting. When signalling through ALK1, 
TGFβ has been shown to upregulate MMP-13 (Blaney Davidson et al. 2009). 
The addition of a pro-inflammatory stimuli, such as IL-1 + OSM, could result in 
an even greater increase in MMP-13 and conceivably MMP-1. It has been 
shown that IL-1+OSM represents a good model of pro-inflammatory stimulus 
(Chan et al. 2017). Signalling through ALK1 has also been demonstrated to 
increase the phosphorylation of p38 (C. G. Chen et al. 2012), which is important 
in IL-1+OSM,  AP1-driven, MMP-1 and -13 upregulation (Proctor et al. 2014). 
Both these findings suggest an increase in matrix-degrading proteins, which 
would be very damaging in a patient. TGFβ would be released, intended to 
reduce the inflammatory response, but instead would only serve to exacerbate 
the situation by increasing matrix degradation. It is also possible that the 
change in signalling would then result in an upregulation of Smad6, a primary 
regulator of ALK1 signalling (König et al. 2005), which could then start to target 
ALK1 for destruction by one of the Smurf proteins (as Smad7 may do for ALK5). 
It is also worth noting that ALK1 requires ALK5 in order to have an effect, so the 
reduction in ALK5 protein may also affect its ability to signal (M. J. Goumans et 
al. 2003). The change from ALK5 to ALK1 signalling as well as the actions of 
the Smurfs proteins could potentially contribute to what could be an intriguing 
but complex interaction between TGFβ, IL-1 and OSM. 
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4.4.3 Summary  
 TGFβ represses the IL-1+OSM-driven upregulation of MMP-1/-13 
mRNA, post 12 hours. This repression is robust by 24 hours and 
increased at 48 hours for MMP-13. For MMP-1 the repression is robust 
at 24 and 48 hours but is at a similar level.  
 
  TGFβ must bind to ALK5 receptors to repress IL-1+OSM-driven 
upregulation of MMP-13 mRNA. 
 
 
 
 
 
 
 
.  
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Chapter 5. Modelling the changing effects of TGFβ on pro-inflammatory 
stimuli with age. 
5.1 Introduction  
The data presented throughout chapters 3 and 4 demonstrated why I chose 
TGFβ as the pathway to design and build a computational model around.  The 
TGFβ-mediated repression of IL-1+OSM-driven MMP-13 expression data, 
presented in both chapters, was key to this decision, as well as the data that I 
will base model construction upon throughout this chapter. In order to better 
understand the interaction TGFβ has with IL-1+OSM, I will modify and combine 
two previous models (Proctor et al. 2014; Wang Hui et al. 2014) looking at how 
TGFβ mediates its effect and how it changes with age.  
The signalling cascades for both IL-1 and OSM are complex and include a lot of 
cross talk. Their synergistic upregulation of MMP-13 seems to be mainly caused 
by their effect on activator protein 1 (AP-1). IL-1 binds to the IL-1 receptor (IL-
1R) and by a series of downstream regulators leads to phosphorylation of c-
Jun; this, in turn, binds to c-Fos forming a transcriptionally active part of AP-1 
(Chambers et al. 2013). This heterodimer has a high affinity for the promoter 
regions of the MMPs (Chambers et al. 2013). Regardless, c-Fos mRNA has a 
short half-life and as IL-1 only slightly increases its transcription, the majority of 
c-Jun forms homodimers which have a much lower affinity for DNA promoter 
regions (Sen and Packer 1996). Previous studies suggest that p38 can 
phosphorylate c-Fos resulting in increased transcription (Tanos et al. 2005). 
OSM signals primarily through the JAK/STAT pathway which can stimulate p38-
mediated phosphorylation of c-Fos (Tanos et al. 2005). The resulting c-Fos/c-
Jun heterodimers may result in changes of AP-1 composition that could explain 
the synergistic effect both cytokines have on MMP-13 expression (Proctor et al. 
2014). I have demonstrated that the protective effect of TGFβ requires the ALK5 
receptor but how is unknown. My initial hypothesis, based on literature and work 
done previously by our group, was that JunB was leading to competitive 
inhibition of the AP-1 complex that mediated the repression.  
In this chapter I will design and test a model that expands on how TGFβ could 
mediate this repression through ALK5, and how this might change as it moves 
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towards ALK1. I will build upon a section of a model presented by Wang Hui et 
al. (2014) which explored age-related changes such as increased levels of 
oxidative stress, apoptosis, MMP-13 and a decrease in chondrocyte autophagy. 
Part of the simulation looked at the change in ALK1/ALK5 receptors over 30 
months in a mouse model and the downstream effects of these changes i.e. 
increasing MMP-13. The model looked at both the deterministic and stochastic 
elements of the pathway, matching them to immunohistochemistry data taken 
from mice between 3-30 months (Wang Hui et al. 2014). I will take this section 
of the model and combine it with another model (Proctor et al. (2014) which 
showed the effect of IL-1+OSM treatment on cartilage cell cultures.  
5.1.1 ODE modelling for TGFβ signalling.  
I will be using an ODE system to model TGFβ because my network, although 
relatively large for an ODE model, will not require excess computing power for 
any tasks. Using ODE will allow me to generate a detailed understanding of the 
system that can be altered to match generated data and also make future 
predictions. As it is also the most commonly used system for TGFβ studies it 
will give me a wealth of information to draw on. Careful planning of models 
before starting is important for structure and parameters (Hasdemir et al. 2015). 
Therefore having previous models assisted with this design. A PN model would 
be unfavourable as the intricate details would be difficult to design. Boolean 
networks are difficult to represent time accurately and also do not allow for 
deterministic simulation, both of which will be important for matching the model 
to experimental data. Finally LP and ABM are both in their infancy for examining 
these types of systems. Therefore, using either system would require 
substantially more effort for no reward.  
Mass action kinetics will be used for the model, as it is the most used rate law 
for mathematical and biological studies that some argue requires no justification 
(Voit et al. 2015). In this case my justification is that the two models that the 
majority of my network is based on are built using mass action equations, which 
proves it can be implemented for this type of study. Although they could be 
adapted, mass action also allows me to switch with ease between deterministic 
and stochastics simulations, allowing me a deeper understanding of the model 
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interactions. Other functions do not allow this, as they are either unsuitable for 
stochastic simulation or must be modified to accommodate it, which then makes 
them unsuitable for deterministic. Mass action kinetics works from the principle 
that the reaction rate is proportional to the probability that reactants will collide 
(Voit et al. 2015). It takes into account the concentration of reactants, the power 
of their molecularity and how many are involved in the reaction (Voit et al. 
2015).  
Advances in computing power have also allowed complex modelling that would 
have previously been impossible. This has led to an increase in the number of 
biologists using computational modelling to unravel complex systems. As a 
result there has been a number of modelling tools designed to facilitate their 
move into an area that was once exclusively for mathematics and physics 
researchers. Most approaches have associated programmes, Boolean using 
CellNetAnalyzer for example (Klamt et al. 2007). However, ODE modelling has 
been the most used and has resulted in a number of programmes being made 
available, including but not limited to simbiology, SBTOOLBOX (both Matlab 
plugins) (MATLAB vR2016a, The MathWorks Inc., Natick, MA) and COPASI (S. 
Hoops et al. 2006). My model has been built in COPASI as it contains many 
tools including pre-set or custom functions; the input of events; deterministic, 
stochastic and hybrid simulations as well as a multitude of analysis tools such 
as: sensitivity analyses, parameter estimations and parameter scans amongst 
others. It is also well maintained and constantly being improved upon. Finally, I 
believe it has the most user friendly interface. 
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5.1.2 Chapter aims 
 Alter and combine two previous computational models to create a model 
that represents IL-1+OSM+TGFβ signalling, whilst still matching the 
profiles seen by the original models.  
 
 Match the model simulation output to data created in the previous 
chapters. 
 
 Test the model by showing its ability to match novel experimental data, 
without modification. Then alter the structure if it cannot.  
 
 Use the model to explore how TGFβ will affect IL-1+OSM-driven MMP-
13 expression with age, as ALK1 becomes the dominant receptor.  
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5.2 Model construction  
In order to create my model I first had to alter the previously published models 
separately to make them compatible. In order to ease the computational burden 
I also reduced complexity where possible, removing or altering any interactions 
that were not necessary for what I was studying. Combining both models in their 
original forms would have resulted in a very large model, which would have 
been difficult to parameterise and simulate.  
5.2.1 IL-1+OSM 
The original IL-1+OSM model was presented in three sections, OSM, pro-MMP 
activation and IL-1 (Proctor et al. 2014) all of which can be seen in appendix 
5.1. As I was only looking at MMP-13 mRNA and had no interest, at that time, in 
its transition to an active MMP, I removed the pro-MMP activation component 
completely. The remaining two sections were simplified but still fit the same 
profiles. To achieve this some approximations were made: Three proteins were 
originally present in the model: DUSP16, MKP1 and PP4. As these were 
upregulated by the same source and only relevant for blocking, I replaced all 
three of these species with one “block” species. This blocked all three reactions 
that the original proteins did. However, each reaction was blocked at a different 
rate, in order to have the same effect that the original proteins would have had. 
The receptor profile for IL-1 was changed to include an internalisation step that 
replaced the need for IRAK and TRAF6. The phosphorylation and subsequent 
nuclear translocation of STAT3 was altered so that it could be represented by a 
single reaction. Finally any mRNAs that were produced, other than MMP-13, 
were removed. The resulting model is represented in Figure 5.1. 
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Figure 5.1 Network 
diagram showing species 
and reactions involved in 
the IL-1+OSM response. 
Schematic representation of 
the simplified IL-1+OSM 
signalling section of my 
newly developed model. 
CellDesigner was used to 
create the schematic.  
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5.2.2 TGFβ 
The TGFβ section of the model is based on the TGFβ section, described in 
Wang Hui et al. (2014), which can be seen in appendix 5.2. It had only minor 
alterations in comparison to the IL-1+OSM section. This was for two reasons: 
1. It was a smaller model.  
2. It was the pathway being explored so required more detail.  
The biggest change was the removal of the SOX9, aggrecan and collagen 
component from the original model as I had no interest in their expression at 
this time. MMP2 was completely removed as it had no effect on the model in 
this form. The role of active RUNX2 was also altered, no longer inducing the 
production of pro-MMP-13 but instead producing MMP-13 mRNA. This change 
was reasonable as RUNX2 induced upregulation of MMP-13 has been shown 
to be at the mRNA level (Ijiri et al. 2005). 
The original models had not been created to be combined and as a result they 
did not share any interactions. Therefore, I performed a literature search to 
identify some ways IL-1, OSM and TGFβ may interact. I then altered my 
version of the model to facilitate TGFβ and IL-1+OSM interactions. The first 
alteration was JunB production through SMAD2 (which represents SMAD2/3 
as explained in chapter 2.3.3) signalling because there is a substantial body of 
evidence showing that it is a direct downstream target of SMAD3 (Ponticos et 
al. 2009; Gervasi et al. 2012) and works to antagonise rapid gene transcription 
(Mauviel et al. 1996; Verrecchia et al. 2001; Selvamurugan et al. 2004). 
Studies have shown it can displace c-Fos in the AP-1 complex and bind to c-
Jun (Ponticos et al. 2009; Mauviel et al. 1996).  It has also been demonstrated 
to limit the effects of IL-1, in particular its effect on MMP synthesis (Emi 
Shimizu et al. 2010). Finally it has been shown to repress gene expression in 
epithelial–mesenchymal transition in cancer due to upregulation by TGFβ. This 
demonstrates TGFβ can produce significantly high JunB expression to limit 
gene transcription (Gervasi et al. 2012). SMAD1 signalling could also now lead 
to an increase in p38 phosphorylation, as shown in C. G. Chen et al. (2012). 
Figure 5.2 shows the complete TGFβ section of my model. 
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Figure 5.2 Network diagram showing all the species and reactions involved in the TGFβ pathway. Schematic representation 
of the modified TGFβ section in my newly developed model. CellDesigner was used to create the schematic. 
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5.3 Model parameterisation 
After altering the structure of the two model components, I combined them 
together to form my complete model (Fig 5.3). The original parameters from 
both models were also incorporated and the parameters for the newly added 
reactions were assigned default values. With this model I attempted to match 
the simulation output to the data that were generated in chapters 3 and 4. 
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Figure 5.3 Network diagram showing species and reactions involved in the IL-1+OSM+TGFβ model. Schematic representation of my 
complete model. Detailing all interactions between the IL-1, OSM and TGFβ signalling pathways. The “block” species is involved in multiple 
reaction but represents one species upregulated by cJun_dimers or cFos_cJun and provides a negative feedback for multiple reactions but at 
different rates. CellDesigner was used to create the schematic.  
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5.3.1 Model fit with hypothesised AP-1 competitive inhibition. 
Initially in the model, TGFβ only interacted with the IL-1+OSM response via the 
JunB protein which was being synthesised by phospho-SMAD2 upon addition of 
TGFβ. This in turn provided competitive inhibition to the formation of AP-1 
components (c-Jun homodimers and c-Jun/c-Fos heterodimers) (Fig 5.3). I 
attempted to match this structure to the time course data generated in chapter 3 
and 4 using parameter estimations (Fig 5.4). The complete model appeared to 
fit these data (Fig 5.4) but when the model was compared with and without 
TGFβ, the addition of TGFβ had no effect (Fig 5.5). The parameter estimations 
had matched the data by changing IL-1+OSM signalling rather than by the 
involvement of TGFβ signalling. 
Figure 5.4 Fitting the model using only AP-1 competitive inhibition. Results of 
parameter estimation ran using COPASI, which allowed alterations to all the 
reactions from the model presented in Fig 5.3. The genetic algorithm was used to 
match MMP-13 mRNA simulation data, during IL-1+OSM+TGFβ treatment, to that 
generated in SW1353 cells. The cross marks represent what the particle number 
should be at the given time point in order to match the level of repression seen in 
SW1353 cells. The solid line shows the model output whilst the dashed line shows 
the simulation COPASI aimed for based on the experimental data. The genetic 
algorithm was executed for 1000 generations with a population size of 20, followed 
by Hooke and Jeeves with an iteration limit of 50.  
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To prevent this I re-ran the parameter estimations but prevented the programme 
from altering any part of the IL-1+OSM component. Under these conditions the 
model could replicate the earlier data but could not replicate the increased 
repression that was seen at 48 hours (Fig 5.6). This suggested that something 
was missing from the model structure, preventing TGFβ from mediating the 
level of repression seen experimentally.  
 
 
 
 
 
 
Figure 5.5 Effect of TGFβ over 48 hour simulation. Deterministic simulation results 
showing the effect of IL1+OSM±TGFβ treatment on the fully parameterised model 
presented in Fig 5.3, over a simulation time of 48 hours. An active form of TGFβ is 
present in the model to replicate experimental conditions.  Curves show how the particle 
numbers of MMP-13 mRNA change over the simulation. Simulations were run using 
COPASI. 
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Figure 5.6 Parameter estimation based on experimental data. Results of a parameter 
estimation run using COPASI for the model presented in Fig 5.3, which allowed 
alterations to the reactions affected by TGFβ addition but not IL-1+OSM. The genetic 
algorithm was used to match MMP-13 mRNA simulation data, during IL-1+OSM+TGFβ 
treatment, to that generated in SW1353 cells. The cross marks represent what the 
particle number should be at the given time point in order to match the level of 
repression seen in SW1353 cells. The solid line shows the model output whilst the 
dashed line shows the simulation based on the experimental data. The genetic algorithm 
was executed for 1000 generations with a population size of 20, followed by Hooke and 
Jeeves with an iteration limit of 50. 
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5.3.2 Model fit with only mRNA degradation 
I hypothesised that the extra repression seen at 48 hours may be a result of 
TGFβ stimulation being able to increase the degradation of MMP-13 mRNA. I 
was unsure what may mediate this but I incorporated it into the model structure 
using a dummy species, upregulated by SMAD2, which could degrade MMP-13 
mRNA. It was upregulated by SMAD2, as I showed previously that repression 
cannot occur without ALK5. The updated model can be seen in Figure 5.7. 
Figure 5.8 is a vastly simplified schematic, which focuses on the receptor 
interactions that mediate IL-1, OSM and TGFβ effects.  
As I had tried to fit the model with only JunB  I wanted to check if the model 
could fit the data with only this newly added component active (Fig 5.9A), before 
combining both interactions. I found it could match the pattern of repression 
seen in the experimental data at the early and late time points (Fig 5.9B). 
However, when I altered the levels of active TGFβ in the model it had a 
substantial effect on the repression (Fig 5.9C).  This was contrary to what was 
seen in the experimental data, where a change in TGFβ concentration had little 
effect on repression (Fig 5.9D)
143 
 
Figure 5.7 Network diagram showing all species and reactions involved in the IL-1+OSM+TGFβ model. Schematic representation of the 
complete model. Detailing all interactions between the IL-1, OSM and TGFβ signalling pathways. Though similar to Figure 5.3, the dummy species 
has now been added that can degrade MMP-13 mRNA. CellDesigner was used to create the schematic. The “block” species is involved in multiple 
reaction but represents one species upregulated by cJun_dimers or cFos_cJun and provides a negative feedback for multiple reactions but at 
different rates. 
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Figure 5.8 A simplified network diagram showing the key interactions between the IL-1, OSM and TGFβ components. Schematic 
representation showing a simplified version of the model presented in Figure 5.7. The focus is specifically on the key reactions that mediate 
the interactions between IL-1, OSM and TGFβ. CellDesigner was used to create the schematic. 
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Figure 5.9 Using MMP-13 mRNA degradation to fit the model. A) Schematic 
representation of a section of the model presented in Fig 5.8 highlighting the 
interactions between AP-1 components (upregulated by IL-1+OSM) and SMAD2 
(phosphorylated by TGFβ). The green circles show the active components whilst the 
red curve shows inactive component (during this simulation). B) Results of a 
parameter estimation ran using COPASI for the model presented in Fig 5.7 using the 
components active in A. Alterations to the reactions affected by TGFβ addition are 
allowed but not for IL-1+OSM. The genetic algorithm was used to match MMP-13 
mRNA simulation data, during IL-1+OSM+TGFβ treatment, to that generated in 
SW1353 cells. The cross marks represent what the particle number should be at the 
given time point in order to match the level of repression seen in SW1353 cells. The 
solid line shows the model output whilst the dashed line shows the simulation based 
on the experimental data. The genetic algorithm was executed for 1000 generations 
with a population size of 20, followed by Hooke and Jeeves with an iteration limit of 
50. C) Simulation results from a deterministic parameter scan (post parameter 
estimation in B) changing the concentration of active TGFβ in the model by 1000 
fold. Run using COPASI over a 48 hour simulation shows how the change affects 
MMP13 mRNA expression. D) Data are first presented in chapter 4 (Fig 4.4). qPCR 
data for SW1353 cells treated for 24 hours with IL-1+OSM or IL-1+OSM+TGFβ at 
concentrations ranging from 0.15ng to 10ng. *** p < 0.001. 
. 
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5.3.3 Model fit with both AP-1 inhibition and mRNA degradation  
Running the parameter estimations, with both AP-1 complex inhibition and the 
mRNA degradation components active (Fig 5.10A) allowed me to match the 
simulation data to experimental data (Fig 5.10B). When both of these 
components were active, changing the concentration of TGFβ had only a minor 
effect on the simulation output (Fig 5.10C). This was in stark contrast to the 
effect seen when only mRNA degradation was active (Fig 5.9) and was a better 
match to the experimental data (Fig 5.10C and D). Figure 5.11A shows the 
model output when simulated with or without TGFβ present. These simulation 
data were representative of the original time course data generated in chapter 
4. There was little difference between IL1+OSM ±TGFβ simulations at 6 and 12 
hours, whereas at 24 hours TGFβ results in 37% repression increasing to 73% 
by 48 hours (Fig 5.11A). This closely mirrored the 42% repression, increasing to 
69% at 48 hours, that was seen in SW1353 cells (Fig 5.11B).  
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Figure 5.10 Fitting the complete model to experimental data. A) Schematic 
representation of a section of the model highlighting the interactions between AP-1 
components (upregulated by IL-1+OSM) and SMAD2 (phosphorylated by TGFβ). 
The green circles show the active components whilst the red shows inactive 
component (during this simulation).  B) Results of a parameter estimation ran using 
COPASI for the model presented in Fig 5.7 using the components active in A. 
Alterations to the reactions affected by TGFβ addition are allowed but not for IL-
1+OSM. The genetic algorithm was used to match MMP-13 mRNA simulation data, 
during IL-1+OSM+TGFβ treatment, to that generated in SW1353 cells. The cross 
marks represent what the particle number should be at the given time point in order 
to match the level of repression seen in SW1353 cells. The solid line shows the 
model output whilst the dashed line shows the simulation based on the 
experimental data. The genetic algorithm was executed for 1000 generations with a 
population size of 20, followed by Hooke and Jeeves with an iteration limit of 50.  C) 
Simulation results from a deterministic parameter scan (post parameter estimation) 
changing the concentration of active TGFβ in the model by 1000 fold. Ran using 
COPASI over a 48 hour simulation time, it shows how the change affects MMP13 
mRNA over 48 hours. D) Data were first presented in Fig 4.4. qPCR data for 
SW1353 cells treated for 24 with IL-1+OSM ± TGFβ at concentrations ranging from 
0.15ng to 10ng. *** p < 0.001 vs IL-1+OSM.  
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Figure 5.11 Complete model run for 48 hours ± TGFβ. A) Deterministic simulation 
results showing the effect of IL1+OSM±TGFβ treatment on the fully parameterised model 
presented in Fig 5.7, over a simulation time of 48 hours. An active form of TGFβ is present 
in the model to replicate experimental conditions.  Curves show how the particle numbers 
of MMP-13 mRNA change over the simulation. The black arrows show the percentage of 
repression seen at 24 and 48 hours, caused by TGFβ addition. Simulations were run using 
COPASI. B) Data are first present in Figure 4.5. Shows the average expression of MMP-
13 at 6, 12, 24 and 48 hours in cells treated with IL1+OSM ±TGFβ. *** p < 0.001. The 
percentages represent the amount of repression mediated by TGFβ at the given time 
point.  
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As both AP-1 complex inhibition and mRNA degradation were necessary for the 
model to fit the data, I looked at the effect that removing either one had on the 
complete model. Removing AP-1 complex inhibition, via JunB, resulted in a 
higher peak at 12 hours. Removing mRNA degradation, via the dummy species, 
resulted in the repression at 24 and 48 hours being reduced. This suggested 
JunB limits the initial peak of MMP-13 expression, whilst increased mRNA 
degradation was responsible for mediating the high levels of repression seen at 
the later time points (Fig 5.12).   
 
Figure 5.12 Effects of mRNA degradation and AP-1 complex inhibition in the 
complete model. Deterministic simulation results showing the effect of 
IL1+OSM±TGFβ treatment on altered versions of the fully parameterised model 
presented in Fig 5.7, over a simulation time of 48 hours treatment. An active form of 
TGFβ is present in the model to replicate experimental conditions. Curves show how 
the particle numbers of MMP-13 mRNA change over the simulation. The red curve 
shows the complete model simulated with IL-1+OSM. All other curves show 
IL1+OSM+TGFβ simulations with: the complete model (red curve); mRNA 
degradation removed (green curve); AP-1 complex inhibition removed (yellow curve). 
Simulations were run using COPASI 
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5.4 Model comparison 
The completed model could now replicate the data from chapter 4. However, I 
wanted to compare this parameterised model to the original IL-1, OSM and 
TGFβ models in order to confirm that the output had not been dramatically 
altered. In the original model presented in Wang Hui et al. (2014) the TGFβ 
component was designed to look at the effect simulation with an inactive form of 
TGFβ had over a 20 month period. Comparing this 20 month simulation in my 
model and the original model showed an almost identical pattern (Fig 5.13).  
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Figure 5.13 Comparison of SMAD signalling and TGFβ receptor expression 
in response to in active TGFβ treatment. Simulation results showing the effect 
of inactive TGFβ on the profiles of SMAD signalling and TGFβ receptor 
expression. Using a simulated time period of 20 months, both the original TGFβ 
model component presented in Wang Hui et al. (2014) (green) and my new 
integrated model presented in Fig 5.7 (blue) were simulated deterministically 
using COPASI. Curves show the amount in particle numbers of A) 
Phosphorylated SMAD1 bound to SMAD4. B) Phosphorylated SMAD2 bound to 
SMAD4. C) ALK1 ALK5 heterodimers. D) ALK5 homodimers.  
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The structure of the IL-1+OSM component from my model had multiple 
alterations from the original presented in Proctor et al. (2014). Despite this, it 
could still match the profiles for the AP-1 components that were seen in the 
original model. Figure 5.14 shows that both of the models showed similar AP-1 
component patterns at 5 hours. The biggest difference was seen in c-Fos 
phosphorylation (Fig 5.14C), where my model showed a slightly higher peak 
and a longer response. The difference was not significant enough to cause a 
concern as they did still have a very similar pattern. Also, the profile of c-Jun/c-
Fos dimerisation, which proceeds c-Fos phosphorylation, had a near identical 
profile. c-Jun/c-Fos heterodimerisation was the only AP-1 component that took 
longer than 5 hours to completely leave the system. Comparison of the two 
models at 48 hours showed that c-Jun/c-Fos dimers persisted in the model for 
the same amount of time, with an analogous rate of decay (Fig 5.15).  
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Figure 5.14 Comparison of AP-1 component profiles after IL-1+OSM 
simulation. Simulation results showing the effect of IL-1+OSM treatment on 
the profile of AP-1 components, using a simulated time period of 5 hours. Both 
the original IL1+OSM model described in Proctor et al. (2014) (green) and my 
new integrated model presented in Fig 5.7 (blue), were simulated 
deterministically using COPASI. Curves show the level of A) c-Jun 
phosphorylation. B) c-Jun homodimer formation. C) c-Fos phosphorylation. D) 
c-Fos/c-Jun heterodimer formation.  
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Figure 5.15 Comparing the formation of c-Fos/c-Jun Heterodimers during a 
48 hour simulation. Simulation results showing the effect of IL-1+OSM treatment 
on the formation of c-Fos/c-Jun heterodimers, using a simulated time period of 48 
hours. Both the original IL1+OSM model described in Proctor et al. (2014) (green) 
and my new integrated model presented in Fig 5.7 (blue) were simulated 
deterministically using COPASI.  
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5.5 Model testing and predictions 
It is argued that most model structures, whether correct or not, can fit given data 
with enough time and effort. As I had created a model that fit to the 
experimental data generated previously, I needed to confirm it could make 
correct predictions. Testing model predictions provides a lot more confidence in 
the model structure if they match. However, if the predictions are not correct 
then the model structure needs to be altered.  
5.5.1 TGFβ-mediated repression after 6 hour exposure to cells. 
Treating SW1353 cells with TGFβ for 6 hours prior to IL-1+OSM stimulation was 
sufficient to mediate repression of MMP-13, even if TGFβ was no longer 
present (Fig 5.16A). However, no repression was seen 6 hours after IL-1+OSM 
treatment. When the cells had been pre-treated with TGFβ repression was seen 
by 12 hours of IL-1+OSM treatment, which was not seen without pre-treat (Fig 
5.16A). Once established, repression of MMP-13 mRNA could be seen up to at 
least 48 hours after stimulation, even if TGFβ was removed (Fig 5.16A).Unlike 
the previous data, the pre-treatment experiments were done in parallel with the 
modelling. My complete model (Fig 5.7) was run with TGFβ present for 6 hours 
prior to IL-1+OSM simulation, via an event. This, without alteration, produced a 
similar pattern of repression to the experimental data. This provided confidence 
that the model could make accurate predictions about the effects of TGFβ on a 
pro-inflammatory stimulus (Fig 5.16B). 
5.5.2 Importance of new protein synthesis  
The model includes de novo synthesis of the dummy species and JunB, which 
are required for TGFβ to mediate its effect. Emetine blocks new protein 
synthesis by binding to the 40S subunit of the ribosome. I pre-treated the cells 
with emetine to see if once emetine was removed treatment with IL-1+OSM 
could still mediate its full effect.  By pre-treating with a combination TGFβ and 
emetine, I hoped to remove the protective effect of TGFβ.  However, even after 
it was removed from the cells emetine continued to have an effect, preventing 
new protein synthesis. This resulted in a substantial reduction in MMP-13 
expression in IL-1+OSM treated cells at 24 hours (Fig 5.17). This was probably 
 
 
 
160 
 
 
a result of IL-1+OSM no longer being able to induce c-Fos synthesis. IL-
1+OSM±TGFβ still resulted in a significant upregulation of MMP-13 expression 
at 24 hours after emetine pre-treatment, but this was most likely an IL-1-
mediated response (Fig 5.17B).  Emetine pre-treatment led to an upregulation 
of MMP-13 by itself and also caused some cell death. This experiment was also 
repeated with cycloheximide and Actinomycin D but this resulted in complete 
cell death (data not shown). 
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Figure 5.16 6 hour pre-treatment with TGFβ was enough to mediate repression 
of IL-1 and OSM effects. A) Pooled data from SW1353 cells stimulated with IL-1 
(0.5ng/ml), OSM (10ng/ml) and TGFβ (10ng/ml) for 6, 12, 24 or 48 hours, following 6 
hours pre-treatment with serum free media or TGFβ (10ng/ml). qPCR was then 
performed on the isolated mRNA to measure MMP-13 expression. Data are 
presented as fold change relative to IL-1+OSM (mean ± SEM). Percentages 
represent the percentage of repression in IL-1+OSM+TGFβ treated samples, relative 
to IL-1+OSM alone at the relevant time point. n=14-19 across 3 experiments on 
separate cell populations. Statistics calculated using unpaired student t-test, where * 
p < 0.05; ** p < 0.01; *** p < 0.001 B) Deterministic simulation results showing the 
effect of IL1+OSM±TGFβ treatment on the fully parameterised model presented in 
Fig 5.7, over a simulation time of 54 hours. An event triggers IL-1 and OSM 
stimulation 6 hours after TGFβ (red) or unstimulated (blue) pre-treat. An active form 
of TGFβ is present in the model to replicate experimental conditions.  Curves show 
how the particle numbers of MMP-13 mRNA change over the simulation. The black 
arrows show the percentages of repression seen at 18, 30 and 54 hours, caused by 
the presence of TGFβ. Simulations were run using COPASI. 
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Figure 5.17 The effect of 6 hour emetine pre-treatment IL-1+OSM+TGFβ signalling. SW1353 cells stimulated with IL-1 (0.5ng/ml), OSM 
(10ng/ml) and TGFβ (10ng/ml) for 24 hours, following 6 hours pre-treatment with TGFβ (10ng/ml), emetine (10μM/ml) or serum free media. 
qPCR was then performed on the isolated mRNA to measure MMP-13 expression. Data are presented as fold change relative to control (mean 
± SEM, n=4-6). Statistics calculated using unpaired student t-test, where * p < 0.05; ** p < 0.01; *** p < 0.001. A) Data shown for all conditions 
B) Data from the same experiment with the serum free media pre-treat excluded to aid the visualisation of smaller fold changes. 
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5.5.3 Increased signalling through ALK1 with age alters the TGF response 
to a pro-inflammatory stimulus.  
The decreased abundance of ALK5 with age, combined with ALK1 remaining 
relatively constant, alters the ratio of ALK1/ALK5. This results in ALK5 
homodimers which are abundant in young organisms becoming less prevalent 
with age, whilst ALK5/ALK1 heterodimers levels decrease at a much lower rate. 
The computational model was set up to simulate this change over a 
representative 20 months (Fig 5.18A). Initially ALK5 homodimer are abundant 
but they decrease and after 8 months ALK1/ALK5 heterodimer start to become 
the dominant receptor; this coincides with a gradual increase in MMP-13 mRNA 
(Fig 5.18A). 3 events were triggered across the 20 months which introduced an 
IL-1+OSM stimulation. The first event was at 4 months, the second at 8 months 
and the third at 19 months.  It is important to note that IL-1+OSM would leave 
the system quickly after the events.  
I used this to examine how an ageing system reacts to a pro-inflammatory 
stimulus (IL-1+OSM). Early in the system (~4 months), I saw that the pro-
inflammatory stimulus was greatly reduced and MMP-13 mRNA levels returned 
to zero very quickly (Fig 5.18B). As the ratio began to change at ~8 months, I 
still saw the repression of MMP-13 mRNA but it was reduced. However, MMP-
13 mRNA returned to basal level of expression much faster than with IL-1+OSM 
alone (Fig 5.18C). By ~19 months, when ALK1 had been the dominant receptor 
for a number of months, MMP13 mRNA has a higher basal level prior to the 
simulation, than for the previous two simulations. IL-1+OSM produced a potent 
increase in MMP-13 mRNA at 19 months but there was still some repression 
mediated by TGFβ (Fig 5.18D). However, because of the higher basal level of 
MMP-13, this response appeared almost as strong as IL-1+OSM alone. The 
increased MMP-13 also took much longer to return to basal expression than 
when ALK5 was dominant (Fig 5.18D). When MMP-13 returns to basal 
expression after the 19 month simulation, it was also higher than before 
stimulation (Fig 5.18A and D). Table 5.1 shows that the repression seen 
decreases at a linear rate across the 20 month simulation, with peak MMP-13 
mRNA levels increasing by ~2.5-3.5% each month, when compared to the 
previous month. 
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Figure 5.18 Changing responses of TGFβ to a pro-inflammatory stimulus over 20 
months. Deterministic simulation results for the model presented in Figure 5.7 ran for 
20 months simulation time, using COPASI.  The simulation was run with an inactive 
form of TGFβ present to also allow for the activation and deactivation of the growth 
factor. IL-1+OSM were triggered using events at three time points at which the 
ALK5/ALK1 ratio had changed. A) Shows the fully 20 month simulation B, C and D) 
Highlight the time marginally before, during and after the change in MMP-13 mRNA 
expression following the events (B=~4 months, C=~8 months and D=~19 months). 
The light blue and green lines show the respective changes in the ALK5 homodimers 
and ALK1 ALK5 heterodimers over 20 months. The dark blue line shows the 
expression of MMP-13 mRNA across the simulation, whilst the red line shows MMP-
13 mRNA expression in the model with TGFβ removed.  
 
Table 5.1 Change in TGFβ-mediated repression of IL-1+OSM-driven 
MMP-13 expression, with age. This data expands on figure 5.18 by 
showing the percentage of MMP-13 mRNA repression that TGFβ mediates 
when an IL-1+OSM event is introduced to a 20 month simulation. The 
simulation was run as in figure 5.18 but an IL-1+OSM event was triggered 
every month. The percentage of repression was calculated by comparing 
the peak expression of MMP-13 mRNA at each month when TGFβ was or 
was not present.  
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5.6 Discussion  
TGFβ appears to be affecting the system by both competitive AP-1 inhibition 
and MMP-13 mRNA degradation, without both of which it cannot produce its 
effect in order to fit the experimental data. Some alternatives to the degradation 
of MMP-13 mRNA were explored during the development. For example I looked 
at the effect of SMADs 2/3 also being able to bind to AP-1 components, as well 
as TGFβ affecting the receptors for IL-1+OSM. I also designed a version of the 
model which included an MMP-13 gene, which c-Fos/c-Jun dimers bound too to 
increase repression, with TGFβ preventing this binding. However, fitting these 
versions of the model to experimental data indicated none of them would have 
been capable of matching the experimental data. MMP-13 mRNA instability on 
the other hand improved the fit of the model significantly so I progressed with 
that in the model. It is worth noting that I did significantly more work fitting the 
MMP-13 mRNA instability version of the model but this was a result of it 
showing more promise initially than the other versions of the model.  
There are a number of potential candidates mediated by TGFβ. The primary 
candidate for AP-1 competitive inhibition is JunB, for the reasons given 
previously.  However, there is also evidence that Smad2/3 can interact directly 
to antagonise AP-1 complex binding, in particular to c-Fos and c-Jun (Zhang et 
al. 1998). JunD is also a promising candidate along with the TIMPs which are all 
strongly induced by TGFβ (Hall et al. 2003). How TGFβ leads to MMP-13 
mRNA degradation does not have as clear a candidate but there are a number 
of ways it could potentially be mediated. Both Vinculin and far upstream 
element (FUSE) have been shown to bind to the 3’ UTR of MMP-13, which in 
turn leads to the decay of MMP-13 mRNA (Clark et al. 2008). NAD-dependent 
deacetylase sirtuin-2 (Sirt2) has also been shown to supress MMP-13, possibly 
as a result of TGFβ (Lin et al. 2013). Reports have also suggested that HDAC4 
can repress MMP-13 (Cao et al. 2014) by binding to the MMP-13 promotor (E. 
Shimizu et al. 2010), preventing further transcripts being produced. This is not 
directly increasing degradation but creates a situation where with no new 
production, mRNA leaves the system giving an impression of degradation. This 
protective effect has been questioned by other reports claiming the opposite is 
true and HDAC4 is responsible for an increase in MMP-13 (Lu et al. 2014; 
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Queirolo et al. 2016). There is potential for degradation to be mediated by 
miRNAs as they have been shown on multiple occasions to mediate an effect 
by increasing mRNA degradation. A number of these have been linked to IL-1, 
TGFβ and MMP-13 such as; miR-145,miR-483,miR146a,miR-140 and miR127-
5p (Li et al. 2015). Determining how TGFβ mediates both AP-1 complex 
inhibition and mRNA degradation, is a difficult question to answer but both are 
needed in the model to replicate experimental results. Future work into how 
specifically they are mediated may identify specific therapeutic targets to help 
reduce cartilage damage with age and OA progression.    
5.6.1 Importance of de novo synthesis 
The initial delay in TGFβ-mediated repression of IL-1+OSM-driven MMP-13 
expression (around 12 hours) led me to hypothesise that de novo synthesis 
may be required in order for TGFβ to have an effect. For this reason it was 
included in the model and was required for the model to fit the data. 
Demonstrating that TGFβ could mediate repression after 6 hours pre-treatment, 
even when TGFβ was subsequently removed from the system, further indicated 
that de novo synthesis may be required. This initial delay may be a result of the 
time for new proteins to be transcribed, but once the proteins were present then 
removal of TGFβ would have no effect as further protein synthesis is not 
required. I hypothesised that blocking new protein synthesis would prevent 
TGFβ from repressing IL-1+OSM-driven MMP-13 upregulation. However, OSM 
leads to the synthesis of c-Fos (Tanos et al. 2005) and this may be key in the 
synergistic increase of MMP-13 driven by IL-1+OSM (Proctor et al. 2014). 
Blocking proteins synthesis by TGFβ without affecting the IL-1+OSM response 
was not possible, thus I cannot confirm that de novo synthesis was required for 
TGFβ to have an effect. Although it does further validate the importance of de 
novo synthesis in IL-1+OSM synergy.   
5.6.2 Potential effect of ALK1 dominance  
ALK1 is known to lead to the upregulation of MMP-13 (Blaney Davidson et al. 
2009) and has also been reported to increase phosphorylation of c-Fos through 
p38 (C. G. Chen et al. 2012). I expected that, when it was the dominant 
receptor, an inflammatory stimulus would lead to an even greater increase of 
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MMP-13 than when TGFβ is not present, due to the effect of p38 and the higher 
basal levels of MMP-13. The model suggests that this is inaccurate and 
although repression was greatly reduced when ALK1 is dominant (compared to 
when ALK5 was dominant), there still appeared to be some measure of 
repression. This may be because ALK1 stimulates MMP-13 upregulation 
through a different mechanism to IL-1+OSM. ALK1 is believed to upregulate 
MMP-13 via SMAD1, which can activate Runx2 and  this in turn leads to an 
increase in MMP-13 (Ijiri et al. 2005), whereas, IL-1+OSM mediate their effect 
through AP-1 components (Chambers et al. 2013). As a result the remaining 
ALK5 dimers can still provide some repression as ALK1 has little direct effect. I 
hypothesised there may be a switch in repression when the effect of TGFβ on 
MMP-13 expression becomes markedly less. However, it appeared this change 
happened at a linear rate across the 20 month simulation.  
Despite this, I did find when ALK1 receptor, is the dominant receptor the 
increase in MMP-13 from IL-1+OSM treatment took longer to leave the system 
and return to basal expression (compared to when ALK5 was dominant). As the 
basal expression is already high, this will lead to a longer and more pronounced 
response that could result in damage to already weakened tissue. Therefore, 
inflammation could still potentially lead to more damage in older organisms than 
their younger counterparts, as basal levels of MMP-13 will be higher and any 
inflammatory response may be prolonged.    
TGFβ is stored in a latent form in the synovial fluid (Pedrozo et al. 1998) and is 
constantly being activated in the joint (Gay et al. 2004). This release and 
activation is increased when under load or during exposure to inflammation 
(Lee et al. 2005; Albro et al. 2012). There are no reports of this changing with 
age, but if TGFβ is now dysregulated in these older organisms, the release of 
TGFβ could result in increased inflammatory damage. Whether inflammation is 
general, or a result of injury, it could become more damaging than in younger 
counterparts. Identifying how the TGFβ response has changed with age may 
provide therapeutic targets to help limit this damage in aged individuals, 
averting cartilage damage and OA development or progression. 
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5. 7 Summary  
 
 The IL-1+OSM and TGFβ models were adapted from previous published 
models. Despite being changed for purpose, both sections of my model 
could still replicate the important profiles from the original models.  
 
 The model requires both AP-1 complex inhibition and MMP-13 mRNA 
degradation, in order to match the experimental data accurately.  
 
 TGFβ can mediate repression of IL-1+OSM-driven MMP-13 expression 
after 6 hours pre-treatment, even if it is then removed from the system. 
This was simultaneously shown in the model simulations and the 
experimental data.  
 
 
 Using the model to explore how TGFβ will affect IL-1+OSM, when ALK1 
becomes dominant, suggests there will not be an increase in MMP-13 
expression (compared to IL-1+OSM alone) but instead a prolonged 
inflammatory response. 
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Chapter 6. Exploring the effects of ALK1 over-express in SW1353 cells 
6.1 Introduction  
In the previous chapter my computational model suggested that, as an 
individual aged, ALK1 dominance would reduce the inhibitory effect TGFβ has 
on IL-1+OSM-mediated MMP-13 expression. However, it would not result in a 
greater increase in MMP-13 expression than IL-1+OSM alone, which was 
contrary to our original hypothesis. In order to confirm these model predictions I 
looked to create an experimental model of ALK1 over-expression. This was 
attempted in three ways: (i) stable over-expression with a plasmid, and transient 
over-expression using (ii) lentivirus or (iii) adenovirus.  
6.1.1   
Stable transfection of cells, although initially time consuming, has the advantage 
of reproducible results, which is not always the case with transient over-
expression. Theoretically, any cells which survive the stable transfection 
protocol must have taken up the plasmid of interest and hence over-express the 
gene of interest. Once established, the stable cell line can then be treated as a 
wild-type cell line allowing for multiple experiments to be performed quickly in 
cells with a consistent level of (over) expression (Chambers et al. 2015). Stable 
over-expression of the protein of interest also has the advantage that any post-
translational modifications or necessary subcellular translocation of the proteins 
required for functionality should have sufficient time to occur during cell growth 
(Chambers et al. 2015). 
The time taken to create the stable cell line, however, can become very 
prominent if there are mistakes with the plasmid or if expression does not 
provide the expected results. Transient expression allows for a significantly 
quicker method of over-expressing the gene of interest and looking at its effect 
(Vorburger and Hunt 2002; Federici et al. 2009). The level of over-expression 
with transient transfection is not constant and although this can be a problem, it 
means higher levels of expression are also possible (Vorburger and Hunt 2002; 
Federici et al. 2009).  
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6.1.1 Aims  
 To develop a method that facilitates over-expression of ALK1 to a 
sufficient level for it to become the dominant receptor.  
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6.2 Stable over-expression of ALK1 
To attempt to mimic the changes seen in type I TGFβ receptors in an ageing 
model (both in mice and computationally), I sought to create SW1353 cells that 
stably over-expressed a plasmid containing the ALK1 gene. Physiologically, 
ALK5 is also reduced so it was not an ideal representation. However, as ALK1 
is the preferential binding partner of TGFβ, if there is sufficient over-expression 
it should signal through ALK1. siRNA against ALK5 also allowed me to reduce 
the levels of ALK5 to better represent what is happening with age.  
6.2.1 First attempt at stably over-expressing ALK1. 
I initially used two plasmids to make stable cell lines: the original plasmid 
(mEmerald-ALK1-N-13) and one with an induced stop codon (STOP-ALK1-N-
13). mEmerald-ALK1-N-13 expressed ALK1 but also had a fluorophore 
attached called mEmerald. Due to the size of the mEmerald protein (239 amino 
acids), I was concerned it may interfere with the activity of ALK1 (503 amino 
acids).  In order to address this, I used site direct mutagenesis (SDM) to induce 
a stop codon in the linker sequence upstream of mEmerald but downstream of 
the complete ALK1 sequence (Table 6.1). This new plasmid was named STOP-
ALK1-N-13. When using the SDM technique it is feasible that the primers will 
not anneal due to their nonhomologous sequences, so it was important to check 
there was a product. Figure 6.1 shows the SDM products ran next to the original 
mEmerald-ALK1-N-13 plasmid. The bright band ran at approximately the same 
molecular mass as mEmerald-ALK1-N-13, suggesting that the process had 
been successful. It ran slightly lower because it is single stranded until 
transfected into bacteria. Conversely, mEmerald-ALK1-N-13 is a double 
stranded circular plasmid which caused the two bands seen in the mEmerald-
ALK1-N-13 lane (Fig 6.1). The second band in the STOP-ALK1-N-13 lane was 
the excess primer from SDM (Fig 6.1). The STOP-ALK1-N-13 was then sent for 
sequencing, where it was confirmed that the mutation was as predicted (data 
not shown).  
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Figure 6.1 Confirmation of site directed mutagenesis products. SDM was 
performed on the mEmerald-ALK1-N-13 plasmid using the primers in A. A) The 
primers used for SDM the red nucleotides highlight the nucleotides that differ 
from the normal plasmid sequence. B) An ethidium bromide gel was run 
containing the product of the SDM (STOP-ALK1-N-13) as well as the original 
plasmid mEmerald-ALK1-N-13. 
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I created two stable cell lines in parallel, using the mEmerald-ALK1-N-13 and 
STOP-ALK1-N-13 plasmids. If the stable protocol worked the cells should be 
able to survive in the antibiotic G418, which would normally kill SW1353 cells. 
Both cell lines survived so I assumed they had been transfected successfully. 
Figure 6.2A shows the expression of ALK5 and ALK1 in both of the cell lines. 
ALK5 expression is unaffected in either cell line but ALK1 also appears to be 
unaffected. As the receptor should have been localised to the cell membrane, I 
attempted membrane specific extraction in an attempt to visualise increased 
ALK1 expression. Again there appeared to be no change in ALK1 concentration 
(Fig 6.2B). Looking at the mEmerald-ALK1-N-13 cell line for mEmerald 
expression (Fig 6.3) showed that although there was some green fluorescence 
this was only negligible. This suggested that ALK1 was being over-expressed 
but not to a sufficiently high level to visualise, by Western blots.  
 
 
Table 6.1 Stop codon introduction into the mEmerald-ALK1-N-13 plasmid. 
A small section from the sequence of the SMD and mEmerald-ALK1-N-13 
plasmids, showing where the linker sequence joins the sequences for ALK1 
and mEmerald. Site directed mutagenesis was used to introduce a stop codon 
into the linker sequence, preventing mEmerald from being transcribed.  
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Figure 6.2 TGFβ type I receptors in stable cell lines. ALK1 over-expressing 
SW1353 cell lines (mEmerald-ALK1-N-13 and STOP-ALK1-N-13) were grown 
to confluency in G418. Control cells were also grown to confluency in serum 
containing medium but without G418. The cells were then lysed and A) whole 
cell lysis was performed on 1 million cells. B) Membrane specific lysis was 
performed on 1 million cells.  The samples were then run on 12% SDS-PAGE 
gel and western blots were undertaken for ALK5, ALK1 and GAPDH. A) Is 
representative of 3 experiments on separate SW1353 cell populations. B) Is 
representative of a single experiment. 
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Figure 6.3 Live-cell plasmid expression. SW1353 cells stably over-expressing 
the mEmerald-ALK1-N-13 plasmid were live imaged whilst in G418 serum-
containing medium. A) With a fluorescent filter at 500nM which is optimum for 
visualising the mEmerald fluorophore. Bright green cells show where ALK1 with 
mEmerald attached is being expressed (the red circle highlights an example of 
this). B) The same section of cells imaged without any filter.  
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6.2.2 Creation of the pcDNA3.1_ALK1_HIS plasmid.                                                                                                                                                                                                       
There were two possible reasons why the initial stable cell lines had negligible 
expression. First, plasmids were not linearised prior to transfection which is 
known to reduce transfection efficiency. Secondly, the plasmids may not have 
had a satisfactory promoter sequence. Since the plasmid sequence was not 
publically available, it was not possible to confirm or deny this. In order to 
address the second problem I used in-fusion cloning to remove the ALK1 gene 
and move it to a different plasmid, pcDNA3.1+, which had been used previously 
by our group with success.  I also added a His tag to the protein in order to 
increase the ease of detection. Forward and reverse primers (Fig 6.4A) allowed 
me to remove the ALK1 gene with overhangs. These overhangs could be cut 
with restriction enzymes to give sticky ends (Fig 6.4B), which were homologous 
to cuts in the pcDNA3.1+ plasmid. Figure 6.5 shows the DNA fragments created 
at two different cycle temperatures during replication. Both 64 and 72 degrees 
resulted in fragments being created at the correct molecular weight (1566kb). It 
also shows the pcDNA3.1+ plasmid being linearised by both BamHI and Xbal. 
When both restriction enzymes were combined the plasmid still only had one 
band, suggesting that as predicted they only removed one section of the 
plasmid rather than cutting it into multiple fractions.  
The in-fusion kit then allowed the ALK1 product and the linearised plasmid to be 
combined to create a new plasmid (pcDNA3.1_ALK1_HIS). This plasmid was 
then transfected into bacteria. These cells were left to grow on antibiotic 
containing agar plates, with only the cells that took up the plasmid being able to 
survive. This however does not mean that the plasmid contained ALK1 as the 
plasmid may have re-annealed without incorporating it into its sequence, so I 
ran a colony PCR on a selection of the bacteria colonies using the primers in 
Figure 6.4. Only two colonies appeared to contain the ALK1 gene (Fig 6.6): 
Both of these were subject to a Mini-prep, then sequenced, and were found to 
contain the sequence I was expecting. One of these colonies did have the 
expected sequence and was amplified using a Maxi-prep to produce large 
quantities of pcDNA3.1_ALK1_HIS.  
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Figure 6.4 ALK1 specific primers. A) Primers designed to flank the ALK1 
gene in the mEmerald-ALK1-N-13 plasmid. They also contain a Stop codon, 
Kozak site, His tag and overhangs designed to be cut by BamHI and Xbal. B) 
The expected overhangs when products made using the primers in A are cut 
with BamHI and Xbal. 
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Figure 6.5 Linearisation of pcDNA3.1+ allows incorporation of ALK1 
containing fragments. ALK1 fragments for in-fusion cloning were generated by 
cycling the mEmerald-ALK1-N-13 plasmid at 64 and 72° containing the primers in 
Figure 6.4A and the mEmerald-ALK1-N-13 plasmid. The pcDNA3.1+ plasmid was 
also linearisation by treatment with Xbal and BamHI individually or combined for 4 
hours at 37°. An ethidium bromide gel was run using the products of these 
reactions; the pcDNA3.1+ plasmid was also run as a control (Size 5428bp).  
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Figure 6.6 Colony PCR reveals the colonies that have incorporated the ALK1 
expressing plasmid. In-fusion cloning was used to transfected bacteria with the 
plasmid pcDNA3.1_ALK1_HIS. Colonies that survived in kanamycin (50mg/ml) 
containing agar plates were subject to colony PCR. An ethidium bromide gel was 
run with colony PCR products from 11 colonies. The primers used are shown in 
Figure 6.4 and would only replicate DNA if ALK1 was present. Any product meant 
ALK1 had successfully incorporated in to the plasmid. This was seen for lanes 1 
and 11. 
 
 
 
6.2.3 Second attempt at stably over-expressing ALK1.  
STOP-ALK1-N-13 and pcDNA3.1_ALK1_HIS were both linearised for the 
second attempt at creating a stable cell line. Figure 6.7 shows 
pcDNA3.1_ALK1_HIS linearisation by Mfel and Pvu1 respectively. STOP-ALK1-
N-13 was linearised in the same way by the same restriction enzymes (data not 
shown). These linearised forms of the plasmids were used to transfect SW1353 
cells and left until the cells could survive in G418 containing media. Unlike the 
previous cell line, both plasmids led to an increase of ALK1 protein expression 
(Fig 6.7), with neither of them affecting ALK5 expression and only 
pcDNA3.1_ALK1_HIS being able to express HIS as expected. This was true in 
both whole cell lysates and membrane specific blots (Fig 6.8). To assess if this 
increase in ALK1 protein expression led to downstream changes I looked at the 
expression of ID1 and PAI1. Previous 2 hour treatment with TGFβ (chapter 4) 
led to no increase in ID1 (Fig 4.7). However, in both stable cell lines the same 
treatment resulted in a significant upregulation of ID1 (Fig 6.9A and C), whilst 
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also retaining the effect on PAI1 (Fig 6.9B and D). It has been reported that the 
ALK1 receptor cannot work without the ALK5 receptor present. To further 
explore this I silenced ALK5 using siALK5 to test if ID1 could still be increased. 
When ALK5 was silenced TGFβ stimulation failed to induce PAI1 or ID-1 
expression (Fig 6.9), indicating that ALK5 was required for ALK1 to function. 
pcDNA3.1_ALK1_HIS and STOP-ALK1-N-13 cell lines behaved in the same 
way (Fig 6.9), and as pcDNA3.1_ALK1_HIS had the His tag to aid detection I 
used it for all future experiments.  
Figure 6.7 Linearisation of pcDNA3.1_ALK1_HIS plasmid. The 
pcDNA3.1_ALK1_HIS Plasmid was linearised by treatment with Mfel or 
Pvu1 for 4 hours at 37°. PCR clean-up was then used to purify the resulting 
products and they were run on an ethidium bromide gel to show 
linearisation. Uncut pcDNA3.1_ALK1_HIS plasmid was run as a control.  
 
 
 
183 
 
 
Figure 6.8 TGFβ type 1 receptor composition after second stable transfection. 
ALK1 overexpressing SW1353 cell lines (STOP-ALK1-N-13 and 
pcDNA3.1_ALK1_HIS) were grown to confluency in G418. Control cells were also 
grown to confluency in serum containing media without G418. The cells were then 
lysed and A) whole cell lysis was performed on 1 million cells. B) Membrane 
specific lysis was performed on 1 million cells.  The samples were then run on 12% 
SDS-PAGE gel and western blots were undertaken for ALK5, ALK1, HIS tag and 
GAPDH. Blots are representative of 2 experiments on separate SW1353 cell 
populations.  
 
 
 
 
 
 
 
 
 
 
Figure 6.9 Effect of ALK5 removal on ALK1 over-expressing SW1353 cells. SW1353 cells stably over-expressing A and 
B) pcDNA3.1_ALK1_HIS or C and D) STOP-ALK1-N-13 plasmid were treated for 2 hours with TGFβ (10ng/ml) after 24h pre-
treatment with 50nM of either siCON or siALK5. qPCR was then performed on the isolated mRNA to measure  A) and C) ID1 
expression B) and D) PAI1 expression. Data are presented as fold change relative to control (mean ± SD, n=5-6). Statistics 
calculated using unpaired Student’s t-test, where ** p < 0.01; *** p < 0.001. 
 
 
185 
 
 
With a better understanding of how the stable cell lines were signalling, I 
wanted to look at what effect it would have on the TGFβ-mediated repression of 
IL-1+OSM-driven MMP-13 expression. Comparing the stable cell lines directly 
to regular SW1353 cells (Fig 6.10A) showed that the ALK1 over-expression had 
no effect on the ability of TGFβ to repress IL1+ OSM driven MMP-13 
upregulation.  Significant reduction can still be seen, which was around the 
same level as in wild type SW1353 cells (Fig 6.10A). Silencing ALK5 had the 
same effect as seen in chapter 4, with ALK5 depletion resulting in a loss of 
TGFβ-mediated repression (Fig 6.10B).  TGFβ alone also had no significant 
effect on MMP-13 expression (Fig 6.10). 
 
 
 
 
 
  
Figure 6.10 TGFβ-mediated repression in ALK1 over-expressing SW1353 cells. 
SW1353 cells with or without the pcDNA3.1_ALK1_HIS plasmid stably overexpressed 
were treated for 24 hours with IL1 (0.5ng/ml), OSM (10ng/ml) and TGFβ (10ng/ml). 
qPCR was then performed on the isolated mRNA to measure MMP-13 expression. A) 
Expression in the stable cell line (ALK1+) compared to wild type SW1353 cells. B) 
Expression in the stable cell line when pre-treated with 50nM siCON or siALK5 for 
24h. Data are presented as fold change relative to control (mean ± SD, n=5-6). 
Statistics calculated using unpaired Student’s t-test, where; *** p < 0.001 
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I aimed to find a concentration at which siALK5 would decrease ALK5 levels but 
not alter ALK1 function, allowing signalling to switch from ALK5 toward ALK1. I 
first used the concentrations: 50, 40, 30, 20 and 10nM (Fig 6.11A and B). 
However, these all produced results identical to Figure 6.9. For this reason a 
lower concentration of siALK5 was used.  
ID1 expression was increased with TGFβ treatment but this effect was lost after 
pre-treatment with 10 and 5nM siALK5 (Fig 6.11C). However, at 2.5 and 1nM 
siALK5 pre-treatment TGFβ led to a significantly increase in ID1 expression (Fig 
6.11C). At both 2.5 and 1nM there was no significant difference between pre-
treatment with siCON or siALK5 on the increase in ID1 expression after TGFβ 
treatment (Fig 6.11C). PAI1 expression was significantly increased regardless 
of pre-treatment (Fig 6.11D). However, siALK5 pre-treatment at 2.5 and 1nM 
did reduce the extent to which PAI1 was increased, as the fold change was 
significantly less than pre-treatment with the siCON (Fig 6.11D). At 2.5nM 
siALK5, it appeared that signalling through ALK5 was reduced but ALK1 was 
still able to propagate a signal. For this reason I repeated Figure 6.10 with 
siALK5 at 2.5nM. The effect was that TGFβ-mediated repression was retained 
with no difference to treatment with non-targeting siRNA (Fig 6.12). MMP-13 
expression was also unaffected by TGFβ treatment (Fig 6.12).  
All of these results suggested that, although ALK1 was being over-expressed, 
ALK5 was still the dominant receptor. If ALK1 was the dominant receptor then 
TGFβ should be able to increase MMP-13 mRNA. To look at this I treated cells 
with TGFβ for 24 - 144 hours (Fig 6.13), but saw no significant increase at any 
of these time points. From this I concluded that ALK1 over-expression by this 
method was not sufficient to remove ALK5 dominance of the canonical 
pathway. 
It is worth noting that stable cell lines cannot be maintained indefinitely and 
freeze thawing can result in the over-expression being lost. During these 
experiments one cell line became too old and a second was made. Figure 6.14 
compares the older cell line to the new one, demonstrating that the process can 
be accurately repeated.  
 
 
 
 
 
 
Figure 6.11 Effect of varying siALK5 concentrations on TGFβ-mediated response. SW1353 cells stably over-expressing the 
pcDNA3.1_ALK1_HIS plasmid were treated for 2 hours with TGFβ (10ng/ml), after a 24h pre-treatment with 50nM of either siCON 
or varying concentrations of siALK5. qPCR was then performed on the isolated mRNA to measure  A) and C) ID1 expression B) 
and D) PAI1 expression. Data are presented as fold change relative to control (mean ± SD, n=4-6). Statistics calculated using 
unpaired Student’s t-test, where ** p < 0.01; *** p < 0.001. Data presented are representative of 2 experiments on separate cell 
populations 
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Figure 6.1213 How reduced ALK5 affects TGFβ-mediated repression in ALK1 
over-expressing SW1353 cells. SW1353 cells stably over-expressing the 
pcDNA3.1_ALK1_HIS plasmid were treated for 24 hours with IL1 (0.5ng/ml), OSM 
(10ng/ml) and TGFβ (10ng/ml), after pre-treatment with 2.5nM siCON or siALK5 for 
24h. qPCR was then performed on the isolated mRNA to measure MMP-13 
expression. Data are presented as fold change relative to control (mean ± SD, n=5-6). 
Statistics calculated using unpaired Student’s t-test, where; * p < 0.05. Representative 
of 2 experiments on separate SW1353 cell populations.  
 
 
Figure 6.1312 MMP-13 expression after TGFβ treatment in ALK1 over-expressing 
SW1353 cells. SW1353 cells stably over-expressing the pcDNA3.1_ALK1_HIS 
plasmid were treated for A) 24, 48 and 72 B) 5 and 6 days with TGFβ (10ng/ml). qPCR 
was then performed on the isolated mRNA to measure MMP-13 expression. Data are 
presented as fold change relative to control (mean ± SD, n=5-6). If the treatment took 
longer than 3 days TGFβ was replenished, by removing medium and immediately 
replacing it with fresh TGFβ-containing medium.  
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6.2.4 Adenoviral transduction  
It appeared that over-expressing ALK1 in SW1353 cells was possible but the 
stable cell line did not provide sufficient expression to make it the dominant 
receptor. I aimed to find another system that may be able to provide increased 
ALK1 expression. Adenoviral transduction was a system that had provided 
robust and repeatable over-expression in many previous studies (Thrasher et 
al. 2006; Vorburger and Hunt 2002). An adenovirus that over-expresses ALK1 
(adALK1) was kindly gifted to us by Peter Van Der Kraan (Radboud, Nijmegen, 
Netherlands). 
adALK1 had never been tested on SW1353 cells so I attempted to find an MOI 
at which it may have an affect on the TGFβ response. Figure 6.15 shows the 
effect of pre-treatment of adALK1 at 10,100 and 500 multiplicity of infection 
Figure 6.14 Comparison of the first and second pcDNA3.1_ALK1_HIS stable 
SW1353 cells. SW1353 cells stably over-expressing the pcDNA3.1_ALK1_HIS 
plasmid were treated for 2 hours with TGFβ (10ng/ml). 1 was the original stable cell 
line and 2 was created when 1 was beginning to stop dividing. qPCR was then 
performed on the isolated mRNA to measure ID-1 expression. Data are presented as 
fold change relative to control (mean ± SD, n=5-6). Statistics calculated using unpaired 
Student’s t-test, where *** p < 0.001. 
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(MOI) for 48 hours followed by 2 hour TGFβ treatment. The first time I did this 
experiment (Fig 6.15A and B) TGFβ increased PAI1 at all MOIs. TGFβ 
treatment had no effect on ID1 expression at all MOIs, except for an MOI of 
500, when it appeared to increase ID1 expression significantly (Fig 6.15A). 
Conversely, when the experiment was repeated, adALK1 not only failed to 
increase ID1 expression with TGFβ treatment at any MOI (Fig 6.15C), but led to 
a significant decrease in ID1 expression at 0, 10 and 100 MOI and had no effect 
at 500MOI (Fig 6.15C). Again pre-treatment with adALK1 did not appear to 
effect PAI1 expression, as it was significantly upregulated after 2 hours TGFβ 
treatment at all MOIs (Fig 6.15D).  
I next examined whether adALK1 pre-treatment for 24 or 48 hours could 
upregulate ALK1 to a sufficient level to induce MMP-13 expression after 24 
TGFβ treatments. At 24 hour pre-treatment MOI of 100 resulted in a significant 
increase of MMP-13 mRNA, compared to control (Fig 6.16A). However TGFβ 
addition led to no further increase (Fig 6.16A). At an MOI of 500 there was no 
change in MMP-13 mRNA expression (Fig 6.16A). When cell were pr –treated 
with adALK1 for 48 hours at an MOI of 100 it resulted in a significant increase in 
MMP-13 mRNA (Fig 6.16A). Addition of TGFβ appeared to reverse this effect 
(Fig 16A). Again at an MOI of 500 there was no change in MMP-13 mRNA 
expression (Fig 6.16A). 
There was a highly significant increase in ALK1 mRNA after adALK1 pre-
treatment (Fig 6.16B) but as this was leading to confusing downstream effects, I 
wondered what effect the increase in ALK1 mRNA was having on protein 
expression. Figure 6.17 shows the protein expression of ALK1 after adALK1 
transduction at 10, 100 and 500 MOI. Both ALK1 and ALK5 appear unaffected 
by the treatment. I concluded that although the adenovirus was affecting ALK1 
mRNA, there was no evidence that this was going to have a more pronounced 
effect on ALK1 signalling than the stable cell line.  
 
 
Figure 6.15 Effect of ALK1 adenoviral transduction on TGFβ-mediated response at 2 hours. SW1353 cells were treated for 2 hours with 
TGFβ (10ng/ml), after 48 hour pre-treatment of adALK1 at varying MOIs. qPCR was then performed on the isolated mRNA to measure  ID1 
expression (A and C) or  PAI1 expression (B and D). Data are presented as fold change relative to control (mean ± SD, n=5-6). Statistics 
calculated using unpaired Student’s t-test, where * p < 0.05;** p < 0.01; *** p < 0.001.  
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Figure 6.17 Protein expression after ALK1 adenoviral transduction. SW1353 
cells were treated for 48 hours with adALK1 at 10, 100 or 500 MOI. Whole cell 
lysis was performed and the samples were then run on 12% SDS-PAGE gel. 
Western blots were then undertaken for ALK5, ALK1 and GAPDH. Blots are 
representative of 2 experiments on separate SW1353 cell populations. 
Figure 6.16 Effect of ALK1 adenoviral transduction on ALK1 and MMP-13 
expression. SW1353 cells were treated for 24 hours with TGFβ (10ng/ml) after a 24 
or 48 hour pre-treatment of adALK1 at varying MOIs. qPCR was then performed on 
the isolated mRNA to measure  A) MMP-13 expression B) ALK1 expression. Data are 
presented as fold change relative to control (mean ± SD, n=5-6). Statistics calculated 
using unpaired Student’s t-test, where ** p < 0.01; *** p < 0.001. 
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6.2.5 Lentiviral transduction 
Commercially available lentivirus that over-expressed ALK1 (lenALK1) provided 
another possible technique that may allow higher levels of ALK1 expression. 
Previous work done by our group suggested different lentiviruses lead to peak 
expression at 24 hours whilst other studies take 48, so my initial experiment 
incorporated both of these time scales. Due to previous experience with the 
adenovirus I also looked at protein prior to mRNA. Figure 6.18 shows ALK1 
expression after 24 and 48 hour treatment with 1, 5, 10 or 100 MOI of lenALK1. 
After 48 hours MOI of 1 and 5 appear to have the strongest effect on ALK1 
expression. However, there does appear to be some level of increased 
expression in all lanes (Fig 6.18). At 48 hours 5, 10, 50 and 100 MOI lenALK1 
led to a significant increase in ALK1 mRNA expression (Fig 6.19).  
 
 
 
 
 
 
 
 
 
 
Figure 6.18 Protein expression after ALK1 lentiviral transduction. SW1353 
cells were treated for 24 or 48 hours with lenALK1 at 1, 5, 10, 100 MOI. Whole 
cell lysis was performed and the samples were then run on 12% SDS-PAGE gel. 
Western blots were then undertaken for ALK5, ALK1 and GAPDH.  
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I moved on to look at how the increase in ALK1 mRNA and protein affected the 
expression of PAI1 and ID1 after 2 hour TGFβ treatment.  PAI1 was no longer 
significantly increased by TGFβ in the lenALK1-treated cells (Fig 6.20A). 
Intriguingly, ID1 expression was unaffected by lenALK1 treatment suggesting 
that the cells were signalling through neither ALK1 nor ALK5 (Fig 6.20B).  I 
explored if lack of signalling continued after prolonged TGFβ or could lenALK1 
lead to the upregulation of MMP-13. Based on the protein and mRNA data I 
used an MOI of 5. At three days lenALK1 did not alter the effect of TGFβ on 
MMP-13 (Fig 6.21A). The empty lentiviral control (lenCON) behaved the same 
as lenALK1 (Fig 6.21A). Based on this, I looked at 3 days combining lenALK1 
with siALK5: this time lenALK1 managed to significantly upregulate MMP-13 in 
the control and siCON cells when treated with TGFβ (Fig 6.21B). However, 
when treated with siALK5, TGFβ failed to upregulate MMP-13 higher than the 
untreated cells (Fig 6.21B). This may have been because siALK5+lenALK1 
increased MMP-13 significantly with or without TGFβ, when compared to siCON 
cells (Fig 6.21B). I also ran both of these experiments at 6 days and found that 
MMP-13 mRNA was not significantly affected by any treatment (Fig 6.22). 
Figure 6.19 ALK1 mRNA expression after ALK1 lentiviral transduction. 
SW1353 cells were treated for treated for 2 hours with TGFβ (10ng/ml), after 48 
hours pre-treatment with lenALK1 at various  MOIs. qPCR was then performed on 
the isolated mRNA to measure  ALK1 expression. Data are presented as fold 
change relative to control (mean ± SD, n=5-6). Statistics calculated using 
unpaired Student’s t-test, where *** p < 0.001. 
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Figure 6.2021 Effect of ALK1 lentiviral transduction on TGFβ-mediated 
response, at 2 hours. SW1353 cells were treated for treated for 2 hours with 
TGFβ (10ng/ml), after 48 hours pre-treat with lenALK1 at various MOIs. qPCR 
was then performed on the isolated mRNA to measure  A) PAI1 expression B) 
ID1 expression. Data are presented as fold change relative to control (mean ± 
SD, n=5-6). Statistics calculated using unpaired Student’s t-test, where ** p < 
0.01. 
 
Figure 6.2120 Effect of ALK1 lentiviral transduction on TGFβ-mediated 
MMP-13 expression, at 72 hours. SW1353 cells were treated for 72 hours 
with TGFβ (10ng/ml) after A) 48 hours pre-treat with lenALK1 or lenCON at an 
MOI of 5 and B) 48 hours pre-treat with lenALK1 at an MOI of 5, followed by 
24 hours siCON or siALK5 (2.5nM) treatment. qPCR was then performed on 
the isolated mRNA to measure  MMP-13 expression. Data are presented as 
fold change relative to control (mean ± SD, n=5-6). Statistics calculated using 
unpaired Student’s t-test, where *p < 0.05. 
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Figure 6. 22 Effect of ALK1 lentiviral transduction on TGFβ-mediated MMP-
13 expression at 6 days. SW1353 cells were treated for treated for 6 days with 
TGFβ (10ng/ml) treatment A) after 48 hour pre-treatment of either lenALK1 or 
lenCON (5 MOI). B) After 48 hour pre-treatment of lenALK1 (5 MOI) followed by 
24 hours siCON or siALK5 (2.5nM). qPCR was then performed on the isolated 
mRNA to measure  MMP-13 expression. Data are presented as fold change 
relative to control (mean ± SD, n=5-6). If the treatment took longer than 3 days 
TGFβ was replenished. 
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6.3 Discussion  
Over-expressing ALK1, although problematic, was accomplished. However, 
over-expressing to a sufficient level for ALK1 to become the dominant TGFβ 
receptor has not been possible and the reason(s) for this are unclear. My data 
replicate the well-established dogma that ALK5 is needed for ALK1 signalling 
(M. J. Goumans et al. 2003) but also highlight the delicate balance between the 
two receptors. The stable cell line allowed adequate ALK1 production to 
increase ID1 expression, indicating an increase in SMAD 1/5/8 signalling which 
has been shown to inhibit SMAD 2/3 signalling (M. J. Goumans et al. 2003). It 
would therefore be expected that as this ALK1 response becomes prominent 
the ALK5 response would be inhibited (M. J. Goumans et al. 2003). This should 
result in ALK1 dominance and a subsequent increase in MMP-13 expression 
with TGFβ treatment (Blaney Davidson et al. 2009). Even a reduction in ALK5 
levels in these cells, which did downregulate the ALK5 response, appears 
insufficient to allow ALK1 dominance. This suggests that when ALK1 becomes 
dominant in ageing it may be at a specific ALK1/ALK5 ratio. How tightly 
regulated this system is may further indicate the importance of ALK5 and why 
disease starts to develop when ALK1 is dominant. 
6.3.1 Functionality of ALK1 
Even when a high level of ALK1 protein has been achieved, ALK1 must be 
transported to the cell surface in order to mediate an effect (Mitchell et al. 
2010). I initially created a cell line that stably expressed ALK1 since 
incorporation into the genome means that all protein folding and post-
translational modifications are possible. This should allow ALK1 to be 
incorporated into the membrane and function correctly. All cells should also 
have similar levels of expression, hence there will be similar levels of 
expression between experiments (Chambers et al. 2015). This was seen with 
the stable cell line with a functional ALK1 over-expression having repeatable 
results. Unfortunately, this expression was not sufficient for TGFβ to induce 
MMP-13 expression, which is an established consequence of ALK1 signalling 
(Blaney Davidson et al. 2009).  As a result, transient transfection was attempted 
as it has the potential to induce much higher fold change expression (Vorburger 
and Hunt 2002; Federici et al. 2009). In the case of adenovirus this was seen at 
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the mRNA level but did not reflect in the protein or downstream response to 
TGFβ. Lentivirus has also not shown an immediately obvious ALK1 response. 
However, I have not fully explored transient expression at this point so cannot 
make any firm conclusions.  
It is possible that despite being over-expressed ALK1 failed to have a 
pronounced effect because of an inability to signal. Endoglin has been shown to 
have important implications in ALK1 signalling, and strengthens the interactions 
between the type I and type II receptors to allow increased signalling (Finnson 
et al. 2010). Low expression of endoglin in SW1353 cell may prevent this 
increased level of ALK1 from having its full effect, as there is insufficient 
endoglin to interact with all the newly formed receptors. Barksby et al. (2006) 
preformed RNA microarray on SW1353 cells, looking at the control samples 
from this study showed the basal expression of many genes in SW1353 cells. 
Examining this data allowed me to confirm that endoglin is expressed and to a 
sufficient level for it to be measured by RNA microarray. It is impossible to infer 
from this data the relative protein level expression of endoglin in SW1353 cells 
or how this compares to other cells types. Over-expressing endoglin at the 
same time as ALK1 may allow for increased SMAD 1/5/8 signalling but I am 
unaware of any studies which have shown this yet. It is also possible that low 
levels of TGFBR2 could result in this effect (Bierie and Moses 2006). If TGFBR2 
was responsible a similar effect should be seen in ALK5 signalling, yet ALK5 
signalling through PAI1 is abundant. The Barksby et al. (2006) data also 
indicate there is basal expression of TGFBR2 to a sufficient level for it to be 
measured by RNA microarray.   
6.3.2 Were SW1353 cells the correct cell type? 
Basal expression of ALK5 and ALK1 in SW1353 cells, as shown in chapter 4, 
appears heavily biased towards ALK5. Overcoming this discrepancy is difficult 
as the cells appear incapable of producing high levels of ALK1 protein despite 
increased mRNA expression. Why protein cannot be produced is unclear, but it 
could be the result of many factors such as; insufficient translational machinery, 
a high level of ALK1 degradation, or the formation of inclusion bodies. These 
are aggregates regularly formed from over-expressed protein that has been 
incorrectly folded or transcriptionally modified (Wingfield et al. 2001). The high 
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levels of ALK1 protein may result in the system not being able to correctly 
modify the protein so instead it forms these aggregates that cannot function 
(Thomas and Baneyx 1996). The cells inability to translate high levels of mRNA 
may be why I can only detect increased ALK1 protein when there is a modest 
mRNA increase. This results in insufficient ALK1 to overcome ALK5 dominance.  
This research seems to suggest that SW1353 cells are not an ideal cell type to 
study ALK1 over-expression. Finnson et al. (2010) over-expressed ALK1 in the 
chondrocyte cell line C28/I2. Similarly to SW1353 cells, the basal expression of 
ALK1 could not be detected by western blot. However, despite this, their over-
expression was sufficient to mediate an effect. Using these cells may provide a 
system where I could more easily manipulate the ALK1/ALK5 ratio. Primary 
human chondrocytes may also allow me to better manipulate the ALK1/ALK5 
ratio, in a cell type that is the closest to in vivo human studies. However, tissues 
from late stage OA or older patients would most likely have an altered 
ALK1/ALK5 ratio already, so would undoubtedly present their own challenges 
(van der Kraan 2014). Human tissues are also a lot less readily available than 
cell lines and this could hinder the progression of a study solely reliant on them.  
6.3.3 Future work 
Despite the limited success currently seen with transient expression I would still 
like to perform further tests on both the adeno and lenti-virus. The adenovirus 
has only been tested at MOIs higher than those successful for the lentivirus and 
this was an oversight. Therefore I would like to repeat the experiments at a 
lower MOI to test if a smaller increase in ALK1 mRNA can result in upregulation 
of protein.  For the lentivirus, I would like to repeat the 3 day experiment as it 
currently has some results that are difficult to explain. I would also like to try and 
uncover why both ID-1 and PAI-1 expression was not affected by TGFβ at two 
hours after lentiviral pre-treatment treatment.  
 
  
 
 
 
200 
 
6.4 Summary 
 Throughout this chapter I altered an ALK1 containing plasmid to create 
two new plasmids. Using these and the original plasmid I created a 
SW1353 cell line that stably over-expressed ALK1. Testing this cell line 
showed that although it could signal through ALK1, it was not the 
dominant receptor. Transient over-expression also failed to mediate 
ALK1 dominance.  
 
 Although transient expression has not yet resulted in ALK1 being over-
expressed to a level that it is dominant, future work is needed to 
determine if it possible in SW1353 cells. 
  
 ALK5 is required for ALK1 to function. ALK5 dominance is tightly 
regulated; the ALK1/ALK5 ratio that favours ALK1 is most likely very 
specific.  
 
 The problems encountered in over-expressing ALK1 may be specific to 
SW1353 cells, suggesting future work may be more successful in a 
different cell type. 
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Chapter 7: Model predictions and theoretical interventions 
7.1 Introduction  
The construction of a computational model has the advantage that it can be 
used to make predictions. For example, Passos et al. (2010) expanded on a 
previously developed model of p53 dynamics (Proctor and Gray 2008) to show 
that a small proportion of cells could avoid cell cycle arrest. They then later 
confirmed this experimentally (Passos et al. 2010). Similarly Dolan et al. (2015) 
created an integrated model by combining two previous published models 
Passos et al. (2010) and Dolan et al. (2013). Using the combined model they 
predicted the effect of low dose irradiation on cellular senescence. When they 
tested the model predictions experimentally they found it matched the general 
pattern that was observed,  but some effects were smaller than predicted 
(Dolan et al. 2015).  This demonstrated that although model predictions may not 
always be 100% accurate they can lead to the discovery of novel behaviours 
that otherwise may have gone unnoticed. In this chapter I will use the model 
created in chapter 5 to make predictions that could be tested in future studies. It 
is important to note the simulations were run with an inactive form of TGFβ 
present to allow for the activation and deactivation of the growth factor, across 
the 20 month simulations. 
7.1.1 Theoretical therapeutic interventions  
Mathematical models can also provide a mechanism for testing potential 
interventions to limit disease progression. This allows you to test theoretical 
treatments that may yet not be possible and help to identify how worthwhile 
their development would be.  For example, Tian and Kreeger (2014) created a 
mass action model that they used to look at antibody treatment of the Insulin-
like growth factor 1 (IGF) pathway in ovarian cancer. It suggested that blocking 
IGF1–IGF1R binding would have a more pronounced effect on proliferation than 
neutralising IGF directly. Proctor and Gartland (2016) used a model to look at 
treatments that could reverse age-related bone loss. They demonstrated that 
not just the treatment but also the timing of its addition could have significant 
effects on its function, thus providing predictions for future studies.  
1D11 is an antibody that targets TGFβ, leading to its degradation. It has been 
demonstrated that injection of this antibody into the subchondral bone can 
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attenuate surgically induced OA progression in mice and rats (Gehua Zhen et 
al. 2013). A reduction was show in the number of MMP-13 positive cells and 
cartilage damage was reduced (Gehua Zhen et al. 2013). They claimed that 
TGFβ signalling had not been reduced in cartilage so  the intervention would not 
affect normal cartilage homeostasis (Gehua Zhen et al. 2013). However, 
incorporating this antibody into my model may allow me to examine how it 
would affect the increase in MMP-13 caused by a shift in the ALK1/ALK5 ratio 
with age.   
7.1.2 Alterations to the model  
The original model present by Wang Hui et al. (2014), from which the TGFβ 
portion of my model is based upon, partially focused on how the change in 
TGFβ type I receptors affected RUNX2 driven MMP-13 mRNA expression. The 
model was made so that SMAD1 could activate RUNX2 whilst SMAD2 was 
required to deactivate it, meaning RUNX2 was incapable of becoming inactive 
without TGFβ (or ALK5) present. In my model I was also only interested in how 
the interactions of TGFβ and RUNX2 change as the TGFβ type I receptors 
change, so I left this section unaltered. However, it is a simplification and 
RUNX2 can be inactivated by other mechanisms, independent of  TGFβ 
(Jonason et al. 2009). The inclusion of another mechanism for RUNX2 
deactivation is required to model the attenuation of TGFβ signalling.  
7.1.3 Chapter aims 
 Use the model to test theoretical therapeutic interventions which may 
help to reduce the negative changes associated with TGFβ in age e.g. 
increased MMP-13 mRNA or reduced protection against pro-
inflammatory stimuli.  
 
 Explore the model to examine the stochastic behaviours between IL-1, 
OSM and TGFβ. 
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7.2 Results 
7.2.1 Therapeutic interventions.  
As mentioned in the introduction, the original model assumption that RUNX2 
cannot be inactivated without TGFβ may be an issue when exploring 
therapeutic interventions. To address this I added a reaction that allowed 
RUNX2 to transition from an active to inactivate state without a stimulus, whilst 
still requiring active SMAD1 for activation. Figure 7.1 shows that this small 
change had little effect on the overall model predictions across 20 months.  
 
 
 
Figure 7.1 Effects of an additional RUNX2 inactivation reaction, on my 
complete model. Deterministic simulation results for my complete model, 
presented in chapter 5, showing the change in MMP-13 mRNA across 20 months 
simulation time. IL-1+OSM were triggered using events at ~4, ~9 and ~19 months. 
RUNX2+ represents an extra reaction added to the model, which allows RUNX2 to 
move from its active form to its inactive form without SMAD2 involvement. The 
simulations were run using COPASI.   
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7.2.1.1 Anti-TGFβ treatment  
In order to look at how the 1D11 antibody may interact with the system that I 
have created, I made a species “Anti-TGF”, which could bind to TGFβ and 
degrade it in both its inactive and active forms (see appendix 7.1). The model 
also included degradation of anti-TGF so that it would gradually decay and 
leave the system. Leaving the system took Anti-TGF ~34 hours, the same 
length of time it was reported as taking to leave murine models by Xie et al. 
(2016) (see appendix 7.2 and 7.3). I wanted to look at how addition of Anti-TGF 
affected TGFβ signalling across 20 months and how these changes may affect 
the interaction between TGFβ and pro-inflammatory stimuli. The simulations 
began without Anti-TGF but it was introduced at ~6 months as an event. ~6 
months was chosen as the time point as ALK1 becomes the dominant receptor 
after ~8 months. Therefore, I wanted to treat with Anti-TGF when ALK5 was 
beginning to lose dominance but when MMP-13 mRNA levels had not started to 
increase. I found that when Anti-TGF was first introduced at ~6 months the 
effects varied depending on how many subsequent times the antibody was 
added (Fig 7.2A). Focusing on the baseline expression of MMP-13 mRNA, 
rather than the 3 pro-inflammatory events (IL-1+OSM) at ~4, 9 and 19 months, 
a single introduction of Anti-TGF (at ~6 months) moved TGFβ signalling towards 
an ALK1 response. This led to an initial increase in MMP-13 mRNA that 
continued until 20 months (Fig 7.2A). A second addition ~ 24 days later, also 
resulted in an initial increase in MMP-13 mRNA but this reached a plateau and 
decreased gradually towards 20 months (Fig 7.2A). A third simulated 
intervention, after another ~24 days was required to completely nullify the 
upregulation of MMP-13 mRNA across the entire 20 months (Fig 7.2A).  
Looking at the model output suggests this is because removing some, but not 
all, of the TGFβ in the system drives it to signal through the receptor it has the 
highest affinity for, namely ALK1. So although both SMAD1 and SMAD2 have 
reduced phosphorylation, SMAD1 is not reduced by the same magnitude and 
this leads to activation of RUNX2.  
Addition of Anti-TGF led to an increase of MMP-13 mRNA at both the ~9 and 19 
month pro-inflammatory events, compared to IL-1+OSM+TGFβ (Fig 7.2B and 
C). Also only when Anti-TGF was added to the system at three intervals ~24 
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days apart (starting at ~6 months), did the treatments not lead to larger 
increases of MMP-13 mRNA then IL-1+OSM alone, at both ~9 and 19 months 
(Fig 7.2B and C). Figure 7.3 shows three treatments with different time intervals 
(~1 days, ~6 days, ~12 days, or ~24 days) between the first, second and third 
Anti-TGF addition. The simulations suggested that treatments were more 
effective with longer intervals between Anti-TGF additions (Fig 7.3).  
In both Figure 7.2 and 7.3 the ~6 month Anti-TGF treatment meant that the pro-
inflammatory events (IL-1+OSM) at ~9 and ~19 months had a more pronounced 
effect than they would have without treatment. Therefore, I examined whether 
the treatment could still be effective later in the simulation, when ALK1 had 
become the dominant receptor. Treating with Anti-TGF at ~15 months, again 
focusing on baseline MMP-13 mRNA rather than the 3 pro-inflammatory events 
at ~4, 9 and 19 months, suggested a single induction of Anti-TGF led to a 
significant increase in MMP-13 mRNA (Fig 7.4A). The result is MMP-13 mRNA 
reaching higher levels than it would without treatment. A second and third 
induction of Anti-TGF, with a gap of ~24 days between each addition, was 
sufficient to alleviate the effect on MMP-13 mRNA, with the three treatments 
having a marginally stronger effect (Fig 7.4A).   
After two or three Anti-TGF treatments (at ~15 months) the pro-inflammatory 
event at ~19 month had approximately the same effect as IL-1+OSM alone (no 
TGFβ in the simulation), but had a more pronounced effect with only one Anti-
TGF treatment (Fig 7.4B). The delay in the Anti-TGF treatments has a different 
effect at this later time point than the earlier one. Every ~day is still the least 
effective resulting in an increase in MMP-13 mRNA and a stronger pro-
inflammatory response at ~19 months, than the other delays (Fig 7.5). However 
the ~6 days and ~12 days delays are both sufficient to mediate a constant 
reduction in MMP-13 mRNA (Fig 7.5). Leaving the delay to ~24 day reduces 
MMP-13 mRNA eventually but there is slight peak at ~16 months where MMP-
13 mRNA increases (Fig 7.5). This increase is only minor but suggests the 
smaller delays are better when giving the treatment at a later time point.  
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Figure 7.2 The effects of Anti-TGF treatment, starting at 6 months, on MMP-13 
mRNA expression. A) Deterministic simulation results for my complete model, 
presented in chapter 5, with an extra reaction to allow RUNX2 inactivation. The data 
show the change in MMP-13 mRNA across a 20 months simulation time.  IL-1+OSM 
were triggered using events at ~4, ~9 and ~19 months. The model also contained the 
species “Anti-TGF” which targeted and degraded both active and inactive TGFβ. Anti-
TGF concentration was at zero when the simulation started but at ~6 months Anti-TGF 
was added to the system, using an event. Anti-TGF was added either once, twice or 
thrice with a ~24 days interval between each addition. B, C) Highlights the time 
marginally before, during and after the change in MMP-13 mRNA expression following 
the IL-1+OSM events (B=~9 months and C=~19 months).  
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Figure 7.3 The effect of time delays on Anti-TGF treatment, starting at 6 months. 
A) Deterministic simulation results for my complete model, presented in chapter 5, with 
an extra reaction to allow RUNX2 inactivation. The data show the change in MMP-13 
mRNA across a 20 months simulation time.  IL-1+OSM were triggered using events at 
~4, ~9 and ~19 months. The model also contained the species “Anti-TGF” which 
targeted and degraded both active and inactive TGFβ. Anti-TGF concentration was at 
zero when the simulation started but at ~6 months Anti-TGF was added to the system, 
using an event. Anti-TGF was added three times to the model with a ~24 days, ~12 
days, ~6 days or ~1 day interval between each addition. B, C) Highlight the time 
marginally before, during and after the change in MMP-13 mRNA expression following 
the IL-1+OSM events (B=~9 months and C=~19 months). 
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Figure 7.4 The effects of Anti-TGF treatment, at 15 months, on MMP-13 mRNA 
expression. A) Deterministic simulation results for my complete model, presented in 
chapter 5, with an extra reaction to allow RUNX2 inactivation. The data show the 
change in MMP-13 mRNA across a 20 months simulation time.  IL-1+OSM were 
triggered using events at ~4, ~9 and ~19 months. The model also contained the 
species “Anti-TGF” which targeted and degraded both active and inactive TGFβ. Anti-
TGF concentration was at zero when the simulation started but at ~15 months Anti-
TGF was added to the system, using an event. Anti-TGF was added either once, twice 
or thrice with a ~24 days interval between each addition. B) Highlights the time 
marginally before, during and after the change in MMP-13 mRNA expression following 
the IL-1+OSM event at ~19 month. 
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Figure 7.5 The effect of time delays on Anti-TGF treatment, starting at 15 
months. A) Deterministic simulation results for my complete model, presented in 
chapter 5, with an extra reaction to allow RUNX2 inactivation. The data show the 
change in MMP-13 mRNA across a 20 months simulation time.  IL-1+OSM were 
triggered using events at ~4, ~9 and ~19 months. The model also contained the 
species “Anti-TGF” which targeted and degraded both active and inactive TGFβ. Anti-
TGF concentration was at zero when the simulation started but at ~15 months Anti-
TGF was added to the system, using an event. Anti-TGF was added three times to the 
model with a 24 days, ~12 days, ~6 days or ~1 day interval between each addition. B) 
Highlight the time marginally before, during and after the change in MMP-13 mRNA 
expression following the IL-1+OSM event at ~19 month. 
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7.2.1.2 Anti-ALK1 treatment  
Although I am unaware of an antibody that targets ALK1, I used the model to 
test how targeting ALK1 would affect the system. To simulate this I made ALK1 
the target of Anti-TGF, and changed the species name to “Anti-ALK1”. I treated 
with Anti-ALK1 at two different time points to see how they compared, ~6 and 
~15 months (Fig 7.6). The model showed that multiple treatments of Anti-ALK1 
did not affect the results, regardless of the time delay between treatments (data 
not shown). Therefore, I only gave one treatment in the future experiments. The 
~6 month treatment with Anti-ALK1 reduced basal expression of MMP-13 
mRNA throughout the simulation, but in the later time points there was still a 
steady increase. It also marginally increased the repression of the pro-
inflammatory stimuli by TGFβ at ~19 months (Fig 7.6). On the other hand, the 
late (~15 month) Anti-ALK1 treatment resulted in a larger reduction of MMP-13 
mRNA after 15 months, whilst also increasing the repression seen by TGFβ on 
the pro-inflammatory stimulus at ~19 months (Fig 7.6). It is worth noting that 
addition of Anti-ALK1 at both ~6 and ~15 months had no further effects.  
Although MMP-13 mRNA was marginally lower when the second treatment was 
added, it then followed the same pattern as a single treatment at ~15 months 
(data not shown).  
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Figure 7.6 The effects of Anti-ALK1 treatment, at 6 or 15 months, on MMP-13 
mRNA expression. A) Deterministic simulation results for my complete model, 
presented in chapter 5, with an extra reaction to allow RUNX2 inactivation. The 
data show the change in MMP-13 mRNA across a 20 months simulation time.  IL-
1+OSM were triggered using events at ~4, ~9 and ~19 months. The model also 
contained the species “Anti-ALK1” which targeted the ALK1 receptor for 
degredation. Anti-ALK1 concentration was at zero when the simulation started but 
at either ~6 months (early) or ~15 months (late) Anti-ALK1 was added to the 
system, using an event. B, C) Highlighted the time marginally before, during and 
after the change in MMP-13 mRNA expression following the IL-1+OSM events 
(B=~9 months and C=~19 months). 
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7.2.1.3 Pro-ALK5 treatment  
Simulating the effects of removing ALK5 with an antibody in the same way as 
ALK1, exacerbated the negative effects of TGFβ, resulting in increased MMP-
13 mRNA both at basal and during pro-inflammatory stimuli (data not shown). 
However, overexpression of ALK5 had positive effects (Fig 7.7). Currently I am 
unaware of any treatments that would allow overexpression of ALK5 in patients. 
In the model I created an event that increased the levels of ALK5 in the system. 
I found that if this increased expression was early in the model it reduced the 
level of MMP-13 mRNA at the later time points. There was also an increase in 
TGFβ-mediated repression of the pro-inflammatory stimuli at both ~9 and ~19 
months (Fig 7.7). Increasing ALK5 levels at the later time point (~15 months) led 
to a marginally greater reduction in MMP-13 mRNA at >15 months,  when 
compared to the early treatment. It also restored the TGFβ-mediated repression 
of the pro-inflammatory stimulus at ~19 months to a level comparable with ~9 
months (Fig 7.7). When both treatments were added their effects were 
combined resulting in MMP-13 mRNA levels never increasing and TGFβ-
mediated repression of the pro-inflammatory stimulus remaining relatively 
constant through the simulation (Fig 7.8).  
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Figure 7.7 The effects of ALK5 addition, at 6 or 15 months, on MMP-13 mRNA 
expression. A) Deterministic simulation results for my complete model, presented in 
chapter 5, with an extra reaction to allow RUNX2 inactivation. The data show the 
change in MMP-13 mRNA across a 20 months simulation time.  IL-1+OSM were 
triggered using events at ~4, ~9 and ~19 months. ALK5 level was restored to the its 
initial level of 500 particle number, using an event, at either ~6 months (early) or ~15 
months (late). B, C) Highlighted the time marginally before, during and after the change 
in MMP-13 mRNA expression following the IL-1+OSM events (B=~9 months and C=~19 
months). 
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7.2.1.4 Altering SMAD levels  
SMAD4 is required for SMAD1 and SMAD2 to have their downstream effect. So 
I looked at how altering the expression in the model, via an event, would effect 
TGFβ signalling. Either increasing or decreasing SMAD4 levels had only minor 
effects at the early time points, unless it was completely removed which 
stopped signalling completely (data not shown).  At a later time point, ~15 
months increasing SMAD4 led to a reduction of MMP-13 mRNA, whilst 
decreasing SMAD4 led to a more potent increase in MMP-13 mRNA (Fig 7.9). 
This suggests that SMAD4 levels are important for propagating SMAD2 
signalling when ALK1 starts to become dominant, with a loss in SMAD4 still 
allowing SMAD1 signalling but preventing SMAD2 from opposing its effects. I 
also altered the levels of SMAD7 in the same way as SMAD4 but seen only 
minor changes in behaviour (data not shown).  
Figure 7.8 The effects of ALK5 addition, at 6 and 15 months, on MMP-13 mRNA 
expression. A) Deterministic simulation results for my complete model, presented in 
chapter 5, with an extra reaction to allow RUNX2 inactivation. The data show the 
change in MMP-13 mRNA across a 20 months simulation time.  IL-1+OSM were 
triggered using events at ~4, ~9 and ~19 months. ALK5 level was restored to the its 
initial level of 500 particle number, using events, at ~6 months (early intervention) and 
~15 months (late intervention).  
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Figure 7.9 The effects of altered SMAD4 expression, at 15 months, on MMP-
13 mRNA expression. A) Deterministic simulation results for my complete 
model, presented in chapter 5, with an extra reaction to allow RUNX2 
inactivation. The data show the change in MMP-13 mRNA across a 20 months 
simulation time.  IL-1+OSM were triggered using events at ~4, ~9 and ~19 
months. SMAD4 concentration was either increased to 1000 particle number or 
deacreased to 400 particle number at ~15 months. B, C) Highlight the time 
marginally before, during and after the change in MMP-13 mRNA expression 
following the IL-1+OSM events (B=~9 months and C=~19 months). 
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7.2.2 TGFβ reduces the impact of an inflammatory response whilst 
increasing stability. 
The stochastic nature of inflammatory responses means that the effects can 
have a large variability. So in addition to examining the effects of interventions 
on MMP-13 mRNA expression, I decided to inspect the effect of stochasticity on 
the TGFβ-mediated repression of IL-1+OSM. Stochastic simulation provides 
information not just on just the pattern of expression but also how variable that 
response is. The amount of MMP-13 mRNA that was generated during IL-
1+OSM stimulation was very variable in the model (Fig 7.10) and when TGFβ 
was added to this system the first 12 hours of simulation had a similar level of 
variability. However, post 12 hours there was a reduction in not only the average 
level of MMP-13 mRNA but also the variability (Fig 7.10A). When the system 
was stimulated with IL-1+OSM treatment, after 6 hours pre-treatment with 
TGFβ, this reduced variability was even more pronounced (Fig 7.10B).   
 
 
 
 
Figure 7.10 Average behaviour of 100 stochastic model runs showing inherent variation in the system. Stochastic simulation results showing the 
average behaviour ± the standard deviations of 100 stochastic runs of the complete (presented in chapter 5) A) Model run over a simulation time of 48 
hours. The model was run with IL-1+OSM±TGFβ B) Model run over a simulation time of 54 hours. An event triggers IL-1 and OSM stimulation 6 hours after 
TGFβ pre-treatment.  An active form of TGFβ was used in all simulations.  Curves show how the particle numbers of MMP-13 mRNA change over the 
simulation. The coloured shading shows the variation at each time point. Simulations were run using COPASI. 
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7.3 Discussion. 
It is important to note that the model I have created only looks at the changing role of 
TGFβ with age, in the context of inflammatory damage. So any predictions made do 
not encompass the effect interventions would have on other key TGFβ-mediated 
processes; for example how Anti-TGF would affect normal cartilage homeostasis. 
Despite this, the interventions I have looked at have shown some exciting behaviours 
and they may provide direction for future studies.  
7.3.1 Incomplete removal of TGFβ favours ALK1 signalling. 
The model is unable to regenerate TGFβ, if it is removed from the system (justified in 
chapter 2). Physiologically this is not accurate as in vivo latent TGFβ is continually 
released (Pedrozo et al. 1998). However, the model does suggest that when targeting 
TGFβ in cartilage it is important to completely remove TGFβ from the system, as at 
lower levels it will signal through ALK1. The model suggests that under normal 
conditions there is an abundance of TGFβ molecules over type I receptors and as there 
is significantly more ALK5, it becomes the dominant receptor. ALK1 is the preferential 
binding partner of TGFβ (van der Kraan et al. 2012) so when TGFβ is in low 
abundance it tries to signal predominantly through that receptor. As there is now more 
receptors than TGFβ molecules this results in ALK5 signalling being affected more by 
the reduction in TGFβ. If correct, this prediction could have implication in TGFβ 
targeting therapies as attempting to remove TGFβ to elevate joint damage may result 
in increased damaged.  
7.3.2 Similarities between all theoretic interventions. 
Unsurprisingly targeting ALK1 for degradation or overexpressing ALK5 had positive 
effects, with either treatment reducing baseline MMP-13 mRNA expression and 
restoring the protective effect of TGFβ on IL-1+OSM-driven MMP-13 mRNA 
expression. However, what was evident is that the time at which the interference took 
place was important in the effect. Finding the most effective time to target TGFβ may 
be key in developing therapeutics that will help it regain the protective functions that it 
has in younger animals. It appears that therapeutics will be most effective if they can 
be prescribed just as the ALK1 receptor is starting to become dominant. The model 
also suggested that attempting to overexpress ALK5 will be a more promising 
treatment than targeting ALK1. This is based on the effects of overexpressing ALK5 
being more prolonged and combining treatments could theoretically reverse all effects 
on MMP-13 mRNA. Interestingly although targeting ALK1, ALK5 or TGFβ directly had 
strong effects, targeting SMAD4 had comparatively minor effects and targeting SMAD7 
had negligible effects to the system.   
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The model also predicted that targeting TGFβ itself will require more than one 
treatment. The reason for this in the model is that TGFβ is bound to receptors so 
cannot be targeted for degradation, when the receptors are recycled it is released and 
can then bind to new receptors. What was evident is that the intervals between Anti-
TGF treatments had to be significant to see any effect. Therefore, a larger dose may 
not be sufficient to mediate the optimum effects.  
7.3.3 Stabilising the inflammatory response.  
Stochastic simulations predicted that TGFβ adds stability to a pro-inflammatory 
response. Throughout this thesis I have looked at the negative effects of inflammation 
in OA development. However, when functioning correctly inflammation is an important 
biological response that helps to eliminate causes of cell injury, degrade necrotic cells 
and the damaged parts of tissues, as well as initiating repair (Rock and Kono 2008). 
Therefore inflammatory responses are normally beneficial but they can become chronic 
and lead to damage, and as a result must be tightly regulated (Martel-Pelletier et al. 
2008).  
 
In cartilage MMP-13 is upregulated in response to inflammation and has important 
roles in maintaining healthy cartilage, as well as degrading damaged cartilage 
components to allow repair and maintenance to the system (Masaki Inada et al. 2004). 
It is when this becomes dysregulated that we start to see disease. The variability of the 
IL-1+OSM response can lead to damage, with high levels of MMP-13 leading to 
degradation of cartilage that could cause early onset of cartilage damage (Goldring and 
Otero 2011). Conversely, not enough upregulation of MMP-13 could result in the body 
not being able to properly turn over tissues. Therefore, a uniform response is a key way 
of controlling damage during an inflammatory response and TGFβ may add the stability 
that allows the body to regulate this response. A loss of this with age could also 
contribute to an incoherent system and OA development.  
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7.3.4 Summary  
 
 Targeting TGFβ for degradation protected against an increase in baseline 
MMP-13 mRNA with age but removed any protective effect against pro-
inflammatory stimuli.  
 
 Targeting ALK1 for degradation or increasing ALK5 concentration protected 
against MMP-13 mRNA with age and restored the protective effect against pro-
inflammatory stimuli.  
 
 SMAD4 had only minor effects on MMP-13 mRNA expression and SMAD7 had 
no effects.  
 
 At what time interval  interventions were added to the system, as well as their 
quantity was important for their effects. Anti-TGF, was also effected by the time  
delay between each intervention. 
 
 TGFβ provides stability to a pro-inflammatory response, reducing variability to 
make the increase in MMP-13 mRNA more uniform.  
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7.4 Future work 
Designing experiments to validate the prediction that TGFβ provides stability to pro-
inflammatory stimuli  could allow me to explore how a change in that effect may occur 
with age. I would also like to expand the model, in order to make more accurate 
predictions, by including TGFβ turnover into the model. This would also allow me to 
factor in daily loading, which has been suggested to increase TGFβ signalling (Gehua 
Zhen and Xu Cao 2014). Both of these changes may provide a more accurate 
prediction of how TGFβ attenuation would affect the system. It would also be 
interesting to include other roles of TGFβ in cartilage homeostasis: for example 
terminal differentiation of chondrocytes. Then I would explore how process such as this 
could be affected by therapeutic intervention.  
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Chapter 8. Bioinformatic analysis provides insight into OA as a whole. 
8.1 Introduction  
Large scale bioinformatic studies have been used to better understand disease 
progression by identifying the common events that lead to a diseased 
phenotype. In cancer studies, collecting and analysing data sets from multiple 
sources has resulted in common transcriptional profiles being identified (Daniel 
R. Rhodes et al. 2004).  In chapter 3 I first introduced a cytoscape network that 
was representative of human OA. This highlighted the role of inflammation in 
human OA and led to me focus my attention on two cytokine pathways (IL-1 
and OSM) and their interaction with the TGFβ signalling pathway. However, we 
know that there are multiple pathways involved in the initiation and progression 
of OA and that there will be considerable crosstalk between them.  Therefore I 
used bioinformatics tools to explore the OA network to identify processes that 
may drive OA, and more specifically the genes involved in these process. The 
network also allowed me to give my model context in a global environment. 
PhenomeScape is a cytoscape plugin that can identify sub-networks from a 
main network, whilst also providing functional processes of these sub-networks. 
The programme also identifies which genes are up- and down-regulated in 
these sub-networks, and can link individual genes to specific phenotypes (Soul 
et al. 2016). To identify these sub-networks a separate gene list relative to your 
disease of interest must be overlaid. For this I used publically available 
microarray data specifically for human knee OA (S. L. Dunn et al. 2016). This 
data is available at ArrayExpress with the identifier E-MTAB-4304.  
By overlaying the genes from my model to the network I aimed to demonstrate 
how dysregulation of the IL-1+OSM+TGFβ pathways can lead to changes in 
genes important in other pathways. In addition, the analysis will reveal how 
components of my model interact with other genes and pathways. This 
information could be used to suggest future extensions to the model 
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8.1.1 Chapter aims  
 Use a cytoscape network representation of human OA to explore sub-
networks to locate genes important in OA development. Identify specific 
phenotypes linked to these genes that may be responsible for disease 
progression.  
 
 Explore the network around my model genes to identify how my model 
network interacts with other genes and pathways. Use these to show 
how the model genes fit into OA development as a whole.  
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8.2 Results  
PhenomeScape has a built in network for human genes that allows you to run 
your data against known gene interactions. However, as I had already created a 
network specific for OA I used it as the major network (Fig 8.1). This network is 
the same as that presented in chapter 3, but prior to gene clustering. I then ran 
the knee specific OA data, from S. L. Dunn et al. (2016),  over my created 
network.  
8.2.1 Knee osteoarthritis sub-networks  
The desired phenotypes have to be specified before PhenomeScape can be 
run; I selected any that related to “cartilage”, “osteoarthritis”, “cytokines”, 
“inflammation”, “signaling” and “chondrocyte”. PhenomeScape was then run 
overlaying the knee OA data (S. L. Dunn et al. 2016). This determined 10 sub-
networks shown combined in Figure 8.2, and individually in Figures 8.3-8.12. 
Table 8.1 shows all of the phenotypes that were connected to genes, as well as 
their identifiers. The sub-networks represent ten processes:  
 Cell adhesion  
 Cellular response to insulin  
 Cell surface receptor signalling pathway 
 Membrane invagination 
 Negative regulation of neural precursor cell proliferation 
 Negative regulation of neuron apoptotic process 
 Response to organic cyclic compound 
 Extracellular matrix organisation 
 Positive regulation of angiogenesis  
 Osteoclast differentiation  
The programme suggests all of these processes are altered in my complete OA 
network and the knee OA data. The network also shows the gene changes that 
justified these predictions, with downregulated genes shown in green and the 
upregulated in red. Many of the phenotypes link the different sub-networks 
genes: for example Hif-1A linked to Plasminogen Activator Urokinase Receptor 
(PLAUR) via “abnormal cytokine level” (Fig 8.2). 
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Figure 8.1 Complete gene 
network, representative of 
human OA. Affymetrix 
microarray data from 50 knee 
OA patients were collected 
from the GEO database, 
normalised, and the genes 
combined. ARACNE then 
inferred the interactions 
between these genes 
providing mutual information 
(MI) values. These gene 
interactions formed a network 
that could be visualised using 
Cytoscape. The nodes (blue 
dots) represent differentially 
expressed genes and the 
edges are connections based 
on MI values. The specific MI 
values can only be viewed in 
cytoscape.  
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Identifier Phenotype 
HP:0002758 Osteoarthritis 
HP:0002815 Abnormality of the knees 
HP:0003088 Premature osteoarthritis 
HP:0100593 Calcification of cartilage 
MP:0000164 abnormal cartilage development 
MP:0000165 abnormal long bone hypertrophic chondrocyte zone 
MP:0000167 decreased chondrocyte number 
MP:0000166 abnormal chondrocyte morphology 
MP:0003120 abnormal tracheal cartilage morphology 
MP:0003408 increased width of hypertrophic chondrocyte zone 
MP:0006433 abnormal articular cartilage morphology 
MP:0008713 abnormal cytokine level 
ZP:0000057 abnormal(ly) decreased size Meckel's cartilage 
ZP:0000064 abnormal(ly) decreased size ceratohyal cartilage 
ZP:0000066 abnormal(ly) absent ceratobranchial cartilage 
ZP:0000126 abnormal(ly) malformed Meckel's cartilage 
ZP:0000269 abnormal(ly) morphology Meckel's cartilage 
ZP:0000906 abnormal(ly) aplastic Meckel's cartilage 
ZP:0000921 abnormal(ly) morphology ceratohyal cartilage 
ZP:0000925 abnormal(ly) aplastic ceratohyal cartilage 
ZP:0001067 abnormal(ly) aplastic ceratobranchial cartilage 
ZP:0001977 abnormal(ly) hypoplastic ceratohyal cartilage 
ZP:0001979 abnormal(ly) split ethmoid cartilage 
ZP:0002100 abnormal(ly) morphology cranial cartilage 
ZP:0003107 abnormal(ly) malformed palatoquadrate cartilage 
ZP:0004231 abnormal(ly) hypoplastic cranial cartilage 
ZP:0004534 abnormal(ly) morphology pectoral fin cartilage 
ZP:0008344 abnormal(ly) decreased process quality collagen fibril 
organization 
ZP:0008484 abnormal(ly) absent ethmoid cartilage 
ZP:0009520 abnormal(ly) premature chondrocyte hypertrophy 
ZP:0009549 abnormal(ly) increased width ceratobranchial cartilage 
Table 8.1 Table of PhenomeScape phenotypes, with identifying 
numbers. PhenomeScape matches gene expression with associated 
phenotypes. This table shows the phenotypes relevant for my data, 
along with their identifiers. HP refers to Human Phenotype Ontology; 
MP refers to Mammalian Phenotype Ontology; ZP refers to zebrafish 
phenotypes. Inclusion of zebrafish and mammalian phenotypes was 
justified in chapter 2.2.7 
 
 
Figure 8.2 Knee OA specific sub-
networks identified with 
PhenomeScape. Phenotypes were 
selected in PhenomeScape that are 
relevant for Osteoarthritis. These 
phenotypes are then linked to the 
input data (knee samples from (S. L. 
Dunn et al. 2016)) to determine 
phenotype-gene associations. After 
which both the expression data and 
the phenotypes are used to calculate 
activity scores with the proteins in the 
original network I compared them to 
(Fig 8.1). The high scoring groups 
are identified as sub-networks. These 
Sub-networks have been combined 
showing how they interact with each 
other. Green represents 
downregulated genes, whilst red 
shows upregulated, compared to the 
control. Table 8.1 shows all of the 
phenotype identifiers present in this 
Figure.  
 
 
 
228 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 PhenomeScape sub-network; Cell adhesion. Individual sub-
network, from Figure 8.2.  
Figure 8.4 PhenomeScape sub-network; Cellular response to insulin. 
Individual sub-network, from Figure 8.2.  
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Figure 8.5 PhenomeScape sub-network; Cell surface receptor signalling 
pathway. Individual sub-network, from Figure 8.2.  
Figure 8.6 PhenomeScape sub-network; Membrane invagination. Individual 
sub-network, from Figure 8.2.  
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Figure 8.8 PhenomeScape sub-network; Negative regulation of neuron 
apoptotic process. Individual sub-network, from Figure 8.2.  
 
Figure 8.7 PhenomeScape sub-network; Negative regulation of neural 
precursor cell proliferation. Individual sub-network, from Figure 8.2.  
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Figure 8.9 PhenomeScape sub-network; Response to organic cyclic 
compound. Individual sub-network, from Figure 8.2.  
Figure 8.10 PhenomeScape sub-network; Extracellular matrix organisation. 
Individual sub-network, from Figure 8.2.  
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Figure 8.11 PhenomeScape sub-network; Positive regulation of 
angiogenesis. Individual sub-network, from Figure 8.2.  
Figure 8.12  PhenomeScape sub-network; Osteoclast differentiation. 
Individual sub-network, from Figure 8.2.  
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8.2.2 Bioinformatic analysis highlights the importance of inflammation in 
OA. 
As previously mentioned in chapter 3, the OA network (Fig 8.1) was clustered to 
better represent interacting genes. I made a list of all the genes present in my 
model (presented in chapter 5), and then overlaid these genes to the clustered 
network. This provided insight into how the model fits in with other processes 
that are important in OA development. For example both SMAD1 and TGFBR1 
were located in the “inflammatory response in plasma membrane” cluster 
(shown in chapter 3, Figure 3.1). Figure 8.13 shows all the model genes that 
were linked to genes in the network, as well as the genes that directly interact 
with them. Both TGFBR1 and SMAD1 were located in the large cluster 
“Inflammatory response in plasma membrane” highlighting the importance of 
TGFβ in OA associated inflammation. Furthermore, both c-Fos (FOS) and JunB 
(JUNB) also had links to genes in the network.  
Figure 8.13 Overlaying model genes to the complete OA network. 
Overlaying the genes for my model to a clustered version of the network 
presented in Figure 8.1 highlighted the genes that were present. 4 genes were 
shown to be present (red) SMAD 1, ALK5 (TGFBR1), c-Fos (FOS) and JunB 
(JUNB). These were extracted along with all the genes that directly interacted 
with them (black), to create these sub-networks.  
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8.3 Discussion 
Using PhenomeScape I found 10 knee OA specific sub-networks. Analysing 
these sub-networks provided some insight into the processes and genes 
important in the development of knee OA. The “Positive regulation of 
angiogenesis” and “Extracellular matrix organisation” subnetworks suggest 
increased blood flow and tissue remodelling, which could suggest growth of the 
tissues. Angiogenesis has also been shown to contribute to structural damage 
and pain in OA (Andia and Maffulli 2013). It does this by facilitating both 
endochondral ossification and the recruitment of inflammatory mediators (Suri 
and Walsh 2012; Gravallese et al. 2003).  
The “Negative regulation of neural precursor cell proliferation” sub-network 
suggests that there is not tissue growth, as precursor cells are important for this 
process (Kim et al. 2010). This is in contrast to the two networks mentioned 
previously and highlights how systems can become dysregulated in OA. 
Precursor cells are also important in cartilage repair, so negative regulation 
could contribute to OA development (Hiraki et al. 2001). However, this process 
refers specifically to neural precursor cells, which to my knowledge have not 
been linked to OA.  
The “Cellular response to insulin” sub-network is interesting as diabetes has 
recently been linked to an increased risk of OA development (Louati et al. 
2015).  Exploring the genes in this sub-network may help provide a functional 
understanding of how altered insulin signalling can lead to OA development. 
Further to this, one gene in particular Aldehyde Dehydrogenase 1 Family 
Member L1 (ALDH1L1) was linked to three abnormal cartilage phenotypes. This 
suggests ALDH1L1 may be changing cartilage morphology when insulin 
signalling is altered. ALDH1L1 was also shown to be upregulated in a porcine 
cartilage model of OA (Schlichting et al. 2014). Understanding how ALDH1L1 is 
leading to altered cartilage, as well as how the other genes in the sub-network 
are affecting OA development, may help us understand the role of diabetes.  
 
 
 
235 
 
 
8.3.1 Individual genes identified from PhenomeScape.  
Many of the individual genes highlighted by the PhenomeScape analysis 
coincide with current literature surrounding OA. For example Hif-1A 
downregulation is linked to four phenotypes, three of which are related to 
altered cartilage and chondrocyte morphology. This is unsurprising given the 
role Hif-1A plays in cartilage homeostasis (as mentioned in detail in chapter 1). 
Future studies into the genes in the sub-networks may help identify changes 
that can lead to OA progression. The following genes have been chosen as 
examples of interesting genes that would benefit from further study.  
8.3.1.1 PAPSS2  
3'-Phosphoadenosine 5'-Phosphosulfate Synthase 2 (PAPSS2) is found in the 
“Cell surface receptor signalling pathway” sub-network and provides a 
phenotype link between four other sub-networks. This suggests it may have a 
role in the development of phenotypes, which could also be driven by other 
genes. This either means that all the genes linked to that phenotype need to be 
dysregulated for it to develop, or that the phenotype can develop because of a 
change in any of the linked genes.  PAPSS2 expression is crucial for proper 
sulfation of cartilage matrix (Ramaswamy et al. 2012), with mutations in 
PAPSS2 leading to a susceptibility to OA (Ikeda et al. 2001). PAPSS2 
upregulation is normally beneficial for cartilage (Ramaswamy et al. 2012), so its 
increased expression linking to abnormal chondrocyte morphology and cartilage 
development is surprising. Further work would be needed to determine if it had 
an altered role in OA tissue or if its upregulation is an attempt to prevent 
cartilage degradation.  
PAPSS2 is upregulated by SOX9 and SMAD3 in cartilage (Chavez et al. 2017). 
Therefore, its upregulation in the network may suggest that TGFβ is still 
signalling through SMAD3, or SOX9 is being stabilised in another way. The 
Transforming Growth Factor Beta Induce (TGFβI) gene is linked to PAPSS2 
and is upregulated by non-canonical TGFβ signalling (Lin et al. 2010). As 
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TGFβI is also upregulated, this further suggests TGFβ signalling is affecting 
genes in the “Cell surface signalling receptor” sub-network.  
8.3.1.2 SPARC 
The Secreted Protein Acidic and Cysteine Rich (SPARC) gene is linked to eight 
phenotypes all of which are related to abnormal cartilage; this indicates that it 
may be important in the development of OA. In these samples SPARC is 
downregulated (Nakamura et al. 1996), but is upregulated by TGFβ in cartilage. 
SPARC is also linked to BMP1 which can activate TGFβ (Ge and Greenspan 
2006). However, BMP1 can also activate BMP 2/4 (Ge and Greenspan 2006; 
Vadon-Le Goff et al. 2015), which are associated with SMAD 1/3/5 signalling 
(Wu et al. 2016). Therefore I hypothesise that these changes may be a result of 
TGFβ signalling changing from signalling primarily through ALK5, to signalling 
through ALK1. Changes in signalling may then result in the increased BMP1 
and decreased SPARC expression (as seen in this data). This change could 
then contribute to the abnormal cartilage development in OA. An important 
caveat is that SPARC has been previously shown to be upregulated in both 
porcine and human OA samples (Sieker et al. 2017; Nakamura et al. 1996).  
8.3.1.3 XYLT1 
The cartilage repair process requires the synthesis of proteoglycan. 
Xylosyltransferase 1 (XYLT1) is a key enzyme that transfers the first sugar 
residue to the proteoglycan core protein, initiating GAG synthesis (McCoy et al. 
2012). XYLT1 expression is decreased in the samples and this is linked to  
phenotypes which relate to abnormal cartilage and chondrocytes. This may 
suggest it is no longer initiating GAG synthesis, which in turn results in the 
abnormal cartilage. Alternatively, abnormal chondrocytes could be causing this 
change in XYLT1 expression. Pothacharoen et al. (2014) suggested using 
sesamin to increase anabolic factors to treat OA, as they showed it had 
anabolic effects on aggrecan production, in primary cultures. They looked at 
XYLT1 expression due to its potent cartilage repair potential and showed it was 
upregulated by sesamin (Pothacharoen et al. 2014).  Despite this, high levels of 
XYLT1 provided a marker of OA severity in a murine model of posttraumatic 
osteoarthritis (McCoy et al. 2012). This suggests that overexpression may also 
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be detrimental to joint health, so research is needed to determine the optimum 
expression of XYLT1. Finally, XYLT1 was in the “Positive regulation of 
angiogenesis” sub-network but no literature currently links XYLT1, angiogenesis 
and OA. Exploring possible links may help explain why XYLT1 can also have a 
negative role in OA development.  
8.3.1.4 FAM134B 
The Reticulophagy Regulator 1 (FAM134B) gene encodes a cis-Golgi 
transmembrane protein, and is linked to the “Knee abnormalities” phenotype. 
However, there is no literature (that I am aware of) which links FAM134B to OA 
progression or development. Exploring if upregulation of FAM134B leads to 
knee abnormalities, or if it is a side effect of knee abnormalities, could 
potentially identify a novel mechanism of OA progression. 
8.3.1.5 Conclusions  
Analysing the sub-networks identified by PhenomeScape identified a number of 
genes for future study. The genes and sub-networks I have discussed are just a 
sub-section, and further analyses into the other genes would also undoubtedly 
find interesting connections to OA. However, this type of study shows both the 
advantages and disadvantages of looking at such a large dataset. I have now 
identified a number of genes for which further study would be interesting, but 
there are no established rules for identifying which would be the most sensible 
to peruse first.  
Some of the genes identified also have interactions with TGFβ, again 
highlighting its important role in OA progression. Further research into some of 
these genes may identify potential pathways that could be incorporated into my 
model. 
8.3.2 Examining the context of my model in a global environment.  
Overlaying my model genes to the complete OA network allowed me to see 
which other genes IL-1, OSM and TGFβ may interact with. This provides a 
better understanding of how problems with the three cytokines could in turn lead 
to problems in other systems. Below I will discuss some of these genes and 
discuss what systems may be being altered by my model genes.  
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8.3.2.1 TGFBR1 and SMAD1 
TGFBR1 is only directly linked to CD84, a neuronal protein also expressed in 
immune cells, which is important in both the adaptive and innate immune 
response (Zaiss et al. 2003). CD84 indirectly links TGFBR1 to multiple genes, 
most of which are already linked to SMAD1. This indicates that SMAD1 may 
affect multiple genes that are dysregulated in OA, and highlights the importance 
of catabolic TGFβ signalling. The gene with the strongest connection to SMAD1 
is EGF-Like Domain Multiple 7 (EGFL7); a gene that has been linked to calcium 
iron binding as well as Notch signalling (Zaiss et al. 2003). It is also believed to 
be important in angiogenesis; playing an important role in bone growth and 
remodelling that could lead to disease (Chim et al. 2013).  
8.3.2.2 JunB 
JunB was linked to the immediate early response 3 (IER3) gene which has 
been shown to be important in not only ERK signalling (Letourneux et al. 2006) 
but also plays a key role in cell stress; in particular apoptosis (Hamidi et al. 
2012). Morinobu et al. (2016) showed that IER3 can induce apoptosis in RA 
patients leading to damage. They also showed TNF and IL-1 β increased IER3 
in OA samples, which then modulated cytokine and chemokine mRNA 
expression in a similar way to in the RA samples. However, they could not 
confirm that it induced apoptosis in OA samples.  Regulator of G-Protein 
Signalling 1 (RGS1) was also linked to JunB. RGS1 has been linked to the 
mechanical loading response (Eliasson et al. 2013), as well as pain in OA 
patients (Thakur et al. 2013), although the mechanism remains unclear.  
8.3.2.3 c-Fos 
c-Fos has four  connections. The first, dual specificity phosphatase (DUSP1), is 
linked to DUSP16 which has been shown to dephosphorylate c-Fos (Caunt and 
Keyse 2013). Therefore, DUSP1 inclusion could be related to a similar action. c-
Fos and Early Growth Response 1 (EGR1) have been shown to be co-regulated 
(Sukhatme et al. 1988) and both are expressed in chondrocytes in response to 
IL-1 (Goldring et al. 1994). EGR1 also has a role in development and has been 
shown to be activated in hypertonic chondrocytes (Levi et al. 1996). Re-initiation 
of developmental pathways and the maturation of chondrocytes can lead to 
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MMP-13 expression and cartilage degradation in OA (Dreier 2010). Work done 
previously in our group showed that Immediate Early Response 2 (IER2) has a 
role in IL-1+OSM-driven MMP-13 expression. Its removal with siRNA resulted in 
reduced MMP-13 expression after 24 hours (Macdonald 2013). The link 
demonstrated between c-Fos, IER2 and EGR1 could be a result of their role in 
inflammation-driven cartilage damage.  
Also closely linked to c-Fos is ZFP36 Ring Finger Protein, a protein that binds to 
ARE-containing mRNAs to promote their degradation (M. Inada et al. 2004). 
The QIAGENs DECipherment Of DNA Elements (DECODE) programme also 
showed there is a c-Fos, c-Jun and AP-1 binding site on the ZFP36 promotor 
region (Kent et al. 2002). This suggests that c-Fos increases ZFP36 expression 
in OA, although the effect of this is not clear. 
8.3.2.4 Conclusions 
Overlaying my model genes gave me some biological insight into how exactly 
gene changes in my model can interact with a range of different pathways. It 
also identified some interactions that may not have been discovered without it. 
Specific gene interactions highlight how changes in genes from one pathway 
can then lead to crosstalk with other pathways, altering them and helping drive 
disease progression.  Further exploration into these interactions and 
incorporating them into the model could help to identify interesting targets for 
future study and possible drug interventions.  
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8.3.2 Summary  
 Overlaying knee specific data to my complete OA cytoscape network 
using PhenomeScape created 10 sub-networks that represent altered 
processes in knee OA. Future research into the genes in these pathways 
could provide a better understanding of how OA is developed.  
 
 Overlaying my model genes to my complete cytoscape network allowed 
me to predict some OA associated genes that may be affected by IL-1, 
OSM and TGFβ signalling. This helps to show how alterations in one 
signalling pathway can lead to other altered pathways and OA 
development. It also highlighted important pathways that should be 
considered, if not incorporated into the model in the future.  
 
 The analyses presented in this chapter have identified a number of 
potential targets for future study. The challenge will be to choose the 
most sensible candidates to progress with.   
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Chapter 9 Final discussion 
9.1 TGFβ-mediated repression of IL-1+OSM-driven MMP-13 mRNA 
expression.  
Matrix-degrading enzymes play important roles in the development of OA and of 
these, MMP-13 is believed to be the most important (Poole et al. 2002; L. 
Troeberg and H. Nagase 2012). TGFβ has been shown in multiple studies to 
protect against the damaging effects of pro-inflammatory stimuli (Marie et al. 
2006; Shull et al. 1992; Wang Hui et al. 2014). Throughout chapters 3 and 4 I 
confirmed that TGFβ can reduce the IL-1+OSM-driven expression of MMP-1/13 
mRNA in SW1353 cells and that this repressive effect is robust. Furthermore, I 
demonstrated that TGFβ could mediate repression after 6 hours pre-treatment, 
even if it is was no longer present in the experiment. This effect, along with the 
initial delay in repression, led me to conclude that de novo synthesis of a tertiary 
mediator is required to mediate the effect. Model data presented in chapter 7 
also showed TGFβ reduced the variability in IL-1+OSM-driven MMP-13 mRNA 
upregulation that was seen with IL-1+OSM alone. Having these two layers of 
repression implies that TGFβ has a vital role in reducing the effect of pro-
inflammatory stimuli, allowing MMPs to regulate turnover (Masaki Inada et al. 
2004), but preventing them from causing excess damage. Although TGFβ 
affects a lot of non-canonical pathways (Hartsough and Mulder 1995; A. Nakao 
et al. 1997; Bhowmick et al. 2001), the SMAD2/3 pathway was my primary 
candidate to mediate the repressive effect due to the important role of SMAD2/3 
in maintaining cartilage homeostasis (Gehua Zhen and Xu Cao 2014).  
Knockdown of ALK5 (upstream of SMAD2/3 (M.-J. Goumans et al. 2003)) 
showed TGFβ was unable to mediate repression without this receptor.  
9.1.1 How does TGFβ mediate repression?  
My data, as presented in chapter 5, suggest that TGFβ can inhibit IL-1+OSM-
driven MMP-13 mRNA upregulation through two methods: AP-1 complex 
competitive inhibition and increased instability of MMP-13 mRNA. In order to 
determine if both these components were necessary, I used a series of 
parameter estimations for different models, to see which could best fit the data. 
The literature suggested that there was a tertiary mediator leading to 
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competitive inhibition of the AP-1 complex that mediated MMP-13 mRNA 
repression (Emi Shimizu et al. 2010). We showed this by having JunB protein 
being synthesised upon addition of TGFβ. This then bound to c-Jun, inhibiting 
the formation of c-Jun homodimer or heterodimer with c-Fos (Ponticos et al. 
2009; Mauviel et al. 1996). Alone, this AP-1 competitive inhibition was not 
enough to replicate the experimental findings. This implied that something else 
was involved. Looking at the experimental data there was a large change in 
mRNA expression between 24 and 48 hours and so I hypothesised that this 
could be due to mRNA instability. I am unsure what would mediate this, so the 
model contained a dummy species that was increased with TGFβ addition and 
could decrease MMP-13 mRNA stability. When the model was fitted with both 
components it not only replicated the observed data, but also correctly predicted 
the effect 6 hour TGFβ pre-treatment would have on the system. This suggests 
that TGFβ is affecting the system at two levels and cannot produce its effect 
without both mechanisms occurring together. 
9.2 Alternative pro-inflammatory stimuli.  
Throughout this thesis, IL-1+OSM has been used as a model of pro-
inflammatory stimuli. However, there are other pro-inflammatory cytokines, with 
an established link to TGFβ that could be incorporated into my model instead, 
or in addition to, IL-1+OSM. TNF-α synergises with OSM to upregulate MMPs, 
and this effect is repressed by TGFβ, much the same as IL-1+OSM (Wang Hui 
et al. 2014). Interferon gamma (IFN-γ) expression is also known to be regulated 
by TGFβ (Lin et al. 2005). I have shown that ALK5 is required for TGFβ to have 
its protective effect on IL-1+OSM signalling, which has previously been shown 
to be more abundant in young cartilage, but the ALK1/ALK5 ratio moves 
towards ALK1 with age (Blaney Davidson et al. 2009). It has also been shown 
that following injury, OA changes appear sooner in older patients than they do 
in their younger counterparts (Roos et al. 1995).  Whilst it is true that the 
structure of cartilage changes as it ages (Loeser 2010), it is also feasible that 
the reduction in ALK5 is restricting its ability to resist injury. If the regulation of 
TNF-α, IFN-γ, and possibly other unknown pro-inflammatory cytokines, are all 
mediated by ALK5, then the loss of this receptor with age could explain why 
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older cartilage is damaged more readily by injury, as a previously mechanism of 
reducing damage will now be lost.  
9.3 Lack of MMP-13 in microarray data  
Throughout this thesis I have discussed the importance of MMP-13 in the 
development of OA. However, MMP-13 was not present in the microarray 
network representative of OA in humans. It is difficult to ascertain the exact 
reason why this is, but I predict it is most likely a result of the way ARACNE 
infers interactions. ARACNE uses mutual information which measures how the 
state of one random variable affects another (Margolin et al. 2006). MMP-13 
expression is normally the end point of a signalling cascade, therefore it does 
not directly affect the expression of other genes and is also upregulated by 
multiple different pathways (Fanjul-Fernández et al. 2010). This means that 
although MMP-13 may be upregulated in the samples, no individual gene 
provides meaningful information about the state of MMP-13 expression, or vice 
versa. Therefore, it is unlikely a single gene could have a significant ARACNE 
connection to MMP-13, as upregulation of multiple genes will effect MMP-13 
expression and ARACNE cannot always determine the most important. It is also 
important to note the ARACNE programme was run in late 2015 so any genes 
linked to MMP-13 since 2016 will not be included; for example ATF3 (Chan et 
al. 2017).   
9.4 Changing role of TGFβ 
9.4.1 ALK1/ALK5  
Though the change in ALK1/ALK5 ratio with age is established (Blaney 
Davidson et al. 2009), the cause of the change is unknown. My model predicts, 
as originally presented in Wang Hui et al. (2014), that both ALK5 homodimers 
and ALK1/ALK5 heterodimers bind to TGFβ to mediate their effect and are then 
inactivated by SMAD7. During this inactivation the receptors are degraded; both 
ALK5 and ALK1 are resynthesised in the model, but this degradation happens 
at a higher rate than resynthesis. Therefore, the overall number of receptors 
decreases. ALK5 is affected more by this process due to its abundance, which 
results in more ALK5 homodimers being activated, and subsequently degraded 
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(M.-J. Goumans et al. 2003). Furthermore, as ALK1 must be bound to ALK5 to 
mediate its effect (M.-J. Goumans et al. 2003), for every ALK1 degraded an 
ALK5 molecule also degrades. Therefore, it would be difficult for degradation of 
ALK1 to exceed degradation of ALK5. This is supported by research that shows 
SMAD7 can recruit E3 ubiquitin ligases, Smurf1 and Smurf2, which can in turn 
target ALK5 for degradation through the proteasomal pathway (Yan et al. 2009). 
ALK1 may also avoid degradation as it has been suggested the ALK1 pathway 
is predominantly regulated by SMAD6 (König et al. 2005), rather than SMAD7.  
There are many other processes that could be responsible for the change in the 
ALK1/ALK5 ratio. For example, receptor shedding is important for signal 
cessation by removal of functioning receptors (Levine 2004), as well as 
providing soluble cytokine receptors which have antagonist properties by 
binding excess cytokines (Levine 2004). Shedding of the LRP1receptor can be 
increased under certain conditions such as chronic inflammation (Yamamoto et 
al. 2017). If shedding of TGFβ type I receptors also increased with age, it would 
conceivably have a greater effect on ALK5, again due to its abundance and 
because ALK1 binds to ALK5. Though this hypothesis is different to that 
currently in the model, the basic concept is similar and the model could be 
adapted to fit it. Research into the change in ALK1/ALK5 ratio is currently 
ongoing but testing hypotheses using a model could help understand if, or how, 
something could drive the changes seen with age.   
An attempt to overexpress ALK 1 in chapter 6 highlighted how delicate the 
ALK1/ALK5 balance is. Knocking out ALK5 removed the effect of both 
receptors, as ALK5 is required for ALK1 to signal (M.-J. Goumans et al. 2003). 
Overexpressing ALK1 allowed it to mediate increased ID1 expression. 
However, MMP-13 could not be upregulated, which would be expected if TGFβ 
was predominantly signalling through ALK1 (Blaney Davidson et al. 2009), 
therefore ALK5 still appeared to be the dominant receptor. Understanding of the 
sensitive balance between the receptors will be important for any future 
treatments that target these receptors. This was demonstrated in chapter 7 
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where the timing of theoretical treatments had a clear impact on how much 
effect they had on the system.  
9.4.2 Effects of clock genes 
A circadian rhythm (CR) is a roughly 24 hour cycle affecting the physiological 
processes of living beings. CR is a fundamental regulatory factor in many 
aspects of biology such as: sleep, metabolism and blood pressure (Laposky et 
al. 2008). Clock genes are responsible for mediating the CR in these processes, 
several of which were shown to be disrupted during early cartilage degeneration 
in a murine model (Gossan et al. 2013). Recent publications have also linked an 
altered CR with OA. Akagi et al. (2017) found that two key CR genes were 
altered in OA cartilage: Brain and Muscle ARNT-Like 1 (BMAL1) or Nuclear 
Receptor Subfamily 1 Group D Member 1 (NR1D1). They also found that 
knockdown of either BMAL1 or NR1D1 affected the TGFβ signalling pathway, 
but they found no difference in the levels of SMAD2/3 or SMAD1/5/8 (Akagi et 
al. 2017). Michal Dudek et al. (2016) also linked altered CR to TGFβ signalling. 
However, they looked specifically at BMAL1 showing that a knockout of BMAL1 
corresponded with an increase in SMAD1/5/8 phosphorylation and a decrease 
in SMAD2/3 phosphorylation. This change may have been the result of a 
change in ALK1 expression, as the BMAL1 knockout showed a different 
expression pattern; in wild type mice ALK1 expression was cyclic whilst in the 
BMAL1 knockout ALK1 was constantly upregulated (Michal Dudek et al. 2016). 
How these changes across the day change the effect of TGFβ on pro-
inflammatory stimuli could be interesting as it suggests the timing of an event 
could affect how the body deals with it. For example if a pro-inflammatory event 
occurred at 9am, when ALK1 levels are high (Michal Dudek et al. 2016), it may 
cause a longer response than at 9pm, when ALK1 levels are reduced (Michal 
Dudek et al. 2016). In chapter 5 my data suggested that age results in a 
prolonged pro-inflammatory response in the presence of TGFβ than the 
younger counterpart. As BMAL1 appears to affect SMAD phosphorylation and 
type I receptor composition (Michal Dudek et al. 2016), it could alter the TGFβ 
effect on pro-inflammatory stimuli in a similar way to ageing.  
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9.5 How TGFβ links to key OA pathways 
Despite the important role TGFβ plays in OA development (addressed in 
chapters 1 and 3), there are many other inflammatory pathways that play a role.  
Exploring the interactions between these pathways may be important in 
understanding OA as a whole.  chapter 8 presented a way of combining 
modelled genes with a large scale bioinformatic study. This method identified a 
number of genes that interact with the model, highlighting in particular notch 
signalling. Notch signalling has been shown to synergise with SMAD3 
signalling. This interaction is direct, as notch signalling can attract SMAD3 to 
DNA binding sites to effect transcription (Blokzijl et al. 2003).  
PhenomeScape analysis also showed the range of sub-networks that represent 
processes involved in OA development, as well as gene lists to help uncover 
how these may be mediated. For example it identified a sub-network 
responsible for insulin signalling, which is interesting as diabetes has recently 
been linked with an increased risk of OA (Louati et al. 2015). Currently the 
reason for this link  is not understood, so genes in the sub-network may help to 
uncover how a change in insulin signalling could lead to OA development.  
These types of analyses highlight the complexity of OA but also provide a 
structure that will hopefully lead to a more detailed understanding of the 
disease.  
9.6 Therapeutic targets  
As discussed in more detail in chapter 4, Chen et al. (2015) argued that 
inhibition of TGFβ, rather than activation, should be considered for treatment.  
They used TGFBR2 inhibitors to delay OA development after DMM surgery 
(Chen et al. 2015). They later showed that TGFβ was low in cartilage of wild 
type mice preDMM surgery (Fang et al. 2017). My model allowed me to test 
predictions about potential therapeutic targets, which highlighted future 
considerations in design of therapeutics. Gehua Zhen et al. (2013) also showed 
that targeting TGFβ could attenuate OA development in mice. This study used 
an anti-TGFβ antibody, 1D11. Incorporating this into the model showed that 
treatments had to be given multiple times and at regular intervals to have 
positive effects. This is in agreement with murine data from Xie et al. (2016) 
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which showed systematic neutralisation of TGFβ with 1D11 was more effective 
if given three times a week when compared to once or twice.  
The model also predicted that 1D11 could lead to an increase in MMP-13 when 
administered only once, as the reduced level of TGFβ will primarily signal 
through ALK1. This was in agreement with Fang et al. (2017) who suggested 
TGFβ may work in a dose-dependent manner, as either above or below a 
certain threshold it will lead to damage. However, there were no signs of extra 
joint damage with reduced 1D11 administration in the Xie et al. (2016) study. 
The model predicted that after 1D11 treatment(s), TGFβ would lose the 
protective effect against pro-inflammatory stimuli and the timing of 1D11 
administration(s) was important for the desired effects. I am unaware of any 
study that has addressed these predictions but they may be important 
considerations in the development of an anti-TGFβ drug treatment.   
9.7 Alterations with hindsight 
Reflecting on the data collected throughout my thesis allowed me to assess 
what could have been done differently.  
9.7.1 ALK1 overexpression 
Attempting to over-express ALK1 in the SW1353 cell line was a large part of my 
PhD. Despite some success, it did not produce the results originally expected, 
such as upregulating MMP-13, which prevented me from drawing any firm 
conclusions. This appears to be because SW1353 cell were not the correct cell 
line for over-expression. The levels of ALK5 in these cells appear 
insurmountably higher than ALK1. Attempting these experiments in another cell 
line, such as the C28/I2 used by Finnson et al. (2010), may have allowed the 
over-expression experiments to be more successful. However, it would have 
required repeating all experiments performed on the SW1353 cell to confirm the 
behaviour was the same, which there was insufficient time to do. 
9.7.2 Ambition in early stages 
Originally, I aimed to build a model of different inflammatory pathways and then 
combine these to give an overview of inflammation in OA. This project proved to 
be too ambitious; in hindsight focussing on one pathway from the start would 
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have given me more time to explore more of the elements discussed in future 
work.  
9.8 Future work 
9.8.1 Incorporating other pathways into the model 
The interaction of other inflammatory pathways with TGFβ is interesting as they 
also regularly affect SMAD signalling. Incorporating these pathways into the 
model may help explain why TGFβ moves towards ALK1 signalling with age, or 
reveal a target area to help reverse these changes. For example, WNT 
signalling, as discussed in chapter 1, can affect the expression of genes that 
skew TGFβ signalling towards ALK1 signalling (M. H. van den Bosch et al. 
2014). Incorporating WNT into the model may help to explain how this shift 
occurs. Notch signalling also synergises with SMAD3 (Blokzijl et al. 2003), so 
looking at how this synergy could affect TGFβ signalling (especially with age) 
could reveal some interesting interactions.         
I would also like to look at how TGFβ interacts with other pro-inflammatory 
cytokines. It has already been shown that TGFβ can repress TNF-α and IFN-γ 
responses (Lin et al. 2005; Wang Hui et al. 2014). Identifying if there are more 
pro-inflammatory responses TGFβ represses, and if ALK5 is also required for 
these interactions, could highlight how important the loss of ALK5 with age is. 
For example, repeating the IL-1+OSM±TGFβ experiments with a range of 
different cytokines could should how many cytokine responses TGFβ can 
repress.  
9.8.2 Exploring computational predictions 
Examining the complete OA network by overlaying my model genes and using 
PhenomeScape analysis produced a large list of potential genes for further 
study. The next step would be to confirm that these genes are upregulated in 
OA tissues before choosing the most interesting candidates to continue 
studying.   
9.8.3 Importance of cycling TGF or clock genes incorporated into model 
Changes in the expression of the CR gene BMAL1 appears to have similar 
effects on TGFβ signalling as ageing. Changing the current model to show how 
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BMAL1 changes throughout the day, and how this affects pro-inflammatory 
stimuli may help better understand the importance of CR in OA. Incorporating 
ageing into this model may show how changes in TGFβ signalling with age can 
be affected by changes in BMAL1.   
9.8.4 Examine model predictions experimentally  
In the model JunB provides competitive inhibition to c-Jun, preventing formation 
of c-Jun homodimers and c-Jun/c-Fos heterodimers after IL-1+OSM treatment. 
DNA affinity pull down assays would allow specific examination at the binding 
site of MMP-13, to help determine if there is reduced c-Jun/c-Fos heterodimer 
binding when TGFβ is present. As mentioned in chapter 2 ATF3 is believed to 
have an important role downstream of c-Jun/c-Fos (Chan et al. 2017), so 
measuring its binding may be significant.  
As discussed in chapter 5, JunB is not the only protein that may be important in 
the competitive inhibition to c-Jun. For this reason siRNA against JunB may be 
able to determine its importance in this process.  
The model also predicted that TGFβ could induce degradation of MMP-13 
mRNA. However, the cause of this is unclear. In chapter 5 some possible genes 
are discussed, exploring these with siRNA may reduce the repressive effect of 
TGFβ.I also think it may be worth performing a microRNA screen on IL-
1+OSM±TGFβ samples, as these have been known to alter mRNA stability 
(Valinezhad Orang et al. 2014).  
The prediction that TGFβ can reduce variability to an inflammatory response 
was presented in chapter 8. Confirming this prediction experimentally could be 
difficult, but could identify a novel role of TGFβ with important implications. 
Single cell experiments could be interesting as they would allow you to measure 
the stochasticity of the response in lone cells as well as the complete 
population, for example single cell RNA-sequencing (Svensson et al. 2017).  
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Chapter 10 Appendix 
 
 
 
 
                                   
 
 
 
 
Appendix 5.1 Network diagram showing species and reactions involved in the IL-
1+OSM response. A, B, C) Schematic representation of IL-1+OSM signalling, as described 
in Proctor et al. (2014).A) OSM section B) MMP activation section C) IL-1 section. Cell 
designer was used to create the schematics. Appendix 1 
 
 
 
 
Appendix 5.2 Network diagram showing all the species and reactions involved in the TGFβ pathway. A) Schematic 
representation of the TGFβ component from the model presented in Wang Hui et al. (2014). CellDesigner was used to create the 
schematic. Appendix 2 
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Appendix 7.1 Degradation of Anti-TGF. Deterministic simulation results 
showing the degradation of Anti-TGF across 50 hours simulation time. The 
simulation was run using COPASI.   
Appendix 3 
 
 255 
 
 
Appendix 7.2 Effect of Anti-TGF on active TGFβ. Deterministic simulation results 
showing the effect Anti-TGF has on the levels of active TGFβ. Ran across 70 days 
simulation time. The simulation was run using COPASI.   
Appendix 5 
 
Appendix 7.3 Effect of Anti-TGF on inactive TGFβ. Deterministic simulation results 
showing the effect Anti-TGF has on the levels of inactive TGFβ. Ran across 70 days 
simulation time. The simulation was run using COPASI.   
Appendix 4 
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